

# EAU Guidelines on Chronic Pelvic Pain

D. Engeler (Chair), A.P. Baranowski, B. Berghmans,  
J. Borovicka, A.M. Cottrell, P. Dinis-Oliveira, S. Eneil,  
J. Hughes, E.J. Messelink (Vice-chair), A.C. de C Williams  
Guidelines Associates: L. Pacheco-Figueiredo, B. Parsons,  
S. Goonewardene

# TABLE OF CONTENTS

# PAGE

1.	INTRODUCTION	4
1.1	Aim	4
1.2	Publication history	4
1.3	Available Publications	4
1.4	Panel composition	4
1.5	Terminology	5
2.	METHODOLOGY	12
2.1	Methods	12
2.2	Review	13
2.3	Future goals	13
3.	EPIDEMIOLOGY, AETIOLOGY AND PATHOPHYSIOLOGY	13
3.1	Chronic visceral pain	13
3.1.1	Incidence	14
3.1.2	Prevalence	14
3.1.3	Influence on Quality of Life	14
3.1.4	Costs	14
3.1.5	Risk Factors and underlying causes	14
3.1.5.1	Risk factors	14
3.1.5.2	Underlying causes	15
3.1.5.3	Clinical paradigms in visceral pain	18
3.2	Pelvic Pain	19
3.2.1	Incidence	19
3.2.2	Prevalence	19
3.2.2.1	Prostate Pain syndrome	19
3.2.2.2	Bladder Pain syndrome	19
3.2.2.3	Sexual pain syndrome	19
3.2.2.4	Myofascial pain syndromes	20
3.2.3	Influence on QoL	20
3.2.4	Costs	20
3.2.5	Risk factors and underlying causes	20
3.2.5.1	Prostate Pain Syndrome	20
3.2.5.2	Bladder Pain syndrome	20
3.2.5.3	Scrotal Pain Syndrome	20
3.2.5.4	Urethral Pain Syndrome	21
3.2.5.5	Vaginal and vulvar pain syndromes	21
3.2.5.6	Chronic Pelvic Pain and Prolapse/Incontinence Mesh	21
3.2.5.7	Associated conditions in pelvic pain syndromes	22
3.3	Abdominal aspects of pelvic pain	24
3.3.1	Incidence	24
3.3.2	Prevalence	24
3.3.3	Influence on QOL	24
3.3.4	Costs	25
3.3.5	Risk factors & underlying causes	25
3.4	Summary of evidence and recommendations: CPP and mechanisms	25
4.	DIAGNOSTIC EVALUATION	25
4.1	General Evaluation	25
4.1.1	History	25
4.1.1.1	Anxiety, depression, and overall function	25
4.1.1.2	Urological aspects	26
4.1.1.3	Gynaecological aspects	26
4.1.1.4	Gastrointestinal aspects	26
4.1.1.5	Peripheral nerve aspects	27
4.1.1.6	Myofascial aspects	28
4.1.2	Physical Evaluation	28
4.2	Supplemental evaluation	29
4.2.1	Assessing pain and related symptoms	29
4.2.2	Focused myofascial evaluation	30

4.2.3	Neurological	30
4.2.4	Imaging	30
4.2.5	Laboratory Tests	31
4.2.6	Invasive tests	31
4.3	Diagnostic algorithm	33
4.4	Other painful conditions without a urological cause	34
4.5	Summary of evidence and recommendations: diagnostic evaluation	35
4.5.1	Diagnostic evaluation of PPS	35
4.5.2	Diagnostic evaluation of BPS	36
4.5.3	Diagnostic evaluation of scrotal pain syndrome	36
4.5.4	Diagnostic evaluation of urethral pain syndrome	36
4.5.5	Diagnostic evaluation of gynaecological aspects chronic pelvic pain	36
4.5.6	Diagnostic evaluation of anorectal pain syndrome	37
4.5.7	Diagnostic evaluation of pudendal neuralgia	37
4.5.8	Diagnostic evaluation of sexological aspects in CPP	37
4.5.9	Diagnostic evaluation of psychological aspects of CPP	37
4.5.10	Diagnostic evaluation of pelvic floor function	38
5.	MANAGEMENT	38
5.1	Conservative management	38
5.1.1	Pain education	38
5.1.2	Physical therapy	38
5.1.3	Psychological therapy	40
5.1.4	Dietary treatment	41
5.2	Pharmacological management	41
5.2.1	Drugs for chronic pelvic pain syndrome	41
5.2.1.1	Mechanisms of action	41
5.2.1.2	Comparisons of agents used in pelvic pain syndromes	41
5.2.2	Analgesics	45
5.2.2.1	Mechanisms of action	46
5.2.2.2	Comparisons within and between groups in terms of efficacy and safety	46
5.3	Surgical management	48
5.3.1	Surgery	48
5.3.2	Neuromodulation	50
5.3.3	Nerve blocks	51
5.4	Summary of evidence and recommendations: management	52
5.4.1	Management of PPS	52
5.4.2	Management of BPS	53
5.4.3	Management of scrotal pain syndrome	54
5.4.4	Management of urethral pain syndrome	54
5.4.5	Management of gynaecological aspects of chronic pelvic pain	54
5.4.6	Management of anorectal pain syndrome	54
5.4.7	Management of pudendal neuralgia	55
5.4.8	Management of sexological aspects in CPP	55
5.4.9	Management of psychological aspects in CPP	55
5.4.10	Management of pelvic floor dysfunction	55
5.4.11	Management of chronic/non-acute urogenital pain by opioids	56
6.	EVALUATION OF TREATMENT RESULTS	56
6.1	Evaluation of treatment	56
6.1.1	Treatment has not been effective	56
6.1.1.1	Alternative treatment	56
6.1.1.2	Referral to next envelope of care	56
6.1.1.3	Self-management and shared care	56
6.1.2	Treatment has been effective	56
7.	REFERENCES	57
8.	CONFLICT OF INTEREST	85
9.	CITATION INFORMATION	85

# 1. INTRODUCTION

## 1.1 Aim

This guideline plays an important role in the process of consolidation and improvement of care for patients with abdominal and pelvic pain. From both literature and daily practice it has become clear that abdominal and pelvic pain are areas still under development. This guideline has been recognised as a cornerstone for important developments that have taken place in the past ten years.

This guideline aims to expand the awareness of caregivers in the field of abdominal and pelvic pain and to assist those who treat patients with abdominal and pelvic pain in their daily practice. The guideline is a useful instrument not only for urologists, but also for gynaecologists, surgeons, physiotherapists, psychologists and pain doctors.

It must be emphasised that guidelines present the best evidence available to the experts. However following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

## Structure and scope

The panel wishes to take advantage of modern methods of delivering guideline information to clinicians dealing with these patients. In 2016, a stepped information structure was made, in alignment with stepped care protocols, using new digital information sources like websites and apps to aid this process. Furthermore, the guideline was changed according to the template used in all other non-oncology guidelines of the EAU. It was recognised that structuring a guideline on chronic pain is quite different from structuring one on another subject. A multi-disciplinary approach is of utmost importance and demands a broad view. In 2016, the guideline was rewritten to be centred around pain instead of being organ-centred. It is partly theoretical to show the importance of using this pain-centred approach. The biggest part, however, deals with the practical approach to diagnostics, treatment and management of patients with abdominal and pelvic pain.

## 1.2 Publication history

The EAU Guidelines on Chronic Pelvic Pain were first published in 2003 [1] which formed the basis of a scientific publication in European Urology in 2004 [2]. Also, in the 2003 edition the concept of Chronic Pelvic Pain Syndromes (CPPS) was introduced, which is now referred to as “pain as a disease process”. Partial updates of the CPP Guidelines were published in 2008 and formed the basis for another scientific publication in European Urology in the year 2010 [3, 4]. Two chapters were added at that time: Chapter 5 ‘Gastrointestinal aspects of chronic pelvic pain’ and Chapter 7 ‘Sexological aspects of chronic pelvic pain’. In the 2014 edition minor revisions were made in Chapter 5 ‘Gastrointestinal aspects of chronic pelvic pain’ and Chapter 8 ‘Psychological aspects of chronic pelvic pain’.

For the 2015 edition the Panel critically reviewed the sub-chapter on bladder pain syndrome which is now a comprehensive part of the guideline [5].

## 1.3 Available Publications

Alongside the full text version, a quick reference document (Pocket Guidelines) is available in print and as an app for iOS and android devices. These are abridged versions which may require consultation together with the full text version. This reference document follows the updating cycle of the underlying large texts. All available material can be viewed at the EAU website. The EAU website also includes a selection of EAU Guideline articles as well as translations produced by national urological associations: [uroweb.org/guideline/chronicpelvicpain/](http://uroweb.org/guideline/chronicpelvicpain/).

## 1.4 Panel composition

The panel of experts responsible for this document include four urologists, (one of which has a sub-specialisation in neuro-urology and one is a sexologist), two consultants in pain medicine, a uro-gynaecologist, a psychologist, a gastroenterologist and a pelvic physiotherapist, health scientist and (clinical) epidemiologist.

The Panel is also grateful to Ms. J. Birch for her expertise, time and diligence in undertaking a review of these guidelines from a patient perspective.

## 1.5 Terminology

### **Definitions of CPP terminology**

#### **Classification**

Much debate over the classification of CPP has occurred, is ongoing and will continue in the future. Classification involves three aspects of defining a condition: phenotyping, terminology and taxonomy.

#### **Phenotyping**

Phenotyping is describing the condition. For example, chronic bladder pain may be associated with the presence of Hunner's ulcers and glomerulation on cystoscopy, whereas other bladder pain conditions may have a normal appearance on cystoscopy. These are two different phenotypes. The same is true for irritable bowel syndrome (IBS), which may be sub-divided into that associated primarily with diarrhoea or that with constipation. Phenotyping is based upon mechanisms when they are known (e.g., infection, ischaemic, auto-immune, or neuropathic). In the absence of well-defined mechanisms, describing the condition by its symptoms, signs and, where possible, by investigations, has been demonstrated to have clinical and research validity in many situations. When pain is the main symptom and pain as a disease process is considered the cause, the condition is often referred to as a pain syndrome - a well-defined collection of symptoms, signs and investigation results associated with pain mechanisms and pain perception as the primary complaint.

#### **Terminology**

Terminology is the words that are used within classification, both to name the phenotype and within the definition of the phenotype. Examples of names for phenotypes associated with the bladder include interstitial cystitis, painful bladder syndrome or bladder pain syndrome (BPS). The EAU, the International Society for the study of BPS (known as ESSIC), the International Association for the Study of Pain (IASP) and several other groups now prefer the term bladder pain syndrome. In the pain syndromes, the role of the nervous system in generating the sensations is thought to be pivotal, but the term syndrome is also comprehensive and takes into account the emotional, cognitive, behavioural, sexual and functional consequences of the chronic pain.

When defining the phenotype, the terminology used in that definition must also be clear and if necessary defined. One of the most important guiding principles is that spurious terminology should be avoided. Terms that end in "itis" in particular should be avoided unless infection and or inflammation is proven and considered to be the cause of the pain [6]. It must be appreciated that end-organ inflammation may be secondary and neurogenic in origin and not a primary cause of the pain.

#### **Taxonomy**

Taxonomy places the phenotypes into a relationship hierarchy. The EAU approach sub-divides CPP into conditions that are pain syndromes and those that are non-pain syndromes. The latter are conditions that have well-recognised pathology (e.g., infection, neuropathy or inflammation), whereas the former syndromes do not and pain as a disease process is the mechanism. Other terms for the non-pain syndromes include "classical conditions", "well-defined conditions" and "confusable diseases". Although the EAU approach deals primarily with urological conditions, this approach to classification can be applied to all conditions associated with pain perception within the pelvis; the classification has been developed to include non-urological pain and was accepted by the IASP for publication in January 2012.

### **Classification of CPP syndromes**

#### **Importance of classification**

It should be obvious to all that a condition cannot be treated unless it is defined. However, the reasons for classifying CPP go far beyond that.

#### **Clues to the mechanism**

As a result of systematic phenotypic and taxonomic classifications, similarities and differences between conditions become clear. Drawing comparisons between the phenotypes of different disorders allows one to compare disorders such as bladder and bowel pain syndromes, thus facilitating research and treatment.

#### **Guidelines for best treatment options**

As conditions become better defined, more specific treatment approaches can be adopted. In particular, there will be a move away from treatments based upon spurious terms (e.g., antibiotics and non-steroidal anti-inflammatory drugs for the "-itis" conditions). Generic treatments aimed at groups of conditions will be more commonplace and based upon research evidence.

## Research platform

Only by clearly defining the phenotype being investigated can research be valued or applied to the clinical situation.

## Patient needs

A diagnosis, or name, for a set of symptoms can provide patients with a sense of being understood, as well as hope for relief. It may therefore help in acceptance of the problem as chronic, resolution of unfounded fears about its implications (if not life-threatening), and engagement in therapeutic endeavours, as well as in self-management. However, it may also lead to accessing information of variable quality associated with the diagnosis or name, and the possibility of generating new concerns about long-term consequences or about appropriateness of treatment.

## IASP definitions

### Sub-dividing pain syndromes

There is much debate on the sub-divisions of the pain syndromes within the hierarchical taxonomy. The EAU has led the way in this regard and the guiding principles are as follows [2]:

1. The pain syndromes are defined by a process of exclusion. In particular, there should be no evidence of infection or inflammation. Investigations by end-organ specialists should therefore be aimed at obtaining a differential diagnosis; repeated, unnecessary investigations are detrimental in the management of chronic pain syndromes.
2. A sub-division phenotype should only be used if there is adequate evidence to support its use. For instance, in non-specific, poorly localised pelvic pain without obvious pathology, only the term chronic pelvic pain syndrome (CPPS) should be used. If the pain can be localised to an organ, then a more specific term, such as rectal pain syndrome, may be used. If the pain is localised to multiple organs, then the syndrome is a regional pain syndrome and the term CPPS should once again be considered. As well as defining the patient by a specific end-organ phenotype, there are several other more general descriptors that need to be considered. These are primarily psychological (e.g., cognitive or emotional), sexual, behavioural and functional. Psychological and behavioural factors are well-established factors which relate to quality of life (QoL) issues and prognosis. In North America a research programme, the MAPP program (Multi-disciplinary Approach to the study of Chronic Pelvic Pain research) has been devised to investigate the importance of these factors and looks at all types of pelvic pain irrespective of the end-organ where the pain is perceived. It also looks at systemic disorder associations, such as the co-occurrence of fibromyalgia, facial pain, or auto-immune disorders.
3. In 2004 the panel introduced the concept of managing the polysymptomatic nature of CPP, since then others have developed their own schemes, such as Nickel's UPOINT [7], modified by Magri *et al.* [8]. In light of these and other publications, the symptom classification table has been updated (Table 1).

The debate in relation to sub-dividing the pain syndromes remains ongoing. As more information is collected suggesting that the central nervous system (CNS) is involved, and indeed may be the main cause of many CPP conditions (e.g., bladder, genitalia, colorectal or myofascial), there is a general tendency to move away from end-organ nomenclature. Only time and good research will determine whether this is appropriate. To enable such research, it is essential to have a framework of classification within which to work. Any hierarchical taxonomy must be flexible to allow change.

The classification has been set up according to the axis system used by IASP.

**Table 1: EAU classification of chronic pelvic pain syndromes**

Axis I Region	Axis II System	Axis III End-organ as pain syndrome as identified from Hx, Ex and Ix	Axis IV Referral characteristics	Axis V Temporal characteristics	Axis VI Character	Axis VII Associated symptoms	Axis VIII Psychological symptoms
Chronic pelvic pain  OR Pelvic pain syndrome	Urological	Prostate	Suprapubic Inguinal Urethral Penile/clitoral Perineal Rectal Back Buttocks Thighs	ONSET Acute Chronic  ONGOING Sporadic Cyclical Continuous  TIME Filling Emptying Immediate post Late post  TRIGGER Provoked Spontaneous	Aching Burning Stabbing Electric	UROLOGICAL Frequency Nocturia Hesitance Dysfunctional flow Urgency Incontinence	ANXIETY About pain or putative cause of pain  Catastrophic thinking about pain
		Bladder					
	Gynaecological	Scrotal Testicular Epididymal				GYNAECOLOGICAL Menstrual Menopause  GASTROINTESTINAL Constipation Diarrhoea Bloating Urgency Incontinence	DEPRESSION Attributed to pain or impact of pain  Attributed to other causes  Unattributed  PTSD SYMPTOMS Re-experiencing Avoidance
		Penile Urethral					
		Post-vasectomy					
		Vulvar Vestibular Clitoral					
		Endometriosis associated					
		CPPS with cyclical exacerbations					
		Dysmenorrhoea					
		Irritable bowel					
		Chronic anal					
		Intermittent chronic anal					
Gastrointestinal	Peripheral nerves	Pudendal pain syndrome				NEUROLOGICAL Dysaesthesia Hyperaesthesia Allodynia Hyperalgesia  SEXUOLOGICAL Satisfaction Female dyspareunia Sexual avoidance Erectile dysfunction Medication  MUSCLE Function impairment Fasciculation  CUTANEOUS Trophic changes Sensory changes	
		Dyspareunia					
		Pelvic pain with sexual dysfunction					
Sexological	Psychological	Any pelvic organ					
Musculo-skeletal		Pelvic floor muscle Abdominal muscle Spinal Coccyx					

Hx = History; Ex = Examination; Ix = Investigation; PTSD = post-traumatic stress disorder.

## **Pain syndromes**

The original EAU classification [2] was inspired by the IASP classification [9] and much work around what has become known as “pain as a disease” and its associated psychological, behavioural, sexual and functional correlates. After ten years of work developing the initial ideas, an updated version was accepted by the IASP Council for publication in January 2012.

### **Definition of chronic pelvic pain**

Chronic pelvic pain is chronic or persistent pain perceived\* in structures related to the pelvis of either men or women. It is often associated with negative cognitive, behavioural, sexual and emotional consequences as well as with symptoms suggestive of lower urinary tract, sexual, bowel, pelvic floor or gynaecological dysfunction. [\*Perceived indicates that the patient and clinician, to the best of their ability from the history, examination and investigations (where appropriate) has localised the pain as being discerned in a specified anatomical pelvic area.]

In the case of documented nociceptive pain that becomes chronic/persistent through time, pain must have been continuous or recurrent for at least six months. That is, it can be cyclical over a six-month period, such as the cyclical pain of dysmenorrhoea. Although arbitrary, six months was chosen because three months was not considered long enough if cyclical pain conditions are included. If non-acute and central sensitisation pain mechanisms are well documented, then the pain may be regarded as chronic, irrespective of the time period. Cyclical pain is included in the classification and hence dysmenorrhoea needs to be considered as a chronic pain syndrome if it is persistent and associated with negative cognitive, behavioural, sexual, or emotional consequences.

Chronic pelvic pain may be sub-divided into conditions with well-defined classical pathology (such as infection or cancer) and those with no obvious pathology. For the purpose of this classification, the term “specific disease-associated pelvic pain” is proposed for the former, and “chronic pelvic pain syndrome” for the latter. The following classification only deals with CPPS.

### **Definition of chronic pelvic pain syndrome**

Chronic pelvic pain syndrome is the occurrence of CPP when there is no proven infection or other obvious local pathology that may account for the pain. It is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological dysfunction. Chronic Pelvic Pain Syndrome is a sub-division of CPP.

### **Further subdivision of CPPS**

Pain perception in CPPS may be focused within a single organ, more than one pelvic organ and even associated with systemic symptoms such as chronic fatigue syndrome (CFS), fibromyalgia (FM) or Sjögren's syndrome. When the pain is localised to a single organ, some specialists may wish to consider using an end organ term such as Bladder Pain Syndrome (Table 2). The use of such a phrase with the terminology “syndrome” indicates that, although peripheral mechanisms may exist, CNS neuromodulation may be more important and systemic associations may occur. When the pain is localised to more than one organ site, the term CPPS should be used. Many, including some of the panel members never sub-divide by anatomy and prefer to refer to patients with pain perceived within the pelvis, and no specific disease process, as suffering from CPPS, sub-divided by psychological and functional symptoms.

### **Psychological considerations for classification**

Many CPPSs are associated with a range of concurrent negative psychological, behavioural and sexual consequences that must be described and assessed. Examples that need to be considered are depression, anxiety, fears about pain or its implications, unhelpful coping strategies, and distress in relationships. Both anxiety and depression can be significant important concomitant symptoms that are relevant to pain, disability and poor QoL. Catastrophic interpretation of pain has been shown to be a particularly salient variable, predicting patients' report of pain, disability, and poor QoL, over and above psychosocial variables such as depression or behavioural factors such as self-reported sexual dysfunction. It is suggested that CPPS sometimes creates a sense of helplessness that can be reported as overwhelming, and may be associated with the refractory nature of the patients' symptoms. It is important to note that many of these biopsychosocial consequences are common to other persistent pain problems but may show varying degrees of importance for any one individual suffering from CPPS. In all patients with CPPS, these consequences must be clearly described as part of the phenotype (where the term phenotype is used to indicate the observable characteristics of the syndrome).



**Functional considerations for classification**

Functional disorders, for the purpose of this document, are pathologies that have arisen secondary to changes in the control mechanisms of an organ or system. That is, they are disorders characterised by disturbance of function. As an example, slow colonic transit is a functional disorder of the bowel - the normal function of the bowel is not occurring as a result of changes in the mechanisms that produce defecation, and therefore bowel control is abnormal. The term is not used in the sense of a psychiatric functional disorder. Many CPPSs are associated with functional abnormalities at a local and even systemic level. These also need to be defined as a part of the phenotype.

Functional pain disorders may not express significant pathology in the organs that appear responsible for the primary symptoms, but they are associated with substantial neurobiological, physiological and sometimes anatomical changes in the CNS.

**Multi-system sub-division**

It is recognised that the end-organ where the pain is perceived may not be the centre of pain generation. This classification is based upon the most effective and accepted method of classifying and identifying different pain syndromes, that is, by site of presentation. It is argued that keeping the end-organ name in the classification is inappropriate because, in most cases, there are multi-systemic causes and effects, with the result that symptoms are perceived in several areas. This is an area in which discussions are ongoing, and despite there being strong arguments for both keeping and dispensing with end-organ classification, the panel have not taken the umbrella approach of referring to all pain perceived in the pelvis as CPPS.

**Dyspareunia**

Dyspareunia is defined as pain perceived within the pelvis associated with penetrative sex. It tells us nothing about the mechanism and may be applied to women and men. It is usually applied to penile penetration, but is often associated with pain during insertion of any object. It may apply to anal as well as vaginal intercourse. It is classically sub-divided into superficial and deep.

**Perineal pain syndrome**

Perineal pain syndrome is a neuropathic-type pain that is perceived in the distribution area of the pudendal nerve, and may be associated with symptoms and signs of rectal, urinary tract or sexual dysfunction. There is no proven obvious pathology. It is often associated with negative cognitive, behavioural, sexual and emotional consequences, as well as with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological dysfunction. Perineal pain syndrome should be distinguished from pudendal neuralgia which is a specific disease associated with pelvic pain that is caused by nerve damage.

**Table 2: Chronic Pelvic Pain Syndromes**

<b>Urological Pain Syndromes</b>	
<b>Prostate pain syndrome</b>	Prostate pain syndrome (PPS) is the occurrence of persistent or recurrent episodic pain (which is convincingly reproduced by prostate palpation). There is no proven infection or other obvious local pathology. Prostate pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract and sexual dysfunction. The term “chronic prostatitis” continues to be equated with that of PPS. In the authors’ and others’ opinion, this is an inappropriate term, although it is recognised that it has a long history of use. The National Institutes of Health (NIH) consensus [10] includes infection (types I and II), which the authors feel should not be considered under PPS, but as specific disease-associated pelvic pain. The term prostaticodynia has also been used in the past but is no longer recommended by the expert panel. Please note that some of the authors of the IASP document disagree with this term and suggest that CPPS of the male is used instead of PPS, which has been agreed by the majority.

<b>Bladder pain syndrome</b>	Bladder pain syndrome is the occurrence of persistent or recurrent pain perceived in the urinary bladder region, accompanied by at least one other symptom, such as pain worsening with bladder filling and day-time and/or night-time urinary frequency. There is no proven infection or other obvious local pathology. Bladder pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract and sexual dysfunction. BPS is believed to represent a heterogeneous spectrum of disorders. There may be specific types of inflammation as a feature in subsets of patients. Localisation of the pain can be difficult by examination, and consequently, another localising symptom is required. Cystoscopy with hydrodistension and biopsy may be indicated to define phenotypes. Recently, ESSIC has suggested a standardised scheme of sub-classifications [11] to acknowledge differences and make it easier to compare various studies. Other terms that have been used include “interstitial cystitis”, “painful bladder syndrome”, and “PBS/IC” or “BPS/IC”. These terms are no longer recommended.
<b>Scrotal pain syndrome</b>	Scrotal pain syndrome is the occurrence of persistent or recurrent episodic pain localised within the organs of the scrotum, and may be associated with symptoms suggestive of lower urinary tract or sexual dysfunction. There is no proven infection or other obvious local pathology. Scrotal pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences. Scrotal pain syndrome is a generic term and is used when the site of the pain is not clearly testicular or epididymal. The pain is not in the skin of the scrotum as such, but perceived within its contents, in a similar way to idiopathic chest pain.
<b>Testicular pain syndrome</b>	Testicular pain syndrome is the occurrence of persistent or recurrent episodic pain perceived in the testes, and may be associated with symptoms suggestive of lower urinary tract or sexual dysfunction. There is no proven infection or other obvious local pathology. Testicular pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences. Previous terms have included orchitis, orchialgia and orchiodynia. These terms are no longer recommended.
<b>Epididymal pain syndrome</b>	Epididymal pain syndrome is the occurrence of persistent or recurrent episodic pain perceived in the epididymis, and may be associated with symptoms suggestive of lower urinary tract or sexual dysfunction. There is no proven infection or other obvious local pathology. Epididymal pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences.
<b>Penile pain syndrome</b>	Penile pain syndrome is the occurrence of pain within the penis that is not primarily in the urethra, in the absence of proven infection or other obvious local pathology. Penile pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract and sexual dysfunction.
<b>Urethral pain syndrome</b>	Urethral pain syndrome is the occurrence of chronic or recurrent episodic pain perceived in the urethra, in the absence of proven infection or other obvious local pathology. Urethral pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological dysfunction. Urethral pain syndrome may occur in men and women.
<b>Post-vasectomy scrotal pain syndrome</b>	Post-vasectomy scrotal pain syndrome is a scrotal pain syndrome that follows vasectomy. Post-vasectomy scrotal pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract and sexual dysfunction. Post-vasectomy pain may be as frequent as 1% following vasectomy, possibly more frequent. The mechanisms are poorly understood and for that reason it is considered a special form of scrotal pain syndrome.

<b>Gynaecological Pain Syndromes: external genitalia</b>	
<b>Vulvar pain syndrome</b>	Vulvar pain syndrome is the occurrence of persistent or recurrent episodic vulvar pain. There is no proven infection or other local obvious pathology. It is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological dysfunction. Although pain perceived in the vulva was included under sexual disorders in the DSM-IV-R manual for classifying psychiatric disorders, there is no scientific basis for this classification, and pain perceived in the vulva is best understood as a pain problem that usually has psychological consequences. There is no evidence for its classification as a psychiatric disorder. The International Society for the Study of Vulvovaginal Disease (ISSVD) has used the term vulvodynia, where we use the term vulvar pain syndrome. According to the ISSVD, vulvodynia is vulvar pain that is not accounted for by any physical findings. The ISSVD has defined vulvodynia as “vulvar discomfort, most often described as burning pain, occurring in the absence of relevant visible findings or a specific, clinically identifiable, neurologic disorder”. If physical findings are present, the patient is said to have vulvar pain due to a specified cause. The ISSVD has sub-divided vulvodynia based on pain location and temporal characteristics of the pain (e.g. provoked or unprovoked). The following definitions are based on that approach.
<b>Generalised vulvar pain syndrome</b>	Generalised vulvar pain syndrome refers to a vulvar pain syndrome in which the pain/burning cannot be consistently and precisely localised by point-pressure mapping via probing with a cotton-tipped applicator or similar instrument. Rather, the pain is diffuse and affects all parts of the vulva. The vulvar vestibule (the part that lies between the labia minora into which the urethral meatus and vaginal introitus open) may be involved but the discomfort is not limited to the vestibule. This pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences. Previous terms have included “dysesthetic vulvodynia” and “essential vulvodynia”, but these are no longer recommended.
<b>Localised vulvar pain syndrome</b>	Localised vulvar pain syndrome refers to pain that can be consistently and precisely localised by point-pressure mapping to one or more portions of the vulva. Clinically, the pain usually occurs as a result of provocation (touch, pressure or friction). Localised vulvar pain syndrome can be sub-divided into vestibular pain syndrome and clitoral pain syndrome.
<b>Vestibular pain syndrome</b>	Vestibular pain syndrome refers to pain that can be localised by point-pressure mapping to the vestibule or is well perceived in the area of the vestibule.
<b>Clitoral pain syndrome</b>	Clitoral pain syndrome refers to pain that can be localised by point-pressure mapping to the clitoris or is well-perceived in the area of the clitoris.
<b>Gynaecological system: internal pelvic pain syndromes</b>	
<b>Endometriosis associated pain syndrome</b>	Endometriosis-associated pain syndrome is chronic or recurrent pelvic pain in patients with laparoscopically confirmed endometriosis, and the term is used when the symptoms persist despite adequate endometriosis treatment. It is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological dysfunction. Many patients have pain above and beyond the endometriotic lesions; this term is used to cover that group of patients. Endometriosis may be an incidental finding, is not always painful, and the degree of disease seen laparoscopically does not correlate with severity of symptoms. As with other patients, they often have more than one end-organ involved. It has been suggested that this phenotype should be removed from the classification because the endometriosis may be irrelevant.
<b>Chronic pelvic pain syndrome with cyclical exacerbations</b>	Chronic pelvic pain syndrome with cyclical exacerbations covers the non-gynaecological organ pain that frequently shows cyclical exacerbations (e.g., IBS or BPS) as well as pain similar to that associated with endometriosis/adomyosis but where no pathology is identified. This condition is different from dysmenorrhoea, in which pain is only present with menstruation.
<b>Dysmenorrhoea</b>	Dysmenorrhoea is pain with menstruation that is not associated with well-defined pathology. Dysmenorrhoea needs to be considered as a chronic pain syndrome if it is persistent and associated with negative cognitive, behavioural, sexual or emotional consequences.

<b>Gastrointestinal Pelvic Pain Syndromes</b>	
<b>Irritable bowel syndrome</b>	Irritable bowel syndrome is the occurrence of chronic or recurrent episodic pain perceived in the bowel, in the absence of proven infection or other obvious local pathology. Bowel dysfunction is frequent. IBS is often associated with worry and pre-occupation about bowel function, and negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract or gynaecological dysfunction. The above classification is based upon the Rome III Criteria [12]: three months of continuous or recurring symptoms of abdominal pain or irritation that may be relieved with a bowel movement, may be coupled with a change in frequency, or may be related to a change in stool consistency. Two or more of the following are present at least 25% of the time: change in stool frequency (> three bowel movements per day or < three per week); noticeable difference in stool form (hard, loose, watery or poorly formed stools); passage of mucus in stools; bloating or feeling of abdominal distension; or altered stool passage (e.g., sensation of incomplete evacuation, straining, or urgency). Extra-intestinal symptoms include: nausea, fatigue, full sensation after even a small meal, and vomiting.
<b>Chronic anal pain syndrome</b>	Chronic anal pain syndrome is the occurrence of chronic or recurrent episodic pain perceived in the anus, in the absence of proven infection or other obvious local pathology. Chronic anal pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological dysfunction.
<b>Intermittent chronic anal pain syndrome</b>	Intermittent chronic anal pain syndrome refers to severe, brief, episodic pain that seems to arise in the rectum or anal canal and occurs at irregular intervals. This is unrelated to the need to or the process of defecation. It may be considered a sub-group of the chronic anal pain syndromes. It was previously known as “proctalgia fugax” but this term is no longer recommended.
<b>Musculoskeletal System</b>	
<b>Pelvic floor muscle pain syndrome</b>	Pelvic floor muscle pain syndrome is the occurrence of persistent or recurrent episodic pelvic floor pain. There is no proven well-defined local pathology. It is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological dysfunction. This syndrome may be associated with over-activity of, or trigger points within, the pelvic floor muscles. Trigger points may also be found in several muscles, such as the abdominal, thigh and paraspinal muscles and even those not directly related to the pelvis.
<b>Coccyx pain syndrome</b>	Coccyx pain syndrome is the occurrence of chronic or recurrent episodic pain perceived in the region of the coccyx, in the absence of proven infection or other obvious local pathology. Coccyx pain syndrome is often associated with negative cognitive, behavioural, sexual or emotional consequences, as well as with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological dysfunction. The term “coccydynia” was used but is no longer recommended.

## 2. METHODOLOGY

### 2.1 Methods

For each recommendation within the guidelines there is an accompanying online strength rating form, the basis of which is a modified GRADE methodology [13, 14]. Each strength rating form addresses a number of key elements namely:

1. the overall quality of the evidence which exists for the recommendation, references used in this text are graded according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence [15];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.

These key elements are the basis which panels use to define the strength rating of each recommendation. The strength of each recommendation is represented by the words 'strong' or 'weak' [16]. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and nature and variability of patient values and preferences. The strength rating forms will be posted online for consultation.

Additional information can be found in the general Methodology section of this print, and online at the EAU website: <http://www.uroweb.org/guideline/>. A list of associations endorsing the EAU Guidelines can also be viewed online at the above address.

The 2012 full text update was based on a systematic review of literature using the Embase and Medline databases, the Cochrane Central Register of controlled trials and the PsycINFO and Bandolier databases to identify the best evidence from randomised controlled trials (RCTs) (Level of Evidence 1 [LE: 1]) according to the rating schedule adapted from the Oxford Centre for Evidence-based Medicine Levels of Evidence. Where no LE: 1 literature could be identified the search was moved down to the next lower level on the rating scale. Extensive use of free text ensured the sensitivity of the searches, resulting in a substantial body of literature to scan. Searches covered the period January 1995 to July 2011 and were restricted to English language publications. In 2017, a scoping search for the previous five years was performed and the guideline was updated accordingly.

For the 2019 print, a scoping search was performed, covering all areas of the guideline starting from the last cut-off date of May 2017 with a cut-off date of May 2018. Embase, Medline, the Cochrane Central Register of Controlled Trials and Cumulative Index of Nursing and Allied Health Literature databases were searched and were restricted to English language publications. A detailed search strategy is available online: <https://uroweb.org/guideline/chronic-pelvic-pain/>. The gynaecological aspects of the guideline were also updated for the years covering 2016, 2017 and 2018.

## **2.2 Review**

This document was subject to peer review prior to publication in 2015.

## **2.3 Future goals**

The results of ongoing and new systematic reviews will be included in the 2020 update of the Chronic Pelvic Pain Guidelines. Ongoing systematic reviews are:

- What are the benefits and harms of electrical neuromodulation vs. best clinical practice or no treatment in CPP? [17].
- What are the benefits and harms of Botulinum Toxin A vs. best clinical practice or no treatment or sham or placebo in CPP?

# **3. EPIDEMIOLOGY, AETIOLOGY AND PATHOPHYSIOLOGY**

## **3.1 Chronic visceral pain**

### **Definition of pain**

Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage (IASP Taxonomy).

### **Introduction to chronic pelvic pain syndromes**

Over the years much of the focus for CPP has been on peripheral-end-organ mechanisms, such as inflammatory or infective conditions. However, both animal and clinical research have indicated that many of the mechanisms for the CPPs are based within the CNS. Although a peripheral stimulus such as infection may initiate the start of a CPP condition, the condition may become self-perpetuating as a result of CNS modulation. As well as pain, these central mechanisms are associated with several other sensory, functional, behavioural and psychological phenomena. It is this collection of phenomena that forms the basis of the pain syndrome diagnosis and each individual phenomena needs to be addressed in its own right through multi-specialty and multi-disciplinary care. Although ongoing peripheral organ pathology can produce persistent and

chronic pain, the main focus of these guidelines is on CPPSs in which no peripheral ongoing pathology (such as infection or neoplastic disease) is detected. The main exception is when pain is due to peripheral nerve damage.

#### **3.1.1 Incidence**

No adequate data on incidence were found.

#### **3.1.2 Prevalence**

In a large European study undertaken in 2004 [18], it was found that chronic pain of moderate to severe intensity occurs in 19% of adult Europeans, seriously affecting the quality of their social and working lives. There are some differences between countries but not much spread is seen. A more recent study in the UK found a prevalence of CPP of 14.8% in women over 25 years [19].

#### **3.1.3 Influence on Quality of Life**

Assessing the QoL in pelvic pain patients is challenging due to the multi-faceted nature of the complaints and the overlap between the different pelvic pain syndromes [20]. Assessment of QoL is further complicated due to the complex pathology of pain itself [21].

Pelvic pain syndromes do have an impact on QoL [22-24]. This may result in depression, anxiety, impaired emotional functioning, insomnia and fatigue [22, 25]. If these aspects are identified and targeted early in the diagnostic process, the associated pain symptoms may also improve [26]. Addressing comorbidities will help in further improving QoL [24, 27]. Quality of life assessment is therefore important in patients with pelvic pain and should include physical, psychosocial and emotional tools, using standardised and validated instruments [23].

The impact of pain on QoL has been assessed in an extensive European study [18]. In-depth interviews with 4,839 respondents with chronic pain (about 300 per country) showed: 66% had moderate pain (Numeric Rating Scale [NRS] = 5-7) and 34% had severe pain (NRS = 8-10), 46% had constant pain and 54% had intermittent pain. Fifty-nine per cent had suffered with pain for two to fifteen years, 21% had been diagnosed with depression because of their pain, 61% were less able or unable to work outside their home, 19% had lost their job and 13% had changed jobs because of their pain. Sixty per cent visited their doctor about their pain two to nine times in the last six months. Only 2% were currently treated by a pain management specialist.

#### **3.1.4 Costs**

No adequate data on costs were found.

#### **3.1.5 Risk Factors and underlying causes**

##### **3.1.5.1 Risk factors**

Risk factors include many different factors from various areas, including genetic, psychological state, recurrent physical trauma and endocrine factors.

The endocrine system is involved in visceral function. Significant life events, and in particular, early life events may alter the development of the hypothalamic-pituitary-adrenal axis and the chemicals released. Increased vulnerability to stress is thought to be partly due to increased corticotrophin-releasing hormone (CRH) gene expression. Up-regulation of CRH has been implicated in several pain states such as rectal hypersensitivity to rectal distension. This model suggests an action of CRH on mast cells. A range of stress-related illnesses have been suggested, e.g. IBS and BPS. There is evidence accumulating to suggest that the sex hormones also modulate both nociception and pain perception. Stress can also produce long-term biological changes which may form the relation between chronic pain syndromes and significant early life and adverse life events [28]. Asking the patient about these events is important as they have an effect on a patient's psychological wellbeing [29-31].

Genetics also play a role in assessing the risk of developing chronic pain. An individual who has one chronic pain syndrome is more likely to develop another. Family clusters of pain conditions are also observed and animals can be bred to be more prone to apparent chronic pain state. A range of genetic variations have been described that may explain the pain in certain cases; many of these are to do with subtle changes in transmitters and their receptors. However, the picture is more complicated in that developmental, environmental and social factors also influence the situation. Evidence that BPS may have a genetic component has been presented in several identical twin studies, but genetics may contribute to less than one third of total variation in susceptibility to BPS [32, 33].

Studies about integrating the psychological factors of CPPSs are few but the quality is high. Psychological factors are consistently found to be relevant in the maintenance of persistent pelvic and urogenital pain within the current neurobiological understanding of pain. Beliefs about pain contribute to the experience of pain [34] and symptom-related anxiety and central pain amplification may be measurably linked, as in IBS [35], and catastrophic thinking about pain and perceived stress predict worsening of urological chronic pain over a year [36]. Central sensitisation has been demonstrated in symptomatic endometriosis [37] and central changes are evident in association with dysmenorrhoea and increasingly recognised as a risk for female pelvic pain [38]. The various mechanisms of CNS facilitation, amplification and failure of inhibition, mean that there is no simple relationship between physical findings, pain experienced and resulting distress and restriction of activities. Diagnoses that assign women's pain to psychological origins, as is common in primary care [39] due to scepticism about the reality or severity of their pain [40], undermines any therapeutic relationship [41]. Division of aetiology into organic vs. psychogenic is unscientific. Pelvic pain and distress may be related [42, 43] in men as well as in women [44]; the same is true of painful bladder and distress [36, 45]. In a large population based study of men, CPPS was associated with prior anxiety disorder [46]. The only systematic review [47] of risk factors for chronic non-cyclical pelvic pain in women included, as well as medical variables: sexual or physical abuse (Odds Ratio (OR) from 1.51 to 3.49); psychological problems such as anxiety (OR: 2.28, 95% Confidence Interval (CI): 1.41- 3.70) and depression (OR: 2.69, 95% CI: 1.86-3.88); multiple somatic problems (OR: 4.83, 95% CI: 2.50-9.33); and psychosomatic symptoms (OR: 8.01, 95% CI: 5.16-12.44).

Many studies have reported high rates of childhood sexual abuse in adults with persistent pain, particularly in women with pelvic pain [48, 49]. In these studies it is suggested that there is increased frequency of sexual abuse or trauma history, anxiety and depression in women with CPP [50-54]. The only prospective investigation into the relationship between childhood sexual abuse, physical abuse, or neglect, and "medically unexplained pain", including pelvic pain, used court records to compare women with a definite history with matched classmates [31] and concluded that physically and sexually abused individuals were not at risk for increased pain, although women with pain problems as adults were more likely to report earlier sexual or physical abuse or neglect. The correlation between childhood victimisation and pain may concern retrospective explanations for pain; controlling for depression significantly weakens the relationship between childhood abuse and adult pain [55]. Disentangling the influences and inferences requires further prospective studies or careful comparisons [28]. There is some evidence for a specific relationship between rape and CPP (and with fibromyalgia and functional gastrointestinal disorders) [56]; and, recent sexual assault may prompt presentation of pelvic pain [48, 57]. Few studies have been found of sexual or physical abuse in childhood and pelvic pain in men, although it has known adverse effects on health [56, 58]. In the BACH study, it was found that men who reported having experienced sexual, physical, or emotional abuse had increased odds (3.3 compared to 1.7) for symptoms suggestive of CPP. The authors suggested that clinicians may wish to screen for abuse in men presenting with symptoms suggestive of CPP. Conversely, clinicians may wish to inquire about pelvic pain in patients who have experienced abuse [59].

#### 3.1.5.2 *Underlying causes*

The mechanisms that serve as an underlying cause for chronic pelvic pain are:

1. Ongoing acute pain mechanisms [60] (such as those associated with inflammation or infection), which may involve somatic or visceral tissue.
2. Chronic pain mechanisms, which especially involve the CNS [6].
3. Emotional, cognitive, behavioural and sexual responses and mechanisms [61-63].

Symptoms and signs of neuropathic pain appear to be common in CPP patients and assessment of neuropathic pain should be considered in that group of patients. The presence or absence of endometriosis does not seem to change this [64].

Chronic pain mechanisms may include altered resting state neuromotor connectivity, for instance in men with chronic prostatitis/CPPS [65].

Table 3 illustrates some of the differences between the somatic and visceral pain mechanisms. These underlie some of the mechanisms that may produce the classical features of visceral pain; in particular, referred pain and hyperalgesia.

**Table 3: Comparison between visceral and somatic pain**

	<b>Visceral pain</b>	<b>Somatic pain</b>
<b>Effective painful stimuli</b>	Stretching and distension, producing poorly localised pain.	Mechanical, thermal, chemical and electrical stimuli, producing well localised pain.
<b>Summation</b>	Widespread stimulation produces significantly magnified pain.	Widespread stimulation produces a modest increase in pain.
<b>Autonomic involvement</b>	Autonomic features (e.g., nausea and sweating) frequently present.	Autonomic features less frequent.
<b>Referred pain</b>	Pain perceived at a site distant to the cause of the pain is common.	Pain is relatively well localised but well recognised.
<b>Referred hyperalgesia</b>	Referred cutaneous and muscle hyperalgesia is common, as is involvement of other visceral organs.	Hyperalgesia tends to be localised.
<b>Innervation</b>	Low density, unmyelinated C fibres and thinly myelinated A $\delta$ fibres.	Dense innervation with a wide range of nerve fibres.
<b>Primary afferent physiology</b>	Intensity coding. As stimulation increases, afferent firing increases with an increase in sensation and ultimately pain.	Two fibre coding. Separate fibres for pain and normal sensation.
<b>Silent afferents</b>	50-90% of visceral afferents are silent until the time they are switched on.	These fibres are very important in the central sensitisation process. Silent afferents present, but form a lower percentage.
<b>Central mechanisms</b>	Play an important part in the hyperalgesia, viscerovisceral, visceromuscular and muscoviceral hyperalgesia.	Sensations not normally perceived become perceived and non-noxious sensations become painful. Responsible for the allodynia and hyperalgesia of chronic somatic pain.
<b>Abnormalities of function</b>	Central mechanisms associated with visceral pain may be responsible for organ dysfunction.	Somatic pain associated with somatic dysfunction, e.g., muscle spasm.
<b>Central pathways and representation</b>	As well as classical pathways, there is evidence for a separate dorsal horn pathway and central representation.	Classical pain pathways.

#### **Ongoing peripheral pain mechanisms in visceral pain**

In most cases of CPP, ongoing tissue trauma, inflammation or infection is absent [66-69]. However, conditions that produce recurrent trauma, infection or ongoing inflammation may result in CPP in a small proportion of cases. For example, out of a large cohort with acute bacterial prostatitis, 10.5% ended up with a state of CPPS [70]. It is for this reason that the early stages of assessment include looking for these pathologies [11]. Once excluded, ongoing investigations for these causes are rarely helpful and indeed may be detrimental.

When acute pain mechanisms are activated by a nociceptive event, as well as direct activation of the peripheral nociceptor transducers, sensitisation of those transducers may also occur; therefore, magnifying the afferent signalling. Afferents that are not normally active may also become activated by the change, that is, there may be activation of the so-called silent afferents. Although these are mechanisms of acute pain, the increased afferent signalling is often a trigger for the chronic pain mechanisms that maintain the perception of pain in the absence of ongoing peripheral pathology (see below) [71, 72].

There are a number of mechanisms by which the peripheral transducers may exhibit an increase in sensibility:

1. Modification of the peripheral tissue, which may result in the transducers being more exposed to peripheral stimulation.
2. There may be an increase in the chemicals that stimulate the receptors of the transducers [73].
3. There are many modifications in the receptors that result in them being more sensitive.



In general, the effect of 1 and 2 is to lower the threshold and the effect of 3 is to increase responsiveness to external stimuli. Some of the chemicals responsible for the above changes may be released from those cells associated with inflammation, but the peripheral nervous system may also release chemicals in the positive and inhibitory loops [74-76].

### **Central sensitisation as a mechanism in visceral pain**

It is important to appreciate that nociception is the process of transmitting information to centres involved in perception of a stimulus that has the potential to cause tissue damage. Pain is far more complex and involves activation of the nociceptive pathways but also the emotional response. The brain may affect the modulation of pain pathways at the spinal cord level.

Central sensitisation [77] is responsible for a decrease in threshold and an increase in response duration and magnitude of dorsal horn neurons. It is associated with an expansion of the receptive field. As a result, sensitisation increases signalling to the CNS and amplifies what we perceive from a peripheral stimulus. For example, for cutaneous stimuli, light touch would not normally produce pain, however, when central sensitisation is present, light touch may be perceived as painful (allodynia). In visceral hyperalgesia (so called because the afferents are primarily small fibres), visceral stimuli that are normally sub-threshold and not usually perceived, may be perceived. For instance, with central sensitisation, stimuli that are normally sub-threshold may result in a sensation of fullness and a need to void or to defecate. Non-noxious stimuli may be interpreted as pain and stimuli that are normally noxious may be magnified (true hyperalgesia) with an increased perception of pain. As a consequence, one can see that many of the symptoms of BPS and IBS may be explained by central sensitisation. A similar explanation exists for the muscle pain in FM.

It is now well accepted that there are both descending pain-inhibitory and descending pain-facilitatory pathways that originate from the brain [78]. Several neurotransmitters and neuromodulators are involved in descending pain-inhibitory pathways. The main ones are the opioids, 5-hydroxytryptamine and noradrenaline.

The autonomic nervous system also plays a role in sensitisation. There is good evidence that damaged afferent fibres may develop a sensitivity to sympathetic stimulation, both at the site of injury and more centrally, particularly in the dorsal horns. In visceral pain, the efferent output of the CNS may be influenced by central changes (again, those changes may be throughout the neuraxis), and such modification of the efferent message may produce significant end-organ dysfunction. These functional abnormalities can have a significant effect on QoL and must be managed as appropriate.

### **Psychological mechanisms in visceral pain**

Psychological processes of emotions, thought and behaviour involve networks rather than distinct centres. Some of these processes are sophisticated and others fundamental in evolutionary terms, and their interaction with pain processing is complex.

Various psychological processes affect pain neuromodulation at a higher level. Inhibiting or facilitating both the nociceptive signal reaching the consciousness and appraisal and interpretation of that signal, will also modulate the response to the nociceptive message and hence the pain experience. Further, descending pathways represent cognitive, emotional and behavioural states at spinal and peripheral levels. Functional magnetic resonance imaging (fMRI) has indicated that the psychological modulation of visceral pain probably involves multiple pathways. For instance, mood and attentional focus probably act through different areas of the brain when involved in reducing pain [79].

This psychological modulation may act to reduce nociception within a rapid time frame but may also result in long-term vulnerability to chronic visceral pain, through long-term potentiation. This involvement of higher centre learning may be at both a conscious and subconscious level, and is clearly significant in the supratentorial neuroprocessing of nociception and pain. Long-term potentiation [80] may occur at any level within the nervous system, so that pathways for specific or combinations of stimuli may become established, resulting in an individual being vulnerable to perceiving sensations that would not normally be experienced as painful.

An important review [28] of CPP in women identifies the notion that women without physical findings to which pain can be causally attributed differ in psychological characteristics from women with physical findings. It argues for better methodology, and for greater use of idiographic methods. Women with pelvic pain often have other non-pain somatic symptoms, and current or lifetime anxiety and depression disorder [19]; they may have a history of physical or sexual abuse in childhood of unclear significance. Studies that describe these non-pain

somatic symptoms as ‘medically unexplained’ or ‘psychosomatic’ or ‘somatoform’ disorders are unhelpful, misinterpreting absence of physical finding to indicate psychological origins of the complaint [81, 82]. Pain studies describe multiple processes by which pain may spread from one site to another, or in time, including central sensitisation (see previous section), viscerovisceral cross sensitisation in relation to multiple pain sites [83], activation of the hypothalamic-pituitary axis and dysregulation of serotonergic pathways [84] that can render pain levels sensitive to stress. Some pain problems which affect sexual activity are diagnosed as sexual problems (e.g. ‘dyspareunia’) when pain is the central problem and not contingent on sexual activity alone [85]. Better integration of sexology and mainstream psychology for pelvic pain in both men and women is needed [86], building on a biopsychosocial formulation [87, 88].

The term psychosomatic symptoms can best be understood as multiple somatic symptoms not associated with or indicative of any serious disease process. Medical and surgical history may also be important [89]. There have been a few studies of maintenance of, or recovery from, pelvic pain in relation to psychological factors of importance in pain. Those that described pelvic pain as medically unexplained or psychosomatic, due to the lack of physical findings, have been discarded, because such a distinction is inconsistent with known pain mechanisms [81].

### **Understanding the psychological components of pain**

Psychological processes of emotions, thought and behaviour involve networks rather than distinct centres, and their interaction with pain processing is complex, producing inhibition and facilitation of signal processing, appraisal, and response. Models that integrate the psychological factors consistently found to be relevant in the maintenance of persistent pelvic and urogenital pain with current neurobiological understanding of pain are few but the quality is high (see 3.1.5.1).

There is no evidence that women with CPP without physical findings are primarily presenting a psychological problem [28]. Anxiety and post-traumatic stress symptoms are common in some women with CPP [39, 90] and with vulvar pain [91], and may account for substantial variance in health status, treatment use and treatment outcome; for instance, women’s expectations about vulvar pain on penetration predicted pain, sexual function and sexual satisfaction [92]. Negative investigative findings do not necessarily resolve women’s anxieties about the cause of pain [93, 94] and anxiety often focuses on what might be ‘wrong’ [95]. Depression may be related to pain in various ways, as described above. Until measures are available that are adequately standardised in patients with pain, anxiety and distress may be best assessed by questions about concerns about the cause of pain, the hope that diagnosis will validate pain, the struggle with unpredictability, and the implications of pain for everyday life [96, 97]. Reference to the studies of the IMMPACT group [98] is recommended for guidance on outcome measures suitable for pain trials.

Stress can modify the nervous system to produce long-term biological changes. These structural changes may be responsible for significant early life and adverse life events which are associated with chronic pain syndromes [31]. The patient should be asked about adverse life events that may produce these biological responses and affect a patient’s general psychological well-being [30, 31, 99].

#### *3.1.5.3 Clinical paradigms in visceral pain*

##### **Referred pain**

Referred pain is frequently observed and its identification is important for diagnosis and treatment. Referral is usually somatic to somatic, or visceral to somatic. However, there is no reason why pain cannot also be perceived within the area of an organ with the nociceptive signal having arisen from a somatic area. Referred pain may occur as a result of several mechanisms but the main theory is one of convergence-projection. In the convergence-projection theory, afferent fibres from the viscera and the somatic site of referred pain converge onto the same second order projection neurons. The higher centres receiving messages from these projection neurons are unable to separate the two possible sites from the origin of the nociceptive signal [67, 71, 100].

Hyperalgesia refers to an increased sensitivity to normally painful stimuli. In patients that have passed a renal stone, somatic muscle hyperalgesia is frequently present, even a year after expulsion of the stone. Pain to non-painful stimuli (allodynia) may also be present in certain individuals. Somatic tissue hyperaesthesia is associated with urinary and biliary colic, IBS, endometriosis, dysmenorrhoea, and recurrent bladder infections. Vulvar pain syndromes are examples of cutaneous allodynia that, in certain cases, may be associated with visceral pain syndromes, such as BPS. Referred pain with hyperalgesia is thought to be due to central sensitisation of the converging viscerosomatic neurons. Central sensitisation also stimulates efferent activity that could explain the trophic changes that are often found in the somatic tissues.

## **Muscles and pelvic pain**

In the urogenital pain syndromes, muscle tenderness and trigger points may be implicated as a source of pain. Central mechanisms are of great importance in the pathogenesis of this muscle hyperalgesia. The muscles involved may be a part of the spinal, abdominal or pelvic complex of muscles. It is not unknown for adjacent muscles of the lower limbs and the thorax to become involved. Pain may be localised to the trigger points but it is more often associated with classical referral patterns. As well as trigger points, inflammation of the attachments to the bones (enthesitis) and of the bursa (bursitis) may be found [101]. Certain postures affect the different muscles in different ways, and as a consequence, may exacerbate or reduce the pain. Stress has been implicated as both an initiator of pelvic myalgia and as a maintenance factor. As a result, negative sexual encounters may also have a precipitating effect [28].

## **Visceral hyperalgesia**

The increased perception of stimuli in the viscera is known as visceral hyperalgesia, and the underlying mechanisms are thought to be responsible for IBS, BPS and dysmenorrhoea. The mechanisms involved are often acute afferent input (e.g., due to infection) followed by long-term central sensitisation. Viscero-visceral hyperalgesia is thought to be due to two or more organs with converging sensory projections and central sensitisation. For instance, overlap of bladder and uterine afferents or uterine and colon afferents.

## **3.2 Pelvic Pain**

### **3.2.1 Incidence**

No adequate data on incidence were found.

### **3.2.2 Prevalence**

#### **3.2.2.1 Prostate Pain syndrome**

There is only limited information on the true prevalence of PPS in the population. As a result of significant overlap of symptoms with other conditions (e.g. benign prostatic enlargement and BPS), purely symptom-based case definitions may not reflect the true prevalence of PPS [102, 103]. In the literature, population-based prevalence of prostatitis symptoms ranges from 1 to 14.2% [104, 105]. The risk of prostatitis increases with age (men aged 50-59 years have a 3.1-fold greater risk than those aged 20-39 years).

#### **3.2.2.2 Bladder Pain syndrome**

Reports of BPS prevalence have varied greatly, along with the diagnostic criteria and populations studied. Recent reports range from 0.06% to 30% [106-115]. There is a female predominance of about 10:1 [112, 116-118] but possibly no difference in race or ethnicity [102, 119, 120]. The relative proportions of classic and non-lesion disease are unclear. Incidence in studies has ranged from 5 to 50% [121-125]. There is increasing evidence that children under eighteen may also be affected, although prevalence figures are low; therefore, BPS cannot be excluded on the basis of age [126].

#### **3.2.2.3 Sexual pain syndrome**

In the 1980s an association between CPP and sexual dysfunction was postulated. In two reviews the relationship between PPS and health status, with influence on sexual activity, was addressed [127, 128]. In a Chinese study of men with CPP, 1,768 males completed the questionnaires. The overall prevalence of sexual dysfunction was 49%. Erectile dysfunction (ED) is the most investigated sexual dysfunction in PPS patients. The reported prevalence of ED ranges from 15.1% to 48%, varying with evaluation tools and populations [129, 130]. Erectile dysfunction was prevalent in 27.4% of Italian men aged 25-50 [131], 15.2% among Turkish men (significantly higher than in the control group) [132] and 43% among Finnish men with PPS [133]. The prevalence of ED was found to be higher in young men with PPS than in the general population. According to other studies men with pelvic pain had a higher chance of suffering from ED [134, 135]. Recently, a significant correlation between "chronic prostatitis", CPP symptoms (measured by NIH-CPSI) and ED (measured by International Index of Erectile Function [IIEF]) was confirmed [136], while other studies using the same questionnaires were not able to confirm such a correlation [88, 137]. Some studies also report ejaculatory dysfunction, mainly premature ejaculation [129, 130, 138, 139].

In community-based studies in the UK [140], New Zealand [141] and Australia [142], a substantially larger proportion of the women with CPP reported dyspareunia (varying between 29% and 42%) than women without CPP (varying between 11% and 14%). Only a few studies have investigated sexual problems within clinical populations [143]. Another study showed that all of the sexual function domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) were significantly lower in women with CPP than in women without CPP [143]. In line with the results of community based studies, patients with CPP reported more sexual problems such as dyspareunia, problems with desire or arousal and lubrication than women without CPP [143-145]. One study of

patients enrolled in chronic pain treatment programs in England has reported that 73% had pain-related sexual problems [146].

#### 3.2.2.4 *Myofascial pain syndromes*

The relationship between muscular dysfunction (especially over-activity) and pelvic pain has been found in several studies [147]. Rectal pain treated with pelvic floor muscle therapy is only relieved when patients learn to relax their pelvic floor muscles [148, 149]. The vast majority (92.2%) of men visiting a tertiary centre for pelvic pain had dysfunction of the pelvic floor muscles. This finding was true regardless of evidence of inflammation (prostatitis or cystitis) [150]. This relationship has been found in chronic prostatitis [151], BPS [152] and vulvar pain [153]. Dysfunction of the pelvic floor directly affects function of the pelvic viscera and vice versa. Both systems can act as the primary signal to the spinal cord, with a cascade of reactions ascending to the CNS as a result. The muscle itself ends up with a diminished length, leading to restrictions even when it is in a relaxed state.

#### 3.2.3 **Influence on QoL**

Data on the influence on QoL will be included in the next version of the guidelines.

#### 3.2.4 **Costs**

No adequate data on costs were found.

#### 3.2.5 **Risk factors and underlying causes**

The risk factors are unspecific for most of the pain syndromes in the pelvic area. They are described in 3.1.5.1. The underlying causes, including the mechanisms for the different clinical pain syndromes are described here.

##### 3.2.5.1 *Prostate Pain Syndrome*

Pain is the main symptom in PPS. As a common feature of chronic pain syndromes, no single aetiological explanation has been found. One explanation [154] is that the condition probably occurs in susceptible men exposed to one or more initiating factors, which may be single, repetitive or continuous. Several of these potential initiating factors have been proposed, including infectious, genetic, anatomical, neuromuscular, endocrine, immune (including autoimmune), or psychological mechanisms. These factors may then lead to a peripheral self-perpetuating immunological, inflammatory state and/or neurogenic injury, creating acute and then chronic pain. One recent study showed that chronic but not acute histological inflammation of the prostate was significantly associated with symptomatic progression [155]. Based on the peripheral and the central nervous system, sensitisation involving neuroplasticity may lead to a centralised neuropathic pain state [154]. This could also explain why tissue damage is not usually found in PPS. There is growing evidence for a neuropathic origin and association with CNS changes of pain in PPS and anxiety appears to be a risk factor for its development [46].

##### 3.2.5.2 *Bladder Pain syndrome*

An initial unidentified insult to the bladder, leading to urothelial damage, neurogenic inflammation and pain is thought to be the cause of BPS. However, BPS might be a local manifestation of a systemic disorder. No infection has as yet been implicated. Nevertheless, urinary infection is significantly more frequent during childhood and adolescence, in patients with BPS in adulthood [156]. Experimental induction of CPP by O-antigen deficient bacterial strains reinstates the bacterial hypothesis [157]. Pancystitis, with associated perineural inflammatory infiltrates, and mast cell count increase is an essential part of BPS type 3 C [158], but is scant in non-lesion BPS [31, 79, 159, 160]. Cystoscopic and biopsy findings in both lesion and non-lesion BPS are consistent with defects in the urothelial glycosaminoglycan (GAG) layer, which might expose submucosal structures to noxious urine components [161-168] and a consequent cytotoxic effect [169, 170]. Basic and clinical studies indicate that autonomic dysfunction with sympathetic predominance may be implicated in BPS [171, 172].

An association has been reported between BPS and non-bladder syndromes such as FM, CFS, IBS, vulvodynia, depression, panic disorders, migraine, sicca syndrome, temporomandibular joint disorder, allergy, asthma and systemic lupus erythematosus [173-179].

Risk of BPS correlates with a number of non-bladder syndromes in each patient [180]. Recent work showing non-lesion BPS to have significantly more FM, migraine, temporomandibular joint disorder and depression than BPS type 3 C patients, emphasises the need for subtyping [181].

##### 3.2.5.3 *Scrotal Pain Syndrome*

Often scrotal pain is not associated with any specific pathology. Pain is perceived in the testes, epididymis, or the vas deferens. The ilioinguinal, genitofemoral and the pudendal nerves innervate the scrotum [182]. Any

pathology or intervention at the origin or along the course of the nerves may result in pain perceived in the scrotum [183].

Two special forms of scrotal pain syndrome can be described. The first is post-vasectomy scrotal pain syndrome which occurs following vasectomy. The mechanisms are poorly understood and it is for that reason considered a special form of scrotal pain syndrome. Incidence of post-vasectomy pain is 2-20% among all men who have undergone a vasectomy [184]. In men with post-vasectomy pain, 2-6% have a Visual Analogue Scale (VAS) score > 5 [185]. In a large cohort study of 625 men, the likelihood of scrotal pain after six months was 14.7%. The mean pain severity on a VAS score was 3.4/10. In the pain group, 0.9% had quite severe pain, noticeably affecting their daily life. In this cohort, different techniques were used to perform the vasectomy. The risk of post-vasectomy pain was significantly lower in the no-scalpel vasectomy group (11.7% vs. the scalpel group 18.8%) [186].

The second special form of scrotal pain is post-inguinal hernia repair pain. It is seen as a complication of hernia repair, but in trials it is seldom reported or it is put under the term chronic pain (not specified). In studies that have explicitly mentioned scrotal pain, there was a difference in incidence between laparoscopic and open hernia repair. In almost all studies, the frequency of scrotal pain was significantly higher in the laparoscopic than in the open group [183, 187]. In one particular study, there was no difference at one year but after five years, the open group had far fewer patients with scrotal pain [188].

#### 3.2.5.4 Urethral Pain Syndrome

Some mechanisms for the development of urethral pain syndrome have been proposed. The intimate relationship of the urethra with the bladder (both covered with urothelium) suggests that urethral pain syndrome may be a form of BPS. Mechanisms thought to be basic for BPS may also apply to the urethra. This means that the specific testing with potassium has been used to support the theory of epithelial leakage [189, 190]. Another possible mechanism is neuropathic hypersensitivity following urinary tract infection [191]. The relationship with gynaecological and obstetric aspects is unclear. In a small group of patients with urethral pain, it has been found that grand multi-parity and delivery without episiotomy were more often seen in patients with urethral syndrome, using univariate analysis [192].

#### 3.2.5.5 Vaginal and vulvar pain syndromes

Pain in the vagina or the female external genital organs is often due to infection or trauma, as a consequence of childbirth or surgery. Pain is usually a precedent to dyspareunia. When the pain persists for more than six months, it can be diagnosed as vulvar pain syndrome previously known as “vulvodinia” or “chronic vaginal pain” with no known cause. It is still a poorly understood condition, and therefore difficult to treat.

There are two main sub-types of vulvar pain syndrome: generalised, where the pain occurs in different areas of the vulva at different times; and focal, where the pain is at the entrance of the vagina. In generalised vulvar pain syndrome, the pain may be constant or occur occasionally, but touch or pressure does not initiate it, although it may make the pain worse. In focal vulvar pain syndrome, the pain is described as a burning sensation that comes on only after touch or pressure, such as during intercourse.

The possible causes of vulvar pain syndrome are many and include:

- history of sexual abuse;
- history of chronic antibiotic use;
- hypersensitivity to yeast infections, allergies to chemicals or other substances;
- abnormal inflammatory response (genetic and non-genetic) to infection and trauma;
- nerve or muscle injury or irritation;
- hormonal changes.

#### 3.2.5.6 Chronic Pelvic Pain and Prolapse/Incontinence Mesh

Continence and prolapse mesh implants were developed as simple flexible polypropylene plastic acting as a scaffold to treat urinary stress incontinence (USI) and uterovaginal prolapse, respectively. They were deemed easy to insert, but no credence was given as to how safe they were, whether they could be removed should they cause complications, or what to do should they not be effective [193-195]. Most meshes took less than an hour to implant surgically and most patients were treated as day cases, allowing women to leave hospital quickly and get on with their lives. Therefore, rather than undergo complex traditional surgery, women were offered permanent mesh implants, particularly in the treatment of USI where they were considered to be the gold standard [196, 197]. However, over the last few years the insertion of mesh has come with significant ‘health and safety warnings’ [198].

For many, mesh was initially seen not just as an effective treatment but as a permanent one. Complications were thought not to be a significant issue and the figure of 1-3% was often quoted. However, we now know the complication rate was closer to 10% [199]. They included chronic pain [200, 201], as well as chronic infections [202], erosion into the surrounding organs including the vagina, urethra and bladder, as well as nerve and musculo-skeletal damage affecting mobility [200, 203-205]. All had a significant impact on the patients' QoL.

It is as a result of severely debilitating complications following mesh implantation [200, 206], that the field of mesh removal medicine and surgery has emerged.

Early recognition of possible mesh complications is very important. It is normal to wake up in some degree of discomfort after any surgery. However, if the pain after the operation is very severe and much more than expected after this type of surgery, it can be a sign that there was added trauma to the surrounding organs during the procedure. Most pain is often managed with analgesia, but some women might not fully respond to therapy. If the pain is difficult to treat and does not improve over time, it may become necessary to remove the mesh [206]. Leaving a painful mesh in the pelvis, can lead to CPP. The precise mechanism is unknown but it is thought to be a 'neuro-inflammatory' process [207], as has been proposed in hernia mesh neuralgia [208]. The impact of the mesh, regardless of site, appears to be similar.

### 3.2.5.7 *Associated conditions in pelvic pain syndromes*

#### **Nerve damage**

Spinal pathology and any pathology along the course of the nerve involved may result in neuropathic pain in the distribution of these nerves. Neoplastic disease, infection and trauma, surgical incisions and post-operative scarring may result in nerve injury [209].

Pudendal neuralgia is the most often mentioned form of nerve damage in the literature. Anatomical variations may pre-dispose the patient to developing pudendal neuralgia over time or with repeated low-grade trauma (such as sitting for prolonged periods of time or cycling) [210, 211].

The pudendal nerve may be damaged at the level of:

1. The piriformis muscle. For example, as part of a piriformis syndrome: in some cases, the nerve may pass through the muscle and hence be trapped; or in other cases, muscle hypertrophy or spasm is implicated.
2. The sacrospinal/sacrotuberous ligaments, possibly accounting for 42% of cases.
3. Within Alcock's canal (medial to the obturator internus muscle, within the fascia of the muscle), possibly accounting for 26% of cases.
4. Multiple levels in 17% of cases.

The site of injury determines the site of perceived pain and the nature of associated symptoms (e.g., the more distal the damage, the less likely the anal region will be involved).

The clinical presentation depends on different factors. There is a wide age range, as one would expect with a condition that has so many potential causes. There is a suggestion that, the younger the patient, the better the prognosis. Essentially, the sooner the diagnosis is made, as with any compression nerve injury, the better the prognosis, and older patients may have a more protracted problem [212-214]. Six out of ten cases are observed in women. Some special situations can be listed:

- In orthopaedic hip surgery, pressure from the positioning of the patient, where the perineum is placed hard against the brace, can result in pudendal nerve damage [215, 216]. The surgery itself may also directly damage the nerve. Pelvic surgery such as sacrospinous fixation is clearly associated with pudendal nerve damage in some cases [217, 218]. In many types of surgery, including colorectal, urological and gynaecological, pudendal nerve injury may be implicated.
- Fractures of the sacrum or pelvis may result in pudendal nerve/root damage and pain. Falls and trauma to the gluteal region may also produce pudendal nerve damage if associated with significant tissue injury or prolonged pressure.
- Tumours in the pre-sacral space must be considered. Tumours invading the pudendal nerve may occur and there may also be damage from surgery for pelvic cancer [219].
- The pudendal neuralgia of birth trauma is thought to resolve in most cases over a period of months. However, rarely, it appears to continue as painful neuropathy. Multiple pregnancies and births may predispose to stretch neuropathy in later life. This is more difficult to be certain about [220].
- Child birth and repeated abdominal straining associated with chronic constipation [221] are thought to pre-dispose elderly women to post-menopausal pelvic floor descent and stretching of the pudendal nerve with associated pain. Changes in the hormone status may also be a factor. In Urogenital Pain Management Centres, the commonest associations with pudendal neuralgia appear to be: history of

pelvic surgery; prolonged sitting (especially young men working with computer technology); and post-menopausal older women.

### **Sexual dysfunction**

Chronic pelvic pain is a clinical condition that results from the complex interactions of physiological and psychological factors and has a direct impact on the social, marital and professional lives of men and women.

#### *Men*

Chronic pain and its treatment can impair our ability to express sexuality. In a study in England, 73% of patients with chronic pain had some degree of sexual problems as a result of the pain [146]. These problems can occur because of several factors. Psychological factors like decrease in self-esteem, depression and anxiety can contribute to loss of libido. Physiological factors like fatigue, nausea and pain itself can cause sexual dysfunction. Pain medications (opioids, and the selective serotonin re-uptake inhibitors [SSRIs]) can also decrease libido [222] and delay ejaculation. The number of studies on the effects of CPP on sexual function is limited. Sexual dysfunction is often ignored because of a lack of standardised measurements. At present, the most commonly used tool is the IIEF questionnaire [137].

The presence of pelvic pain may increase the risk for ED independent of age [223-225]. On the other hand, cross-sectional data suggest no improvement of lower urinary tract symptoms (LUTS) by an increased frequency of ejaculation [128]. Although mental distress and impaired QoL related to illness could contribute to sexual dysfunction observed in patients with PPS, the presence of erectile and ejaculatory disorders is more frequently related to symptoms suggestive of a more severe inflammatory condition [139]. These arguments are important for the understanding of the close relationship between CPP symptoms, disturbed sexuality, impact on QoL, and psychological implications including depression and more failure anticipation thoughts [127-130, 226, 227]. Sexual dysfunction heightens anger, frustration and depression, all of which place a strain on the patients' relationships. The female partners of men with sexual dysfunction and depression often present with similar symptoms including pain upon intercourse and depressive symptoms. Men with CPP have reported a high frequency of sexual relationship dissolution and psychological symptoms, such as depression and suicidal thinking [127, 224]. Prostate Pain Syndrome patients reported greater sexual and relationship problems [127, 224, 228]. On the other hand, it was found that men with PPS did not report significantly decreased sexual satisfaction compared to controls [229]. There is consensus that therapeutic strategies reducing symptoms of pelvic pain are of relevance in relation to changes in sexual function. Also intimacy and having sex can yield positive experiences that will reduce the pain. The CNS plays an important role in this mechanism.

#### *Women*

Chronic pelvic pain leads to substantial impairment in QoL and several sexual dysfunctions [141, 230-232]. It seems reasonable to expect that pain, extreme fatigue, depressive mood and pain drugs will affect women's sexuality. Women with CPP reported significantly more pain, depression, and anxiety symptoms and were physically more impaired than women in the control group. In comparison with controls, women with CPP reported significantly more sexual avoidance behaviour, non-sensuality, and complaints of "vaginismus" [233]. In one study of CPP patients' feelings and beliefs about their pain or illness, 40 out of 64 participants cited sexual dysfunction as one of the main problems the illness had caused, making it the most frequent complaint [234]. Patients with CPP reported more sexual problems than women with any other type of chronic pain problem [235]. The quality of intimate relationships is closely connected with sexual function [236]. Satisfaction with sexual relationships appears to be associated with higher marital functioning [237]. In addition sexual dissatisfaction is related to sexual dysfunction. When one partner suffers from chronic pain, the ability of both partners to cope with the pain and the extent to which partners are supportive of the chronic pain sufferer have been found to be a predictor of sexual functioning [237].

Approximately two-thirds of patients in another study reported reduced frequency in their sexual relations as a result of CPP [238]. One study demonstrated that CPP patients reported worse sexual function with regard to desire, arousal, lubrication, orgasm, satisfaction, and more frequent and severe pain with vaginal penetration than women without CPP [239]. In an interview with 50 chronic pain sufferers and their spouses, 78% of the pain sufferers and 84% of partners described deterioration, including cessation of their sex life [223]. In a study in patients with back pain, half reported decreased frequency of sex since the onset of chronic pain [146]. The Female Sexual Function Index (FSFI) has been developed as a brief, multi-dimensional self-report instrument for assessing the key dimensions of sexual function in women, which includes desire, subjective arousal, lubrication, orgasm, satisfaction, and pain. Using the FSFI, women with CPP reported worse sexual function in all subscales and total score than women without CPP. The largest differences between women with CPP and without CPP were seen for the domains of pain and arousal. The total score and the subscales of the FSFI had

high levels of internal consistency and test-retest reliability when assessed in a sample of women with CPP. The FSFI also showed good ability to discriminate between women with and without CPP [239].

### **Myofascial pain**

Chronic pelvic pain can simply be a form of myalgia, due to the muscles being used in an abnormal way, in this case, the pelvic floor muscles. Studies in the field of chronic prostatitis support the idea that patients with CPP have more muscle spasm and increased muscle tone and report pain when the pelvic floor muscles are palpated [240]. Muscle relaxation can diminish spasm and pain [241]. Repeated or chronic muscular overload can activate trigger points in the muscle. A report from the Chronic Prostatitis Cohort Study showed that 51% of patients with prostatitis and only 7% of controls had any muscle tenderness. Tenderness in the pelvic floor muscles was only found in the CPP group [151].

In 1999, the first ideas about the neurological aspects of the pelvic floor muscles in relation to CPP were published. The probability of CNS breakdown in the regulation of pelvic floor function was suggested as a mechanism for development of CPP. Of the patients presenting with pelvic pain, 88% had poor to absent pelvic floor function [150]. Basic studies on the role of neurogenic inflammation have also elucidated some important phenomena. Irritation of the prostate, bladder and pelvic floor muscles results in expression of C-fos-positive cells in the CNS. There appears to be convergence of afferent information onto central pathways. Once the central changes have become established, they become independent of the peripheral input that initiated them [242].

Repeated or chronic muscular overload can activate trigger points in the muscle. Trigger points are defined as hyper-irritable spots within a taut band. Other criteria for trigger points are recognition of the pain as 'familiar', and pain on stretching the muscle. Apart from pain, trigger points prevent full lengthening of the muscle, thereby restricting the range of movement. Pain as a result of these trigger points is aggravated by specific movements and alleviated by certain positions. Positions and movements in which the shortened muscle is stretched are painful. Patients know which activities and postures influence pain. Trigger points can be located within the pelvic floor muscles and in adjacent muscles such as the abdominal, gluteal and iliopsoas muscles. Pain is aggravated by pressure on the trigger point (e.g., pain related to sexual intercourse). Pain also worsens after sustained or repeated contractions (e.g., pain related to voiding or defecation).

## **3.3 Abdominal aspects of pelvic pain**

### **3.3.1 Incidence**

Epidemiological data on IBS and CPP are scarce [243]. Chronic Pelvic Pain has been shown to be one of the most common functional disorders in women of reproductive age. The monthly incidence rate of CPP published by Zondervan *et al.* was 1.58/1000 [244].

### **3.3.2 Prevalence**

Using a vague definition of continuous or episodic pain situated below the umbilicus over six months, one study reported that CPP was one of the most common diagnosis in primary care units in Great Britain [244]. The monthly prevalence rate of CPP in this study was 21.5/1,000, with an annual prevalence of 38.3/1,000. The prevalence rates increase significantly with older age and vary significantly between regions in the UK. The overall prevalence of anorectal pain in a sample of USA householders was 6.6% and was more common in women [245]. Irritable Bowel Syndrome is associated with common gynaecologic problems (endometriosis, dyspareunia, and dysmenorrhoea) [246]. Fifty per cent of women who presented with abdominal pain to the gynaecologic clinic or were scheduled for laparoscopy due to CPP had symptoms of IBS [247]. In a survey from Olmsted county 20% of women reported CPP and 40% of those met criteria for IBS [20]. This overlap of CPP and IBS was associated with an increased incidence of somatisation. Not gynaecological surgical procedures but only psychosocial variables predict pain development without a different incidence of IBS in a prospective and controlled study [248]. Clinical features of pelvic floor dysfunction, gynaecological and psychological features are related to disordered anorectal function in IBS patients but do not predict physiological anorectal testing.

### **3.3.3 Influence on QOL**

There is little known on health related quality of life (HRQoL) in patients with CPP. There is a need to develop validated disease specific HRQoL instruments for CPP in addition to sound measurement properties. More data are available in patients with IBS treated at referral centres who have comparable HRQoL scores as patients with other common disorders such as diabetes, end-stage renal disease, and inflammatory bowel disease [249]. Sub-groups of IBS with predominance of diarrhoea or constipation show no difference in



HRQoL. Multi-variate analysis shows that HRQoL in patients with IBS is affected by sex and psychological conditions.

### 3.3.4 **Costs**

Costs combine direct health-care costs and societal costs (productivity loss) such as under-performance and absenteeism from work. The annual costs to society can be calculated by using the average population earnings. In Germany direct care costs are estimated at € 791 and societal costs € 995 per patient with IBS per year which may be comparable to patients with CPP [250].

### 3.3.5 **Risk factors & underlying causes**

Risk factors are covered in Section 3.1.5.

## 3.4 **Summary of evidence and recommendations: CPP and mechanisms**

Summary of evidence	LE
CPP mechanisms are well defined and involve mechanisms of neuroplasticity and neuropathic pain.	2
The mechanisms of neuroplasticity and neuropathic pain result in increased perception of afferent stimuli which may produce abnormal sensations as well as pain.	1
End-organ function can also be altered by the mechanisms of neuroplasticity so that symptoms of function can also occur.	1
The diagnosis of a CPPS as a pain syndrome is essential as it encourages a holistic approach to management with multi-specialty and multi-disciplinary care.	2

Recommendations	Strength rating
All of those involved in the management of Chronic Pelvic Pain (CPP) should have knowledge of peripheral and central pain mechanisms.	Strong
The early assessment of patients with CPP should involve investigations aimed at specific disease-associated pelvic pain.	Strong
The early assessment of patients with CPP should involve assessment of functional, emotional, behavioural, sexual and other quality of life issues, such as effect on work and socialisation.	Strong
Manage CPPS patients in a multi-specialty and multi-disciplinary environment with consideration of all their symptoms.	Strong

## 4. **DIAGNOSTIC EVALUATION**

### 4.1 **General Evaluation**

#### 4.1.1 **History**

History is very important for the evaluation of patients with CPP. Pain syndromes are symptomatic diagnoses, which are derived from a history of pain perceived in the region of the pelvis, and absence of other pathology, for a minimum of three out of the past six months. This implies that specific disease-associated pelvic pain caused by bacterial infection, cancer, drug-induced pathology (e.g. ketamine use) [251], primary anatomical or functional disease of the pelvic organs, and neurogenic disease must be ruled out.

#### 4.1.1.1 **Anxiety, depression, and overall function**

Distress is best understood in the context of pain and of the meaning of pain to the individual and is best assessed ideographically rather than normatively. Almost all diagnostic measures and standardised instruments of anxiety and depression are designed for people without significant physical problems, so are hard to interpret in CPP [252-254].

Anxiety about pain often refers to fears of missed pathology (particularly cancer) as the cause of pain [34], or to uncertainties about treatment and prognosis. These can drive healthcare seeking behaviour [24]. The question: "What do you believe or fear is the cause of your pain?" has been suggested [255]. Anxiety may also concern urinary urgency and frequency as a possible problem in social settings.

Depression or depressed mood are common in chronic pain [256] e.g, often related to losses consequent to chronic pain (work, leisure activities, social relationships, etc.). Due to the lack of suitable assessment instruments, it is better to ask a simple question such as “How does the pain affect you emotionally?” If the answer gives cause for concern about the patient’s emotional state, further assessment should be undertaken by an appropriately qualified colleague.

Most measures of restricted function are designed primarily for musculoskeletal pain and may emphasise mobility problems rather than the difficulties of the individual with pelvic or urogenital pain. A promising specific measure, UPOINT, was introduced and in a later version the sexological aspects were added [257]. However, it may under-assess relevant psychological variables [44]. Generic QoL measures are helpful. If such an instrument is not already used in the clinic, the Brief Pain Inventory [258] provides a broad and economical assessment of interference of pain with various aspects of life in multiple languages. (For further suggested instruments see [259]). In a study, more pain, pain-contingent rest, and urinary symptoms were associated with poorer function [63].

#### 4.1.1.2 *Urological aspects*

Pain may be associated with urological symptoms. A detailed history of lower urinary tract functions should be taken. Dysfunctions of the lower urinary tract may exacerbate symptoms, as pain may interfere with the function of the lower urinary tract. Micturition in all its aspects should be addressed. Special attention should be paid to the influence of micturition on the experience of pain.

#### **Prostate pain syndrome**

Prostate pain syndrome is diagnosed from a history of pain perceived in the region of the prostate (convincingly reproduced by prostate palpation), and absence of other lower urinary tract pathology, for a minimum of three out of the past six months. As mentioned above, specific disease-associated pelvic pain must be ruled out.

A thorough history is an important first step in the evaluation of PPS. It should include type of pain and localisation. Pain is often reported in other pelvic areas outside the prostate such as perineum, rectum, penis, testicles and abdomen [55]. In addition, associated lower urinary tract symptoms, sexual function, psychological, social and economic factors should be addressed. Determination of the severity of disease, its progression and treatment response can be assessed only by means of a validated symptom-scoring instrument (see section 4.2.3). These subjective outcome measures are recommended for the basic evaluation and therapeutic monitoring of patients in urological practice.

#### **Bladder pain syndrome**

Bladder pain syndrome should be diagnosed on the basis of pain, pressure or discomfort associated with the urinary bladder, accompanied by at least one other symptom, such as daytime and/or night-time increased urinary frequency, the exclusion of confusable diseases as the cause of symptoms, and if indicated, cystoscopy with hydrodistension and biopsy (Table 4) [11].

The nature of pain is key to disease definition:

1. pain, pressure or discomfort perceived to be related to the bladder, increasing with increasing bladder content;
2. located suprapubically, sometimes radiating to the groins, vagina, rectum or sacrum;
3. relieved by voiding but soon returns [260-264];
4. aggravated by food or drink [264].

Bladder pain syndrome type 3 can lead to a small capacity fibrotic bladder with or without upper urinary tract outflow obstruction.

#### 4.1.1.3 *Gynaecological aspects*

A detailed medical history outlining the nature, frequency and site of pain; its relationship to precipitating factors and the menstrual cycle, may help define the aetiology. A menstrual and sexual history, including a history of sexually transmitted diseases, vaginal discharge, as well as previous sexual trauma is mandatory as well as up to date cervical cancer screening. A history of obstetric and/or gynaecological surgery is also warranted, particularly if devices such as synthetic mesh were used.

#### 4.1.1.4 *Gastrointestinal aspects*

The predominant symptoms that patients are interviewed about are discomfort or pain in relation to their bowel habits, daily activities, and eating. A precise history of dysfunctional voiding or defecation should be asked, ideally applying symptom questionnaires for urinary and anorectal symptoms (e.g., Rome III criteria for anorectal pain). Excessive straining at most defecations, anal digitations in dyssynergic defecation, and a

sensation of anal blockage may be found in patients with chronic anal pain. History of anxiety and depression with impaired QoL is often encountered in anorectal functional disorders and should be evaluated.

Diagnostic criteria for chronic anal pain syndrome (chronic proctalgia) according to the Rome III criteria are as follows and must include all of the following: chronic or recurrent rectal pain or aching, episodes last at least 20 minutes and exclusion of other causes of rectal pain such as ischaemia, inflammatory bowel disease, cryptitis, intramuscular abscess and fissure, haemorrhoids, prostatitis, and coccygodynia. These criteria should be fulfilled for the past three months with symptom onset at least six months before diagnosis [265].

The chronic anal pain syndrome includes the above diagnostic criteria and exhibits exquisite tenderness during posterior traction on the puborectalis muscle (previously called "Levator Ani Syndrome"). Pathophysiology of pain is thought to be due to over-activity of the pelvic floor muscles.

Intermittent chronic anal pain syndrome (proctalgia fugax) consists of all the following diagnostic criteria, which should be fulfilled for three months: recurrent episodes of pain localised to the anus or lower rectum, episodes last from several seconds to minutes and there is no anorectal pain between episodes. Stressful life events or anxiety may precede the onset of the intermittent chronic anal pain syndrome. The attacks may last from a few seconds to as long as 30 minutes. The pain may be cramping, aching or stabbing and may become unbearable. However, most patients do not report it to their physicians and pain attacks occur less than five times a year in 51% of patients.

#### 4.1.1.5 *Peripheral nerve aspects*

A proportion of patients will be able to relate the onset of pain to an acute event such as surgery, sepsis or trauma, and occasionally, cycling for a prolonged period. Chronic injury is more frequent, such as associated with sitting for prolonged periods over time. Many will be idiopathic.

The pain is classically perceived in the perineum from anus to clitoris/penis. However, less-specific pain distribution may occur, and this may be due to anatomical variation, involvement of branches of the nerve rather than the main nerve, CNS central sensitisation, and consequently, the involvement of other organs and systems in a regional pain syndrome. Other nerves in the vicinity may also be involved, for example, inferior cluneal nerve and perineal branches of the posterior femoral cutaneous nerve. The musculoskeletal system may become involved, confusing the pain picture as aches and pain developing in the muscles due to immobility and disability, possibly magnified by the CNS changes.

Burning is the most predominant adjective used to describe the pain. Crushing and electric may also be used, indicating the two components - a constant pain often associated with acute sharp episodes. Many patients may have the feeling of a swelling or foreign body in the rectum or perineum, often described as a golf or tennis ball. The term pain has different meanings to patients and some would rather use the term discomfort or numbness.

Aggravating factors include any type of pressure being applied, either directly to the nerve or indirectly to other tissue, resulting in pudendal traction. Allodynia is pain on light touch due to involvement of the CNS, and may make sexual contact and the wearing of clothes difficult. These patients often remain standing, and as a consequence, develop a wide range of other aches and pains. Soft seats are often less well-tolerated, whereas sitting on a toilet seat is said to be much better tolerated. If unilateral, sitting on one buttock is common. The pain may be exacerbated by bowel or bladder evacuation.

Pudendal nerve damage may be associated with a range of sensory phenomena. In the distribution of the nerve itself, as well as unprovoked pain; the patient may have paraesthesia (pins and needles); dysaesthesia (unpleasant sensory perceptions usually but not necessarily secondary to provocation, such as the sensation of running cold water); allodynia (pain on light touch); or hyperalgesia (increased pain perception following a painful stimulus, including hot and cold stimuli). Similar sensory abnormalities may be found outside of the area innervated by the damaged nerve, particularly for visceral and muscle hyperalgesia.

The cutaneous sensory dysfunction may be associated with superficial dyspareunia, but also irritation and pain associated with clothes brushing the skin. There may also be a lack of sensation and pain may occur in the presence of numbness. Visceral hypersensitivity may result in an urge to defecate or urinate. This is usually associated with voiding frequency, with small amounts of urine being passed. Pain on visceral filling may occur. Anal pain and loss of motor control may result in poor bowel activity, with constipation and/or incontinence. Ejaculation and orgasm may also be painful or reduced.

Many of those suffering from pudendal neuralgia complain of fatigue and generalised muscle cramps, weakness and pain. Being unable to sit is a major disability, and over time, patients struggle to stand and they often become bedbound. The immobility produces generalised muscle wasting, and minimal activity hurts. As a consequence of the widespread pain and disability, patients often have emotional problems, and in particular, depression. Patients with CPP are also often anxious and have the tendency to catastrophise. Depression, catastrophising and disability are all poor prognostic markers. Cutaneous colour may change due to changes in innervation but also because of neurogenic oedema. The patient may describe the area as swollen due to this oedema, but also due to the lack of afferent perception.

#### 4.1.1.6 *Myofascial aspects*

When taking a history from a patient with pelvic pain, it is important to address the function of all the organs in the pelvic area. The following items certainly should be addressed: lower urinary tract function, anorectal function, sexual function, gynaecological items, presence of pain and psychosocial aspects. One cannot state that there is a pelvic floor dysfunction based only on the history. But there is a suspicion of pelvic floor muscle dysfunction when two or more pelvic organs show dysfunction, for instance a combination of micturition and defecation problems.

#### 4.1.2 **Physical Evaluation**

The clinical examination often serves to confirm or refute the initial impressions gained from a good history. The examination should be aimed at specific questions where the outcome of the examination may change management. Prior to an examination, best practice requires the medical practitioner to explain what will happen and what the aims of the examination are to the patient. Consent to the examination should occur during that discussion and should cover an explanation around the aim to maintain modesty as appropriate and, if necessary, why there is a need for rectal and/or vaginal examination. Finally, the risk of exacerbating the pain should form a part of that request. A record of the discussion should be noted. The possibility of the presence of a chaperone should be discussed with the patient. As well as a local examination, a general musculoskeletal and neurological examination should be considered an integral part of the assessment and undertaken if appropriate. Following the examination, it is good practice to ask the patient if they had any concerns relating to the conduct of the examination and that discussion should be noted.

There is no specific diagnostic test for CPPS, therefore, procedures are on the one hand directed towards identification and exclusion of specific diseases associated with pelvic pain, and on the other hand may be used for phenotypic description. Abdominal and pelvic examination to exclude gross pelvic pathology, as well as to demonstrate the site of tenderness is essential. Abnormalities in muscle function should also be sought. Examination of the external genitalia is a part of the evaluation. In patients with scrotal pain, gentle palpation of each component of the scrotum is performed to search for masses and painful spots. The penis and urethra may be palpated in a similar way. Many authors recommend that one should assess cutaneous allodynia along the dermatomes of the abdomen (T11-L1) and the perineum (S3), and the degree of tenderness should be recorded. The bulbocavernosus reflex in the male may also provide useful information concerning the intactness of the pudendal nerves. Clinical pelvic examination should be a single digit examination if possible. The usual bi-manual examination can generate severe pain so the examiner must proceed with caution. A rectal examination is done to look for prostate abnormalities in male patients including pain on palpation and to examine the rectum and the pelvic floor muscles regarding muscle tenderness and trigger points.

At clinical examination, perianal dermatitis may be found as a sign of faecal incontinence or diarrhoea. Fissures may be easily overlooked and should be searched for thoroughly in patients with anal pain. Rectal digital examination findings may show high or low anal sphincter resting pressure, a tender puborectalis muscle in patients with the Levator Ani Syndrome, and occasionally increased perineal descent. The tenderness during posterior traction on the puborectalis muscle differentiates between Levator Ani Syndrome and unspecified.

Functional Anorectal Pain is used in most studies as the main inclusion criterion. Dyssynergic (paradoxical) contraction of the pelvic muscles when instructed to strain during defecation is a frequent finding in patients with pelvic pain. Attention should be paid to anal or rectal prolapse at straining, and ideally during combined rectal and vaginal examination to diagnose pelvic organ prolapse.

A full clinical examination of the spinal, muscular, nervous and urogenital systems is necessary to aid in diagnosis of pudendal neuralgia, especially to detect signs indicating another pathology. Often, there is little to find in pudendal neuralgia and frequently findings are non-specific. The main pathognomonic features are the signs of nerve injury in the appropriate neurological distribution, for example, allodynia or numbness. Tenderness in response to pressure over the pudendal nerve may aid the clinical diagnosis. This may be

elicited by per rectal or per vaginal examination and palpation in the region of the ischial spine and/or Alcock's canal. Muscle tenderness and the presence of trigger points in the muscles may confuse the picture. Trigger points may be present in a range of muscles, both within the pelvis (levator ani and obturator internus muscles) or externally (e.g., the piriformis, adductors, rectus abdominus or paraspinal muscles).

## 4.2 Supplemental evaluation

If history is suggestive of lower urinary tract, gynaecological, anorectal or other known aetiology disease, diagnostic workup should follow respective guidelines.

### 4.2.1 Assessing pain and related symptoms


Determination of the severity of disease, its progression and treatment response can be assessed only by means of a reliable symptom-scoring instrument. These subjective outcome measures are recommended for the basic evaluation and therapeutic monitoring of patients. Pain should always be assessed (see below) to identify progression and treatment response. As well as doing this in the clinic, the patient can keep a daily record (pain diary). This may need to include other relevant variables such as voiding, sexual activity, activity levels, or analgesic use.

Increased attention to patient reported outcomes gives prominence to patients' views on their disease and pain diaries, in patients' own environments, improve data quality.

Quality of life should also be measured because it can be very poor compared to other chronic diseases [266, 267]. In a study more pain, pain-contingent rest, and urinary symptoms were associated with greater disability (also measured by self-report), and pain was predicted by depression and by catastrophising (helplessness subscale) [63].

Where the primary outcome of treatment is pain relief, it is useful before starting treatment to agree a clinically useful level of relief [268]. The most reliable methods are:

- a five point verbal scale: none, mild, moderate, severe, very severe pain;
- a VAS score from one to ten;
- an eleven point numerical scale.



Pain assessment ratings are not independent of cognitive and emotional variables [62]. Target outcomes of pain severity, distress and disability co-vary only partly, and improvement in one does not necessarily imply improvement in the others. When the primary outcome is pain its meaning should be anchored in discussion of clinically important difference [268].

### Prostate pain syndrome

Reliable, valid indices of symptoms and QoL are the NIH-CPSI [269] and the International Prostate Symptom Score (I-PSS) [270].

### Bladder pain syndrome

Symptom scores may help to assess the patient and act as outcome measures. The O'Leary-Sant Symptom Index, also known as the Interstitial Cystitis Symptom Index (ICSI) was validated in a large study [271].

### Gastrointestinal questionnaire

Functional anorectal pain disorders (anorectal pelvic pain) are defined and characterised by duration, frequency, and quality of pain. More complex questionnaires are used in the setting of IBS. The validated IBS-Symptom Severity Scale (IBS-SSS) includes the broadest measurement of pain-related aspects [272, 273]. However, as different instruments measure different endpoints of chronic abdominal pain in IBS, a comparison of published studies is often impossible.

### Sexual function assessment

In males the most frequent effects on sexual function are ED and Premature ejaculation. These can be evaluated by proper questionnaires namely IIEF and PEDT (Premature Ejaculation Diagnostic Tool). In comparison with controls, women with CPP reported significantly more sexual avoidance behaviour, non-sensuality, and complaints of "vaginismus" [233]. The FSFI has been developed as a brief, multi-dimensional

self-report instrument for assessing the key dimensions of sexual function in women, which includes desire, subjective arousal, lubrication, orgasm, satisfaction, and pain. The corresponding evidence in men is lacking.

#### 4.2.2 **Focused myofascial evaluation**

Pelvic floor muscle testing can be done by the medical doctor but a consultation of the pelvic floor by a physiotherapist is a good alternative. A vaginal or rectal examination is performed to assess the function of the pelvic floor muscles, according to the International Continence Society (ICS) report. This assessment has been tested and shows satisfactory face validity and intra-observer reliability. It can therefore be considered suitable for use in clinical practice [274]. Rectal examination is a good way to test the pelvic floor function in men [275]. There is a growing number of reports on the use of ultrasound (US) in establishing the function of the pelvic floor muscles. The exact place in the diagnostic setting needs to be addressed in the future [276]. In a cohort study of 72 men with CPP, the relationship between the locations of the trigger point and the referred pain was examined. Ninety percent of the patients showed tenderness in the puborectalis muscle and 55% in the abdominal wall muscles. Of the patients in whom trigger points were found in the puborectalis, 93% reported pain in the penis and 57% in the suprapubic region. Patients with trigger points in the abdominal muscles reported pain in the penis (74%), perineum (65%) and rectum (46%) [277]. In addition, a broad musculoskeletal (tender point) evaluation, including muscles outside the pelvis, helps to diagnose the myofascial pain aspects of the pelvic pain in phenotyping pelvic pain patients [278, 279].

#### 4.2.3 **Neurological**

##### **Injections**

An injection of local anaesthetic and steroid at the site of nerve injury may be diagnostic. Differential block of the pudendal nerve helps to provide information in relation to the site where the nerve may be trapped [280-290]. Infiltration at the ischial spine requires the use of a nerve stimulator/locator. Both motor (anal contraction) and sensory endpoints may be noted. The anatomical endpoint may be localised by fluoroscopy, computed tomography (CT) guidance, or the use of US. Ultrasound avoids any form of radiation, whereas CT guidance involves a significant amount of radiation. Currently, fluoroscopy is probably the imaging technique most frequently used because it is readily available to most anaesthetists that perform the block. Currently, infiltration of the pudendal nerve within Alcock's canal is primarily undertaken with the use of CT. As well as injecting around the pudendal nerve, specific blocks of other nerves arising from the pelvis may be performed.

##### **Electrophysiological studies**

These may reveal signs of perineal denervation, increased pudendal nerve latency, or impaired bulbocavernosus reflex [291-295]. However, for an abnormality to be detected, significant nerve damage is probably necessary. Pain may be associated with limited nerve damage, therefore, these investigations are often normal.

#### 4.2.4 **Imaging**

Ancillary studies should be performed according to appropriate guidelines for exclusion of diseases with known aetiology presenting with symptoms identical to those of CPP. Once the latter diagnosis is established studies can be useful to assess functional abnormalities and phenotype conditions such as BPS, and chronic anal pain syndrome.

##### **Ultrasound**

Has limited value but may reassure patients. However, over-investigating may be detrimental.

##### **MRI**

Magnetic resonance neurography has been increasingly used in specialised centres for the diagnosis of the location (proximal vs. peripheral) and degree (total vs. partial) of nerve injury in the peripheral nervous system, earlier and with higher specificity than conduction studies.

##### **MR defecating proctogram**

Magnetic resonance imaging in conjunction with MR defecography has become the most valuable imaging technique to assess anorectal function dynamically. Magnetic resonance imaging studies simultaneously outline the anatomy of the pelvic floor and visualise different structural and functional pathologies, by applying dynamic sequences after filling of the rectum with a viscous contrast medium (e.g., US gel). The following pathologies can be visualised: pelvic floor descent, an abnormal anorectal angle while squeezing and straining, rectal intussusception, rectocele, enterocele and cystocele. However, limitations of MR defecography are the left lateral position and the limited space for the patient, which may reduce the ability to strain and thereby

reduce the sensitivity of the method, underestimating the size of entero- and rectoceles as well as the amount of intussusception.

### **Functional neuroimaging**

Functional neuroimaging, functional magnetic resonance imaging (fMRI) is currently being re-evaluated as a research tool and some groups have raised issues around over interpretation [296]. With regards to pain, fMRI findings may represent a pain matrix or may represent non-specific threat processing [297]. Currently this panel cannot recommend fMRI as a clinical tool.

#### **4.2.5 Laboratory Tests**

##### **Microbiology tests**

###### **Prostate pain syndrome**

Laboratory diagnosis has been classically based on the four-glass test for bacterial localisation [298]. Besides sterile pre-massage urine (voided bladder urine-2), PPS shows  $< 10^3$  cfu/mL of uropathogenic bacteria in expressed prostatic secretions and insignificant numbers of leukocytes or bacterial growth in ejaculates. However, this test is too complex for use by practising urologists. Diagnostic efficiency may be enhanced cost-effectively by a simple screening procedure, that is, the two-glass test or pre-post-massage test (PPMT) [299, 300]. Overall, these tests help only a little in the diagnosis of PPS, because 8% of patients with suggested PPS have been found to have positive prostatic localisation cultures, similar to the percentage of asymptomatic men [301].

###### **Bladder pain syndrome**

Urine dipstick and urine culture (including culture for Tuberculosis if sterile pyuria) are recommended in all patients suspected of having BPS. Urine cytology is also recommended in risk groups.

###### **Gynaecological aspects of chronic pelvic pain**

Vaginal and endocervical swabs to exclude infection are recommended. In specific cases, imaging may be required to help rule out a defined pathology such as sacral neuropathy in endometriosis [302].

#### **4.2.6 Invasive tests**

##### **Anorectal pain**

Anorectal manometry with sensory testing (pressure volume measurement: barostat) may be useful to diagnose dyssynergic defecation and hypersensitivity of the rectum which are typical for patients with CPP and IBS. Flexible rectosigmoidoscopy or colonoscopy should be considered in patients with anorectal pain to rule out coincidental colorectal pathology.

##### **Laparoscopy for females**

Laparoscopy is perhaps the most useful invasive investigation to exclude gynaecological pathology [303, 304] and to assist in the differential diagnosis of CPP in women [305]. Often, it is combined with cystoscopy [306, 307] and/or proctoscopy to help identify the site of multi-compartment pain.

##### **Psychological considerations around laparoscopy**

Three very different studies of laparoscopy suggest that it can improve pain through resolving concerns about serious disease [308], although showing women the photograph of their pelvic contents did not improve pain on explanation alone [309]. Integrating somatic and psychological assessment from the start rather than dealing with psychological concerns only after excluding organic causes of pelvic pain is helpful [310].

##### **Cystoscopy and bladder biopsy**

Despite controversy on the diagnostic and follow-up value of cystoscopy in BPS [311-315], the panel believes that objective findings are important for diagnosis, prognosis and ruling out other treatable conditions (a standardised scheme of diagnostic criteria will also contribute to uniformity and comparability of different studies) [316]. Endoscopically, BPS type 3 displays reddened mucosal areas often associated with small vessels radiating towards a central scar, sometimes covered by a small clot or fibrin deposit - the Hunner lesion [263]. The scar ruptures with increasing bladder distension, producing a characteristic waterfall type of bleeding. There is a strong association between BPS type 3 and reduced bladder capacity under anaesthesia [317]. Non-lesion disease displays a normal bladder mucosa at initial cystoscopy. The development of glomerulations after hydrodistension is considered to be a positive diagnostic sign although they can be observed without BPS [318]. Biopsies are helpful in establishing or supporting the clinical diagnosis of both

classic and non-lesion types of the disease [162, 189, 316, 319, 320]. Important differential diagnoses to exclude, by histological examination, are carcinoma *in situ* and tuberculous cystitis.

**Table 4: ESSIC classification of BPS types according to results of cystoscopy with hydrodistension and biopsies [11]**

	Cystoscopy with hydrodistension			
	Not done	Normal	Glomerulations <sup>a</sup>	Hunner's lesion <sup>b</sup>
Biopsy				
Not done	XX	1X	2X	3X
Normal	XA	1A	2A	3A
Inconclusive	XB	1B	2B	3B
Positive <sup>c</sup>	XC	1C	2C	3C

<sup>a</sup>Cystoscopy: glomerulations grade 2-3.


<sup>b</sup>Lesion per Fall's definition with/without glomerulations.

<sup>c</sup>Histology showing inflammatory infiltrates and/or detrusor mastocytosis and/or granulation tissue and/or intrafascicular fibrosis.



### 4.3 Diagnostic algorithm

Figure 1: Diagnosing chronic pelvic pain



**Figure 2: Phenotyping of pelvic pain - UPOINT classification**

Phenotyping	Assessment
Urology	Urinary flow, micturition diary, cystoscopy, ultrasound, uroflowmetry.
Psychology	Anxiety about pain, depression and loss of function, history of negative sexual experiences.
Organ specific	Ask for gynaecological, gastro-intestinal, ano-rectal, sexological complaints. Gynaecological examination, rectal examination.
Infection	Semen culture and urine culture, vaginal swab, stool culture.
Neurological	Ask for neurological complaints (sensory loss, dysaesthesia). Neurological testing during physical examination: sensory problems, sacral reflexes and muscular function.
Tender muscle	Palpation of the pelvic floor muscles, the abdominal muscles and the gluteal muscles.
Sexological	Erectile function, ejaculatory function, post-orgasmic pain.

#### 4.4 Other painful conditions without a urological cause

##### Dysmenorrhoea

Menstrual pain or 'dysmenorrhoea' may be primary or secondary. Primary dysmenorrhoea classically begins at the onset of ovulatory menstrual cycles and tends to decrease following childbirth [305]. Secondary dysmenorrhoea suggests the development of a pathological process, such as endometriosis [304], adenomyosis [321] or pelvic infection, which need to be excluded.

##### Infection

In pre-menopausal women, a history of Pelvic Inflammatory Disease (PID) must be excluded. A patient's sexual history should be taken along with swabs to exclude chlamydia and gonorrhoea infection. Bacterial and viral genital tract pathogens should also be excluded [322], as they can cause severe pelvic/vaginal/vulvar pain [323] and are associated with ulcerating lesions and inflammation, which may lead to urinary retention [324]. If there is any doubt about the diagnosis, laparoscopy may be helpful, as one of the differential diagnoses is endometriosis.

##### Endometriosis and adenomyosis

The incidence of endometriosis is rising in the developed world. It has widespread impact on women's lives [325], with pain more important than physical findings in determining QoL [326]. The precise aetiology is unknown, but an association with infertility is recognised [327]. A diagnosis is usually made when a history of secondary dysmenorrhoea and/or dyspareunia exists. On examination, there is often tenderness in the lateral vaginal fornices, reduced uterine mobility, tenderness in the recto-vaginal septum, and on occasion, adnexal masses. Laparoscopy is the most useful diagnostic tool [328-331]. Adenomyosis is associated with augmented pain during menses [332a]. It is diagnosed by an US scan of the uterus, which often shows cystic dilatation of the myometrium [332b].

##### Gynaecological malignancy

The spread of gynaecological malignancy of the cervix, uterine body or ovary will cause pelvic pain depending on the site of spread.

##### Injuries related to childbirth

Trauma occurring at the time of childbirth may lead to CPP related to the site of injury [331]. Female sexual dysfunction is perhaps the commonest presenting problem [333], though increasingly women are reporting other symptoms such as pelvic girdle pain and other genito-pelvic pain of different aetiology [334]. There is often a transient problem with oestrogen deficiency in the post-partum period and during breastfeeding, which can compound this situation. Denervation of the pelvic floor can similarly compound the situation [335].

### **Pain associated with pelvic organ prolapse and prolapse surgery**

Pelvic organ prolapse is often asymptomatic, unless it is so marked that it causes back strain, vaginal pain and skin excoriation [336]. Prolapse is often a disease of older women, and it is often associated with post-menopausal oestrogen deficiency, which may lead to pain associated with intercourse. Prolapse surgery may entail the use of non-absorbable mesh (usually in the form of “mesh kits”) [337-339]. Although they may have a role in supporting the vagina, they are also associated with several complications including bladder, bowel and vaginal trauma [338] and neuropathy [340]. Patients need to be fully evaluated and may need specialised imaging, using contrast mediums if necessary, to make a diagnosis of the possible cause of the pain [341-344].

### **Haemorrhoids**

Chronic pelvic pain is rare in haemorrhoidal disease because endoscopic and surgical treatment is mostly effective in acute disease. The most frequent aetiology of pain without significant bleeding is thrombosed external haemorrhoids or an anal fissure. Haemorrhoidal pain on defecation associated with bleeding is usually due to prolapse or ulceration of internal haemorrhoids. Anaemia from haemorrhoidal bleeding is rare but may arise in patients on anti-coagulation therapy, or those with clotting disorders.

### **Anal fissure**

Anal fissures are tears in the distal anal canal and induce pain during and after defecation. The pain can last for several minutes to hours. Persistence of symptoms beyond six weeks or visible transversal anal sphincter fibres define chronicity. Fissures located off the midline are often associated with specific diseases such as Crohn’s disease or anal cancer. Internal anal sphincter spasms and ischaemia are associated with chronic fissures.

### **Proctitis**

Abdominal and pelvic pain in patients with inflammatory bowel disease and proctitis are often difficult to interpret. Faecal calprotectin may help to differentiate between inflammation and functional pain, to spare steroids.

### **Irritable bowel syndrome**

Although IBS can be associated with pelvic pain, the panel consider a full discussion of this topic beyond the scope of these guidelines. A number of high quality clinical guidelines address this topic [345, 346].

## **4.5 Summary of evidence and recommendations: diagnostic evaluation**

### **4.5.1 Diagnostic evaluation of PPS**

<b>Summary of evidence</b>	<b>LE</b>
Prostate pain syndrome is associated with negative cognitive, behavioural, sexual, or emotional consequences, as well as with symptoms suggestive of lower urinary tract and sexual dysfunction.	2b
Prostate pain syndrome has no known single aetiology.	3
Pain in PPS involves mechanisms of neuroplasticity and neuropathic pain.	2a
Prostate pain syndrome has a high impact on QoL.	2b
Depression and catastrophic thinking are associated with more pain and poorer adjustment.	3
The prevalence of PPS-like symptoms is high in population-based studies (> 2%).	2b
Reliable instruments assessing symptom severity as well as phenotypic differences exist.	2b

<b>Recommendations</b>	<b>Strength rating</b>
Adapt diagnostic procedures to the patient. Exclude specific diseases with similar symptoms.	Strong
Use a validated symptom and quality of life scoring instrument, such as the National Institutes of Health Chronic Prostatitis Symptom Index, for initial assessment and follow-up.	Strong
Assess prostate pain syndrome associated negative cognitive, behavioural, sexual, or emotional consequences, as well as symptoms of lower urinary tract and sexual dysfunctions.	Strong

#### 4.5.2 Diagnostic evaluation of BPS

Summary of evidence	LE
BPS has no known single aetiology.	3
Pain in BPS does not correlate with bladder cystoscopic or histologic findings.	2a
BPS Type 3 C can only be confirmed by cystoscopy and histology.	2a
Lesion/non-lesion disease ratios of BPS are highly variable between studies.	2a
The prevalence of BPS-like symptoms is high in population-based studies.	2a
BPS occurs at a level higher than chance with other pain syndromes.	2a
BPS has an adverse impact on QoL.	2a
Reliable instruments assessing symptom severity as well as phenotypical differences exist.	2a

Recommendations	Strength rating
Perform general anaesthetic rigid cystoscopy in patients with bladder pain to subtype and rule out confusable disease.	Strong
Diagnose patients with symptoms according to the EAU definition, after primary exclusion of specific diseases, with bladder pain syndrome (BPS) by subtype and phenotype.	Strong
Assess BPS associated non-bladder diseases systematically.	Strong
Assess BPS associated negative cognitive, behavioural, sexual, or emotional consequences.	Strong
Use a validated symptom and quality of life scoring instrument for initial assessment and follow-up.	Strong

#### 4.5.3 Diagnostic evaluation of scrotal pain syndrome

Summary of evidence	LE
The nerves in the spermatic cord play an important role in scrotal pain.	2b
Ultrasound of the scrotal contents does not aid in diagnosis or treatment of scrotal pain.	2b
Post-vasectomy pain is seen in a substantial number of men undergoing vasectomy.	2b
Scrotal pain is more often noticed after laparoscopic than after open inguinal hernia repair.	1b

#### 4.5.4 Diagnostic evaluation of urethral pain syndrome

Summary of evidence	LE
Urethral pain syndrome may be a part of BPS.	2a
Urethral pain involves mechanisms of neuroplasticity and neuropathic pain.	2b

#### 4.5.5 Diagnostic evaluation of gynaecological aspects chronic pelvic pain

Summary of evidence	LE
Clinical history and examination are mandatory when making a diagnosis.	2a
Laparoscopy is well-tolerated and does not appear to have negative psychological effects.	1b

Recommendations	Strength rating
Take a full history and evaluate to rule out a treatable cause (e.g. endometriosis) in all women with chronic pelvic pain.	Strong
Take a full uro-gynaecological history in those who have had a continence or prolapse non-absorbable mesh inserted and consider specialised imaging of the mesh.	Strong
Refer to a gynaecologist if clinical suspicion of a gynaecological cause for pain following complete urological evaluation. Laparoscopy should be undertaken in accordance with gynaecological guidelines.	Strong

#### 4.5.6 *Diagnostic evaluation of anorectal pain syndrome*

Summary of evidence	LE
Tenderness on traction is the main criterion of the chronic anal pain syndrome.	1a

Recommendation	Strength rating
Anorectal function tests are recommended in patients with anorectal pain.	Strong

#### 4.5.7 *Diagnostic evaluation of pudendal neuralgia*

Summary of evidence	LE
Multiple sensory and functional disorders within the region of the pelvis/urogenital system may occur as a result of injury to one or more of many nerves. The anatomy is complex.	2
There is no single aetiology for the nerve damage and the symptoms and signs may be few or multiple.	1
Investigations are often normal.	2
The peripheral nerve pain syndromes are frequently associated with negative cognitive, behavioural, sexual, or emotional consequences.	1

Recommendations	Strength rating
Rule out confusable diseases, such as neoplastic disease, infection, trauma and spinal pathology.	Strong
If a peripheral nerve pain syndrome is suspected, refer early to an expert in the field, working within a multidisciplinary team environment.	Weak
Imaging and neurophysiology help diagnosis but image and nerve locator guided local anaesthetic injection is preferable.	Weak

#### 4.5.8 *Diagnostic evaluation of sexological aspects in CPP*

Summary of evidence	LE
Chronic pain can lead to decline in sexual activity and satisfaction and may reduce relationship satisfaction.	2a
Patients who reported having sexual, physical or emotional abuse show a higher rate of reporting symptoms of PPS.	2b
Sexual dysfunctions are prevalent in patients with PPS.	2b
In men with PPS the most prevalent sexual complaints are ED and ejaculatory dysfunction.	3
In females with CPPS all sexual function domains are lower. The most reported dysfunctions are sexual avoidance, dyspareunia and "vaginismus".	2a
Vulvar pain syndrome is associated with BPS.	3
Women with BPS suffer significantly more from fear of pain, dyspareunia and decreased desire.	2a
Pelvic floor muscle function is involved in the excitement and orgasm phases of sexual response.	3
Chronic pain can cause disturbances in each of the sexual response cycle phases.	2b

Recommendation	Strength rating
Screen patients presenting with symptoms suggestive for chronic pelvic pain syndrome for abuse, without suggesting a causal relation with the pain.	Weak

#### 4.5.9 *Diagnostic evaluation of psychological aspects of CPP*

Summary of evidence	LE
There is no evidence that distress generates complaints of pelvic pain, or that multiple symptoms suggest unreality of pain.	2b
Current or recent sexual abuse are possible contributory factors in pelvic pain.	2a

Recommendations	Strength rating
Assess patient psychological distress in relation to their pain.	Strong
Ask patients what they think is the cause of their pain to allow the opportunity to inform and reassure.	Strong

#### 4.5.10 *Diagnostic evaluation of pelvic floor function*

Summary of evidence	LE
The ICS classification is suitable for clinical practice.	2a
Over-activity of the pelvic floor muscles is related to chronic pelvic pain, prostate, bladder and vulvar pain.	2a
Over-activity of the pelvic floor muscles is an input to the CNS causing central sensitisation.	2b
There is no accepted standard for diagnosing myofascial trigger points.	2a
There is a relation between the location of trigger point and the region where the pain is perceived.	3

Recommendations	Strength rating
Use the International Continence Society classification on pelvic floor muscle function and dysfunction.	Strong
In patients with chronic pelvic pain syndrome it is recommended to actively look for the presence of myofascial trigger points.	Weak

## 5. MANAGEMENT

The philosophy for the management of CPP is based on a bio-psychosocial model. This is a holistic approach with the patients' active involvement. Single interventions rarely work in isolation and need to be considered within a broader personalised management strategy.

The management strategy may well have elements of self-management. Pharmacological and non-pharmacological interventions should be considered with a clear understanding of the potential outcomes and end points. These may well include: psychology, physiotherapy, drugs and more invasive interventions.

### Treatment philosophy

Providing information that is personalised and responsive to the patient's problems, conveying belief and concern, is a powerful way to allay anxiety [347]. Additional written information or direction to reliable sources of information is useful; practitioners tend to rely on locally produced material or pharmaceutical products of variable quality while endorsing the need for independent materials for patients [348].

### 5.1 Conservative management

#### 5.1.1 *Pain education*

It is always valuable to include education about the causes of pain, including eliciting from patients their anxieties about undiscovered pathology and addressing them. Information improves adherence to treatment and underpins self-management, as shown in many other painful and non-painful disorders but not specifically in pelvic and abdominal pain except by a small qualitative study [24].

#### 5.1.2 *Physical therapy*

The physiotherapist is part of the pain management team, together with the pain doctor and the psychologist. The therapeutic options for physiotherapists may not be the same in every country. Physiotherapists can either specifically treat the pathology of the pelvic floor muscles, or more generally treat myofascial pain if it is part of the pelvic pain syndrome. In most studies that have been done looking at the effect of physiotherapy in pelvic pain, the treatment of the pelvic floor is only part of the pain management. In a review about physiotherapy in women with pelvic pain, it was concluded that recommendations for physiotherapy should be given with caution [349]. The review found six RCTs, of which three showed level 1b evidence with low-risk of bias. One of these three found that Mensendieck somatocognitive therapy showed a pain reduction after one year follow-up of 64%. This approach consists of myofascial relaxation and tension, improving posture and movement in combination with cognitive behaviour therapy (CBT) [350].

### **Pelvic floor muscle pain**

Treating pelvic floor over-activity and myofascial trigger points should be considered in the management of CPP. Treatment should be done by specialised physiotherapists who are trained not only in the musculoskeletal aspects of pain, but also in the psychological mechanisms and the role of the CNS in chronic pain.

For patients with CPP and dysfunction of the pelvic floor muscles, it is very helpful to learn how to relax the muscles when the pain starts. By doing this, the circle of pain-spasm-pain can be interrupted. In the case of shortened muscles, relaxation alone is not enough. Stretching of the muscle is mandatory to regain length and function. Studies on physical therapy for pelvic floor pain syndrome have been sparse. A single blinded RCT with myofascial physical therapy and general massage was carried out in patients with prostate or bladder pain. The global response rate to treatment with massage was significantly better in the prostate than in the bladder pain group (57% vs. 21%). In the prostate pain group, there was no difference between the two treatment arms. In the bladder pain group, myofascial treatment did significantly better than massage. Massage only improved complaints in the prostate pain group. The fact that gender distribution was different in each group is mentioned as a possible confounding factor [351].

### **Myofascial trigger point release**

Treatment of myofascial trigger points can be done by manual therapy, dry needling and wet needling. The evidence for all the different treatments is weak, with most studies showing no significant difference between these techniques, though most studies were small and heterogeneous with regards to the patients and methods. There is no evidence that manual techniques are more effective than no treatment [352]. Most studies of dry needling have compared with wet needling. Different systematic reviews have come to the conclusion that, although there is an effect of needling on pain, it is neither supported nor refuted that this effect is better than placebo [353]. Other reviews have concluded that the same is true for the difference between dry and wet needling [354, 355].

### **Physiotherapy in BPS**

General muscular exercise may be beneficial in some BPS patients [356]. Transvaginal manual therapy of the pelvic floor musculature (Thiele massage) in BPS patients with high-tone dysfunction of the pelvic floor significantly improved several assessment scales [357]. The role of specific levator ani trigger point injections in women with CPP has been studied [358]. Each trigger point was identified by intravaginal palpation and injected with bupivacaine, lidocaine and triamcinolone. Seventy-two percent of women improved with the first trigger point injection, with 33% being completely pain-free. Efficacy and safety of pelvic floor myofascial physical therapy has been compared with global therapeutic massage in women with BPS; global response assessment (GRA) rate was 59% and 26%, respectively. Pain, urgency and frequency ratings, and O'Leary-Sant IC Symptom and Problem Index decreased in both groups during follow-up, and did not differ significantly between the groups. This suggests that myofascial physical therapy is beneficial in women with BPS [359].

### **Anal Pain Syndrome**

An RCT demonstrated that biofeedback treatment was superior to electrogalvanic stimulation and massage for treating chronic anal pain syndrome [148]. One hundred and fifty-seven patients who had at least weekly rectal pain were investigated, but only patients with tenderness on traction of the pelvic floor showed a significant treatment benefit. In patients with tenderness of the puborectalis muscle (Rome II: Highly likely Levator Ani Syndrome), 87% reported adequate relief after one month of biofeedback vs. 45% for electrogalvanic stimulation, and 22% for massage. These results were maintained at twelve months with adequate relief after nine sessions of biofeedback in 58% of the whole group (Rome II: Highly likely and Possible Levator Ani Syndrome), after galvanic stimulation in 27% and massage in 21% of patients. As previously described in dyssynergic defecation, the ability to expel a 50 mL water filled balloon and to relax pelvic floor muscles after biofeedback treatment were predictive of a favourable therapeutic outcome [148]. The pathophysiology of the chronic anal pain syndrome is therefore similar to that of dyssynergic defecation, and this favours the role of the pelvic floor muscles in the pathophysiology of both conditions. Other treatment modalities have been less successful.

### **Treatment of sexual dysfunctions and CPP**

Couples often benefit from early referral for relationship and sexual counselling during their treatment course [360]. Specific behavioural strategies for women who have urogenital complaints and female sexual dysfunction often include exploring alternatives to sexual intercourse (manual or oral pleasuring), different coital positions (female superior or side lying), and pacing, such as limiting thrusting to less than that causes pain. Planning for the time of intercourse is important, and scheduling a clinic visit after intercourse might be useful to identify specific sites and causes of post-coital flares. The corresponding evidence in men is lacking.

Other behavioural changes involve pre- and post-coital voiding, application of ice packs to the genital or suprapubic area [360, 361], and use of vaginal dilators before penile penetration. An alternative is to use natural dilators such as different fingers or sex toys. Hypoallergenic non-irritating lubricants can be used to reduce vulvar, urethral, and vaginal friction, and women with signs of vulvovaginal atrophy may benefit from introital application of minimally absorbed locally applied oestrogen cream [362]. In patients with an overactive pelvic floor, referral for physical therapy, myofascial release, and internal pelvic floor muscle massage may offer relief [363].

#### **Other physical therapy interventions**

**Electromagnetic therapy.** A small, sham-controlled, double-blind study of four weeks showed a significant, sustained effect over a one-year period for CPPS [364].

**Microwave thermotherapy.** In uncontrolled studies significant symptomatic improvement has been reported from heat therapy, for example, transrectal and transurethral thermotherapy [365, 366].

**Extracorporeal shockwave therapy.** A small sham-controlled double-blind study of four times weekly perineal extracorporeal shockwave therapy (n=30) in men with chronic pelvic pain syndrome showed significant improvement in pain, QoL, and voiding compared to the control group (n=30) over twelve weeks [367]. Two other randomised sham-controlled studies, have been published more recently, one comparing ten treatment sessions over two weeks (n=40 vs. n=40) [368], another with four times weekly treatments (n=20 vs. n=20) [369]. Both concluded there was a significant effect in terms of total NIH-CPSI score and pain at twelve weeks. Unfortunately, no long term effects at 24 weeks could be shown in a published follow-up study of the second [370].

**Acupuncture.** In a small three-arm randomised trial of CPPS in men, electro-acupuncture was superior to sham treatment and advice and exercise alone [371]. Another more recent randomised study comparing acupuncture (n=50) vs. sham-controlled (n=50) once weekly treatment for six weeks showed significant long lasting improvement at 24 weeks in terms of response rate and overall symptom scores [372]. Another RCT showed a significant effect for a follow-up of 32 weeks [373]. Two systematic reviews and meta-analyses were published in 2016 analysing seven randomised-controlled studies on a total of 471 participants comparing acupuncture to sham control or oral medical treatment [374, 375]. Both came to the conclusion that acupuncture was effective and safe, significantly reducing total NIH-CPSI scores compared to sham or medical treatment, and should be considered as a treatment option. This is in line with the conclusion of a recent Cochrane systematic review [376] on non-pharmacological treatment options. However, the durability of this effect is not known.

**Posterior tibial nerve stimulation.** One sham-controlled medium-sized study (n=89) demonstrated significant improvement in total NIH-CPSI score and visual analogue scale for pain in men with category IIIB chronic prostatitis/CPP [377].

**Transcutaneous electrical nerve stimulation.** Despite the popularity of transcutaneous electrical nerve stimulation (TENS) and the number of trials undertaken, a systematic review has been unable to provide good evidence for or against its use in the management of chronic pain [378]. Furthermore, rigorous trials should be undertaken to provide some clarity for a commonly used intervention.

#### **5.1.3 Psychological therapy**

Psychological interventions may be directed at pain itself or at adjustment to pain as shown by improved function and mood and reduced health-care use with or without pain reduction. Ideally, treatment follows general principles and practice in the field of chronic pain [379, 380], but these have been neglected in pelvic pain. Two systematic reviews and meta-analyses of the few heterogeneous trials of psychologically based treatment for pelvic pain [381, 382] found some short-term benefits for pain, of around 50%, comparable to that from pharmacotherapy, but this was not sustained at follow-up. Surprisingly, the single component treatments for chronic pelvic pain, counselling about US results [293], and emotional disclosure [383], showed improvements in pain. More standard multi-component psychologically-based programmes are rare but are in the pilot stages [384]. One that combined mixed psychological therapies with acupuncture for endometriosis-related pain [385], reported significant pain reduction at two year follow-up [385]. Three more standard multi-component (including psychological) treatments for pain [310, 350, 386] did not provide pain or symptom relief. Another RCT of multi-component treatment also showed no effect on pain but benefits for distress [387], as did an RCT of mindfulness meditation for women with bladder pain [388]. The importance of multi-disciplinary treatment is emphasised by several reviews [44, 389, 390], and the need for high quality psychological treatment evaluation is underlined [389]. For less disabled and distressed patients, this can be delivered in part over the internet [391]. Several other reviews make positive comments on psychological involvement [392], and recommend addressing psychological concerns from the outset, directed at the pain itself, with the intended outcome of reducing its impact on life [35], or at adjustment to pain, with improved mood and function and reduced health-care use, with or without pain reduction [37].



#### 5.1.4 **Dietary treatment**

Scientific data are limited and dietary restriction alone does not produce significant symptomatic relief; however, consider the involvement of a dietician.

## 5.2 **Pharmacological management**

### 5.2.1 **Drugs for chronic pelvic pain syndrome**

In this section the evidence available for specific CPPSs is presented. Where there is no evidence the reader is directed to the section on analgesics below (5.2.3) where more generic use is discussed. There is a large discrepancy in the treatment effects reported in case series and controlled trials that results from a large placebo effect or publication bias. As a result of the multifactorial origin of for example PPS, one reason for treatment failure in some large randomised placebo-controlled trials may be the heterogeneity of the patient population. One strategy for improving treatment effects may be stratification of patient phenotypes. A prospective series of phenotypically directed treatment for PPS has shown significant improvement of symptoms and QoL [393]. Monotherapeutic strategies for the treatment of PPS may fail [294], therefore, most patients require multimodal treatment aimed at the main symptoms, and taking comorbidity into account. In the past ten years, results from RCTs have led to advances in standard and novel treatment options.

#### 5.2.1.1 *Mechanisms of action*

Mechanisms of action are discussed as appropriate under the drugs headings below.

#### 5.2.1.2 *Comparisons of agents used in pelvic pain syndromes*

### **Prostate Pain Syndrome (PPS)**

#### **Anti-inflammatory drugs**

For non-steroidal anti-inflammatory agents (NSAIDs), a trial with celecoxib reported that the pain sub-score, QoL sub-score, and total NIH-CPSI score were in favour of the treatment arm vs. placebo, but effects were limited to the duration of therapy [295]. In a meta-analysis, two studies of NSAIDs [295, 301] and one with prednisolone [291] were pooled. Anti-inflammatory drugs were 80% more likely to have a favourable response than placebo. In an updated network meta-analysis with more restrictive inclusion criteria regarding documented outcome measures but a wider spectrum of drugs (including glycosaminoglycans, phytotherapy and tanezumab) a significant effect on total NIH-CPSI scores and treatment response rates could be demonstrated. Overall, a moderate treatment effect has been shown for anti-inflammatory drugs, but larger studies are needed for confirmation, and long-term side-effects have to be taken into account.

#### **$\alpha$ -blockers**

Positive results from RCTs of  $\alpha$ -blockers, i.e. terazosin [394, 395], alfuzosin [396], doxazosin [397, 398], tamsulosin [399, 400], and silodosin [401] have led to widespread use of  $\alpha$ -antagonists in the treatment of PPS in recent years. Whereas one systematic review and meta-analysis has not reported a relevant effect of  $\alpha$ -blockers due to study heterogeneity [402], another network meta-analysis of  $\alpha$ -blockers [403] has shown significant improvement in total symptoms, pain, voiding, and QoL scores. In addition, they had a higher rate of favourable response compared to placebo [relative risk (RR) 1.4, 95% CI 1.1-1.8,  $p=0.013$ ]. However, treatment responsiveness, i.e. clinically perceptible or significant improvement, may be lower than expected from the change in mean symptom scores. Overall,  $\alpha$ -blockers seem to have moderate but significant beneficial effects. This probably is not the case for long-standing PPS patients [404]. Future studies should show if longer duration of therapy or some sort of phenotypically directed (e.g. patients with PPS and relevant voiding dysfunction) treatment strategies will improve treatment outcomes.

#### **Antibiotic therapy**

Empirical antibiotic therapy is widely used because some patients have improved with antimicrobial therapy. Patients responding to antibiotics should be maintained on medication for four to six weeks or even longer. Unfortunately, culture, leukocyte and antibody status of prostate-specific specimens do not predict antibiotic response in patients with PPS [405], and prostate biopsy culture findings do not differ from those of healthy controls [406]. The only randomised placebo-controlled trials of sufficient quality have been done for oral antibiotic treatment with ciprofloxacin (six weeks) [154], levofloxacin (six weeks) [407], and tetracycline hydrochloride (twelve weeks) [408]. The studies have been analysed in meta-analyses [403, 409]. Although direct meta-analysis has not shown significant differences in outcome measures, network meta-analysis has suggested significant effects in decreasing total symptom, pain, voiding, and QoL scores compared with placebo. Combination therapy of antibiotics with  $\alpha$ -blockers has shown even better outcomes in network meta-analysis. Despite significant improvement in symptom scores, antibiotic therapy did not lead to

statistically significant higher response rates [409]. In addition, the sample sizes of the studies were relatively small and treatment effects only modest and most of the time below clinical significance. It may be speculated that patients profiting from treatment have had some unrecognised uropathogens. If antibiotics are used, other therapeutic options should be offered after one unsuccessful course of a quinolone or tetracycline antibiotic over six weeks.

### **5- $\alpha$ -reductase inhibitors**

Although a few small pilot studies with 5- $\alpha$ -reductase inhibitors supported the view that finasteride may improve voiding and pain, the first RCT published in a peer-reviewed journal did not support this, but the study lacked power [410]. In another RCT, finasteride provided better amelioration of symptoms compared to saw palmetto over a one-year period, but lacked a placebo-control arm [411]. A six-month placebo-controlled study showed a non-significant tendency towards better outcome in favour of finasteride, possibly because of a lack of statistical power [412]. The NIH-CPSI scores decreased significantly in a subgroup of men enrolled in a prostate cancer risk reduction study treated with dutasteride compared to placebo [413]. Patients (n=427, age 50 to 75, elevated prostate-specific antigen [PSA]) were included if they had significant "prostatitis-like" symptoms at baseline. Based on the evidence, 5- $\alpha$ -reductase inhibitors cannot be recommended for use in PPS in general, but symptom scores may be reduced in a restricted group of older men with an elevated PSA [413].

### **Phytotherapy**

Phytotherapy applies scientific research to the practice of herbal medicine. An adequately powered placebo-controlled RCT of a pollen extract (Cernilton), showed clinically significant symptom improvement over a twelve-week period in inflammatory PPS patients (NIH Cat. IIIA) [414]. The effect was mainly based on a significant effect on pain. Another pollen extract (DEPROX 500) has been shown to significantly improve total symptoms, pain and QoL compared to ibuprofen [415]. A recent systematic review and meta-analysis of pollen extract for the treatment of PPS showed significant improvement in overall QoL [416]. Quercetin, a polyphenolic bioflavonoid with documented antioxidant and anti-inflammatory properties, improved NIH-CPSI scores significantly in a small RCT [417]. In contrast, treatment with saw palmetto, most commonly used for benign prostatic hyperplasia, did not improve symptoms over a one-year period [411]. In a systematic review and meta-analysis, patients treated with phytotherapy were found to have significantly lower pain scores than those treated with placebo [403]. In addition, overall response rate in network meta-analysis was in favour of phytotherapy (RR: 1.6; 95% CI: 1.1-1.6).

**Pregabalin** is an anti-epileptic drug that has been approved for use in neuropathic pain. In an adequately powered randomised placebo-controlled study, which was the only report included in a recently published Cochrane review [418], a six-week course of pregabalin (n=218) compared to placebo (n=106) did not result in a significant reduction of NIH-CPSI total score [419].

**Pentosane polysulphate** is a semi-synthetic drug manufactured from beech-wood hemicellulose. One study using oral high-dose (3 x 300 mg/day) demonstrated a significant improvement in clinical global assessment and QoL over placebo in men with PPS, suggesting a possible common aetiology [420].

**Muscle relaxants** (diazepam, baclofen) are claimed to be helpful in sphincter dysfunction or pelvic floor/perineal muscle spasm, but there have been few prospective clinical trials to support these claims. In one RCT, a triple combination of a muscle relaxant (thiocolchicoside), an anti-inflammatory drug (ibuprofen) and an  $\alpha$ -blocker (doxazosin) was effective in treatment-naïve patients, but not superior to an  $\alpha$ -blocker alone [398].

**Botulinum toxin type A (BTX-A)** showed some effect in the global response assessment and the NIH-CPSI pain subdomain score in a small randomised placebo-controlled study of perineal skeletal muscle injection (100 U). However, patient numbers were low (thirteen in the BTX-A group and sixteen in the placebo group), and follow-up was too short to draw definitive conclusions. Side-effects are unclear [421]. In another randomised-controlled study of intraprostatic injection of BTX-A (100 or 200 U depending on prostate volume) vs. placebo (n=30 in both groups) a significant improvement of total NIH-CPSI and subdomain scores could be shown at six months [422]. However, no real placebo effect could be demonstrated, which suggests unblinding. No definitive conclusion can be drawn.

**Zafirlukast**, a leukotriene antagonist, and prednisone in two low-power placebo-controlled studies failed to show a benefit [291, 423]. More recently, a placebo-controlled phase IIa study of tanezumab, a humanised monoclonal antibody against the pain mediating neurotrophin, nerve growth factor, failed to demonstrate significant effect [424].

**Tanezumab** is a humanised monoclonal antibody that specifically inhibits nerve growth factor (NGF), and should only be used in clinical trials.

### **Allopurinol**

There is insufficient evidence for the use of allopurinol in PPS [425, 426].

## **Bladder Pain Syndrome**

### **Treatments of significant value for BPS**

#### **Anti-histamines**

Mast cells may play a role in BPS. Histamine is one of the substances released by mast cells. Histamine receptor antagonists have been used to block the H1 [427] and H2 [428] receptor subtypes, with variable results. A prospective placebo-controlled RCT of hydroxyzine or oral pentosane polysulphate did not show a significant effect [429].

#### **Amitriptyline**

Amitriptyline is a tricyclic antidepressant. Several reports have indicated improvement of BPS symptoms after oral amitriptyline [117, 430, 431]. Amitriptyline has been shown to be beneficial when compared with placebo plus behavioural modification [432]. Drowsiness is a limiting factor with amitriptyline, nortriptyline is sometimes considered instead.

#### **Pentosane polysulphate**

Is a semi-synthetic drug manufactured from beech-wood hemicellulose. Subjective improvement of pain, urgency, frequency, but not nocturia, has been reported [433, 434]. Pentosane polysulphate had a more favourable effect in BPS type 3 C than in non-lesion disease [435]. Response was not dose dependent but related more to treatment duration. At 32 weeks, about half the patients responded. Combination therapy showed a response rate of 40% compared to 13% with placebo. For patients with an initial minor response to pentosane polysulphate, additional subcutaneous heparin was helpful [436, 437].

#### **Immunosuppressants**

Azathioprine treatment has resulted in disappearance of pain and urinary frequency [438]. Initial evaluation of cyclosporin A (CyA) [439] and methotrexate [440] showed good analgesic effect but limited efficacy for urgency and frequency. Corticosteroids are not recommended in the management of patients with BPS because of a lack of evidence.

#### **Intravesical Treatments**

Intravesical drugs are administered due to poor oral bio-availability establishing high drug concentrations within the bladder, with few systemic side-effects. Disadvantages include the need for intermittent catheterisation which can be painful in BPS patients, cost and risk of infection [441].

- **Local anaesthetics**

There are sporadic reports of successful treatment of BPS with intravesical lidocaine [442, 443]. Alkalisiation of lidocaine improves its pharmacokinetics [444]. Combination of heparin, lidocaine and sodium bicarbonate gave immediate symptom relief in 94% of patients and sustained relief after two weeks in 80% [445]. Intravesical instillation of alkalisied lidocaine or placebo for five consecutive days resulted in significantly sustained symptom relief for up to one month [446].

- **Hyaluronic acid and chondroitin sulphate** are described to repair defects in the GAG layer. Despite the fact that intravesical GAG replenishment has been in use for about twenty years for BPS/IC, most of the studies are uncontrolled and with a small number of patients. Based on the studies available there are differences by virtue of substance classes, whether they are natural GAG layer components, dosage formulations, or concentrations. A recent RCT seems to reinforce the case for GAG layer replenishment, however it lacks a placebo arm [447]. A recent meta-analysis confirms usefulness of GAG layer replenishment. However most retrieved studies are non-randomised and with scarce numbers [448].

- **Intravesical heparin**

Bladder pain syndrome patients were treated with heparin for three months, and over half had control of symptoms, with continued improvement after one year of therapy [449]. Kuo reported another trial of intravesical heparin for three months in women with frequency-urgency syndrome and a positive

potassium test. Symptomatic improvement was reported in 80% of BPS patients [450]. Intravesical heparin plus dorsal tibial nerve stimulation in patients with refractory BPS was studied and it was shown that voiding frequency, pain score and maximum cystometric capacity were significantly better after two and twelve months [451].

- **Hyperbaric oxygen** (HBO) has a moderate effect on a small subgroup of BPS patients. Disadvantages include high cost, limited availability of treatment sites, and time-consuming treatment [436].

### **Treatments of limited value for BPS**

#### **Cimetidine**

There is limited data to suggest that cimetidine improves symptoms of BPS in the short-term [452]. Compared with placebo for three months, cimetidine significantly improved symptom scores, pain and nocturia, although the bladder mucosa showed no histological changes in either group [453].

#### **Prostaglandins**

Misoprostol is a prostaglandin that regulates various immunological cascades. After three months of treatment with misoprostol, 14/25 patients had significantly improved, with twelve showing a sustained response after a further six months [454]. The incidence of adverse drug effects was 64%.

#### **L-Arginine**

Oral treatment with the nitric oxide (NO) synthase substrate L-arginine decreases BPS-related symptoms [455-457]. Nitric oxide is elevated in patients with BPS [458]. However, others have not demonstrated symptomatic relief or changes in NO production after treatment [459, 460].

**Oxybutynin** is an anti-cholinergic drug used in overactive detrusor dysfunction. Intravesical oxybutynin combined with bladder training improves functional bladder capacity, volume at first sensation, and cystometric bladder capacity [461]. However, an effect on pain has not been reported.

**Duloxetine** (a serotonin-noradrenaline re-uptake inhibitor antidepressant with a licence for the management of neuropathic pain) did not significantly improve symptoms of BPS [462]. Administration was safe, but tolerability was poor due to nausea. Based on these preliminary data, duloxetine cannot be recommended for treatment of BPS.

**Clorpactin** is a derivative of hypochloric acid previously used to treat BPS [463-467]. Due to high complication rates, clorpactin instillations can no longer be recommended [463, 464, 466, 468, 469].

**Dimethyl sulphoxide** (DMSO) and *Bacillus Calmette Guérin* (BCG) have been used in the past. There is insufficient evidence to recommend the use of either.

#### **Scrotal Pain Syndrome**

Treatment of chronic scrotal pain is based on the principles of treating chronic pain syndromes, as described throughout these guidelines [470].

#### **Chronic gynaecological pain**

It is difficult to compare the wide variation of drugs from an efficacy and safety perspective as they have such diverse uses/indications.

In those gynaecological patients where CPP is unrelated to any of the well-defined conditions, it is often difficult to determine a therapeutic pathway other than a multi-disciplinary chronic abdomino-pelvic pain management plan. A Cochrane review suggests there may be some evidence (moderate) supporting the use of progestogens. Though efficacious, physicians need to be knowledgeable with progestogenic side effects (e.g. weight gain, bloatedness - the most common adverse effects) which can stop some patients from accepting such medication. Gonadotrophins, such as goserelin, are also thought to help such pain. However, when compared with progestogens, their efficacy remains limited, as is the case when comparing gabapentin with amitriptyline [471]. The quality of evidence is generally low and is drawn from single studies [381].

Current hormonal contraceptives (e.g. the combined oral contraceptive pill and the progesterone-only pill), and intrauterine contraceptive devices (Mirena IUS™) have multiple biologic effects, including a primary or secondary contraceptive action, such as ovulation inhibition, changes in the cervical mucus that inhibit sperm

penetration, changes to the endometrium that affect implantation. Their effectiveness as contraceptives range from 92-99.9% [292, 472].

Gonadotropin-releasing hormone (GnRH) on the other hand binds to specific receptors on pituitary gonadotrophs, leading to desensitisation and consequently to suppressed gonadotropin secretion. By contrast, GnRH antagonists compete with GnRH for receptors thus gonadotrophin secretion, which may be beneficial in certain clinical applications, such as reducing the size of fibroids, endometrial bleeding and endometriosis [473].

### **Pelvic Floor, Abdominal and Chronic Anal Pain**

#### **Botulinum toxin type A (pelvic floor)**

Botulinum toxin type A has been injected into trigger points. It is more expensive than lidocaine and has not been proven to be more effective [474]. Reviews do not support the injection of BTX-A into trigger points [475]. Pelvic floor muscle over-activity plays a role in CPP. Botulinum toxin type A, as a muscle relaxant, can be used to reduce the resting pressure in the pelvic floor muscles. In women with high resting pressure in the pelvic floor muscles, it has been found that BTX-A lowers this pressure significantly. The magnitude of reduction was significantly higher than that in the placebo group. On the VAS pain score, no intergroup differences were found in this relatively small randomised study [476]. Botulinum toxin type A can also be injected at the sphincter level to improve urination or defecation. Relaxation of the urethral sphincter alleviates bladder problems and secondarily the spasm. In a cohort study of thirteen patients with CPP, BTX-A was injected into the external urethral sphincter. Subjectively, eleven patients reported a substantial change in pain symptoms, from a score of 7.2 to 1.6 on a VAS [477].

#### **Botulinum toxin type A (chronic anal pain syndrome)**

In CPP associated with spasm of the levator ani muscles, treatment of the puborectalis and pubococcygeus muscle by BTX-A appears to be promising in some women, as shown in a pilot study (n=12). The inclusion criteria were dependent only on vaginal manometry with over-activity of the pelvic floor muscles, defined as a vaginal resting pressure > 40 cm H<sub>2</sub>O. Although dyspareunia and dysmenorrhoea improved, non-menstrual pelvic pain scores were not significantly altered [478]. In the following double-blinded, randomised, placebo-controlled trial, the same group defined pelvic floor myalgia according to the two criteria of tenderness on contraction and hypertension (> 40 cm H<sub>2</sub>O) and included 60 women. In this larger study, non-menstrual pelvic pain was significantly improved compared to those treated with placebo (VAS score 51 vs. 22; p=0.009). It was concluded therefore that BTX-A is effective at reducing pelvic floor-muscle associated pain with acceptable adverse effects such as occasional urinary and faecal stress incontinence [476]. However, recently, a small RCT failed to show any benefit of BTX-A [479].

#### **Intermittent chronic anal pain syndrome**

Due to the short duration of the episodes, medical treatment and prevention is often not feasible. Inhaled β-2 adrenergic agonist salbutamol was effective in an RCT in patients with frequent symptoms and shortened pain duration [480]. Other treatment options are topic diltiazem and BTX-A [481]. However, there is still some controversy regarding the duration of pain of intermittent chronic and chronic anal pain syndrome. Randomised controlled trials often use different definitions, extending the pain duration (with a shift to chronic pain) in order to include more patients and to better evaluate the study-drug action.

#### **Abdominal pain associated with Irritable Bowel Syndrome**

Linaclotide, a minimally absorbed peptide guanylate cyclase-C agonist at a dose of 290 µg once daily significantly improved abdominal pain (48.9% vs. 34.5% placebo-treated) and bowel symptoms associated with IBS with constipation over 26 weeks of treatment [482]. Diarrhoea was the most common adverse event in patients treated with linaclotide (4.5%). Although it is known to overlap with IBS pelvic pain, effect on the latter was not assessed in this study.

Delta-9-tetrahydrocannabinol (THC) shows only equivocal evidence of analgesic effects in chronic abdominal pain. In a recently published phase II trial no difference was found between THC tablet and a placebo tablet in reducing pain outcome in patients with chronic abdominal pain [483].

#### **5.2.2 Analgesics**

If the use of simple analgesics fails to provide adequate benefit, then consider using neuropathic agents, and if there is no improvement, consider involving a specialist pain management centre with an interest in pelvic pain. Chronic Pelvic Pain is well defined and involves multiple mechanisms as described in previous sections. The management requires a holistic approach with biological, psychological and social components. Few studies

have specifically looked at medications used in CPP [484], therefore, a wider look at the literature has been undertaken and further specific research is required. The agents concerned are divided for ease of description. Combinations often provide a greater benefit than individual agents. They may also allow lower individual dosages and thus minimise side-effects. The aim of using these drugs is to allow patients to improve their QoL. This is best measured by assessing their function as well as pain severity. If the use of these agents does not allow this, then they should be withdrawn. Unfortunately, the failure of one agent does not exclude potential benefit of an alternative. If the benefit is limited by side-effects, then the lowest effective dose should be found (by dose titration). Sometimes, patients will prefer a higher level of pain and have fewer side-effects.

#### 5.2.2.1 *Mechanisms of action*

Mechanisms of action are discussed as appropriate under the drug headings below.

#### 5.2.2.2 *Comparisons within and between groups in terms of efficacy and safety*

##### **Paracetamol (acetaminophen)**

Paracetamol is a well-tolerated analgesic in a class of its own. This is an antipyretic analgesic with a central mechanism of action [485]. It is often available over the counter without prescription. A review questions its routine use as a first-line analgesic based on inadequate evidence of efficacy in many pain conditions including dysmenorrhoea [486]. It will not be effective for all patients and individual responses should be reviewed when deciding on longer term use.

##### **Non-steroidal anti-inflammatory agents (NSAIDs)**

These agents are anti-inflammatory, antipyretic analgesics that act by inhibiting the enzyme cyclooxygenase (COX). They have a peripheral effect, hence their use in conditions involving peripheral or inflammatory mechanisms. They are commonly used for pelvic pain; many are available over the counter and are usually well tolerated. There is no good evidence to suggest one NSAID over another for pelvic pain. Guidelines for use of NSAIDs and COX-2 selective agents have been developed. They have more side-effects than paracetamol, including indigestion, headaches and drowsiness.

The evidence for their benefit in CPP is weak or non-existent and are often limited by side-effects. For pelvic pain in which inflammatory processes are considered important, such as dysmenorrhoea [487], NSAIDs are more effective than placebo and paracetamol, but with a higher incidence of side-effects. For pelvic pain in which central mechanisms may be incriminated, such as endometriosis [488], then the evidence is lacking for NSAIDs despite their common use.

At a practical level, if NSAIDs are considered for use, they should be tried (having regard for the cautions and contraindications) and the patient reviewed for improvement in function as well as analgesia. If this is not achieved, or side-effects are limiting, then they should be withdrawn.

##### **Neuromodulators**

These are agents that are not simple analgesics but used to modulate neuropathic or centrally mediated pain. There are several classes commonly used with recognised benefits in pain medicine. They are taken on a regular basis and all have side-effects that may limit use in some patients. In the UK, the National Institute for Health and Clinical Excellence (NICE) has reviewed the pharmacological management of neuropathic pain [489]. Not all the agents are licensed for use in pain management but there is a history and evidence to demonstrate their benefit. The evidence for treatment of CPP is lacking but is present for other painful conditions. For this chapter, most of the evidence is from non-pelvic pain sources. The general method for using these agents is by titrating the dose against benefit and side-effects. The aim is for patients to have an improvement in their QoL, which is often best assessed by alterations in their function. It is common to use these agents in combination but studies comparing different agents against each other, or in combination, are lacking. Some of these agents are also used for specific conditions. Early identification of neuropathic pain with a simple questionnaire could facilitate targeted therapy with neuromodulators [64].

##### **Antidepressants**

###### **Tricyclic antidepressants**

The tricyclic antidepressants (TCAs) have multiple mechanisms of action including, blockade of acetylcholine receptors, inhibition of serotonin and noradrenaline re-uptake, and blockade of histamine H1 receptors. They also have anxiolytic effects [490] and are frequently limited by their side-effects. Tricyclic antidepressants have a long history of use in pain medicine and have been subjected to a Cochrane review [491], suggesting that they are effective for neuropathic pain. Amitriptyline is the most commonly used member at doses from 10 to

75 mg/day (sometimes rising to 150 mg/day). This is titrated against benefit or side-effects and can be taken at night [489]. Nortriptyline and imipramine are used as alternatives.

### **Other Antidepressants**

Duloxetine is a serotonin-noradrenaline re-uptake inhibitor (SNRI) antidepressant licensed for use in depression, urinary stress incontinence and neuropathic pain. There is moderately strong evidence of benefit in diabetic neuropathy and fibromyalgia at a dose of 60 mg/day [492]. Side-effects are common and may result in its discontinuation.

Selective serotonin re-uptake inhibitors are antidepressants with fewer side-effects. They are effective for depression, but there have been insufficient studies to demonstrate their benefit in pelvic or neuropathic pain [491-493].

### **Anticonvulsants**

Anticonvulsants are commonly used in the management of neuropathic pain. There are general studies and some looking more particularly at pelvic pain. Individual agents have been systematically reviewed. Their use is suggested in the NICE Neuropathic Guidelines [489].

Carbamazepine has a long history of use in neuropathic pain. Evidence exists for its benefit [494]. Trials have tended to be of short duration, showing only moderate benefit. There are side-effects; some of which may be serious. It is no longer a first choice agent. Other anticonvulsant agents are available with fewer serious side-effects.

Gabapentin is commonly used for neuropathic pain and has been systematically reviewed [495]. It provides good quality relief with number needed to treat (NNT) of approximately six. Side-effects are common, notably drowsiness, dizziness and peripheral oedema. For higher dose levels, reference should be made to local formularies, and many clinicians do not routinely exceed 2.4 g/day in divided doses (most commonly three times daily). One study of women with CPP has suggested that gabapentin alone or in combination with amitriptyline provides better analgesia than amitriptyline alone [496]. A more recent pilot study suggests that gabapentin is beneficial and tolerable; a larger study is required to provide a definitive result [497].

Pregabalin is a commonly used neuromodulator with good evidence of efficacy in some neuropathic conditions but the NNT varies depending on the condition [498]. The dose for benefit is in the range of 300 to 600 mg/day. The same systematic review found that doses less than 150 mg/day are unlikely to provide benefit. A review for CPPS (prostate) only found a single reviewable study that does not show overall symptom improvement but suggests individual symptoms may improve (e.g. pain, QoL) and side-effects were common demonstrating the need for further robust studies [418]. As with gabapentin, side-effects are common and may not be tolerated by patients. A formal assessment of efficacy against side-effects is required with the patient in order to determine longer-term treatment. Other anticonvulsants are available but not commonly used for managing pain. Other agents can be used in the management of neuropathic pain but they are best administered only by specialists in the management of pain and familiar with their use. They tend to be considered after the standard options have been exhausted. As with all good pain management, they are used as part of a comprehensive multi-dimensional management plan.

### **Opioids**

Opioids are used for chronic non-malignant pain and may be beneficial for a small number of patients. Often patients will stop taking oral opioids due to side-effects or insufficient analgesic effect [499]. They should only be used in conjunction with a management plan with consultation between clinicians experienced in their use. It is suggested that a pain management unit should be involved along with the patient and their primary care physician.

There are well established guidelines for the use of opioids in pain management as well as considering the potential risks [500]. There is also information available online for patients [500]. Opioids Aware is a web-based resource for patients and healthcare professionals, jointly produced by the Faculty of Pain Medicine of Royal College of Anaesthetists and Public Health England, to support prescribing of opioid medicines for pain. <http://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware/>. There are several agents available in the group. They can be divided into weak (e.g., codeine, dihydrocodeine and tramadol) or strong opioids (e.g., morphine, oxycodone, fentanyl and hydromorphone). Oral administration is preferable, but if poorly tolerated, a percutaneous (patch) route may have advantages. More invasive approaches are less commonly used and within the realms of specialist units. Side-effects are common, including constipation, nausea, reduced QoL,

opioid tolerance, hormonal and immunological effects along with psychological changes and require active management.

There is a growing understanding of opioid-induced hyperalgesia; a situation in which patients taking opioids, paradoxically, become more sensitive to painful stimuli [500]. This is another reason for these drugs to be used in a controlled way for long-term management of non-malignant pain.

Morphine is the standard opioid with which many physicians are familiar. The aim is to use a slow or sustained release preparation starting with a low-dose and titrating the dose every three days to one week against improvement in both function and pain. Side-effects should also be monitored and managed accordingly. Particular attention should be paid to the management of constipation.

**There are a variety of other agents available and some are mentioned below:**

**Transdermal fentanyl** may be considered when oral preparations are restricted (e.g., ileostomy). It may also be beneficial when there are intolerable side-effects from other opioids.

**Methadone** has a long record of use as an opioid. There is a theoretical advantage of benefit with its N-methyl-D-aspartate receptor (NMDA) antagonist activity. This may be relevant in neuropathic pain [501].

**Oxycodone** may have greater efficacy than morphine in some situations, such as hyperalgesic states including visceral pain [502].

**Tramadol** is an established analgesic with dual effects on opioid receptors and serotonin release. More recently, tapentadol, has been released with opioid action and noradrenaline re-uptake inhibition. It is too early to assess its real value in the armamentarium for pain management.

## 5.3 Surgical management

### 5.3.1 Surgery

#### **Bladder Pain Syndrome (BPS)**

##### **Bladder distension**

Although bladder hydrodistension is a common treatment for BPS, the scientific justification is scarce. It can be part of the diagnostic evaluation, but has limited therapeutic role.

##### **Hydrodistension and Botulinum toxin type A**

Botulinum toxin type A may have an antinociceptive effect on bladder afferent pathways, producing symptomatic and urodynamic improvements [125]. Treatment with hydrodistension and hydrodistension plus intravesical BTX-A has been compared [503]. There was symptomatic improvement in all patients. However, in the hydrodistension-only group, 70% returned to their previous symptoms after one month, while in the BTX-A-treated patients, VAS score and functional and cystometric bladder capacity improved at three months. Botulinum toxin type A trigonal-only injection seems effective and long-lasting as 87% of patients reported improvement after three months follow-up [504]. Over 50% reported continued benefit nine months after the first treatment. When re-treatment was needed, similar results were obtained. The authors concluded that this treatment is safe, effective and can be repeated. Adverse effects of BTX-A administration for IC/BPS were significantly less than for overactive bladder syndrome, namely in increased post-void residual volumes and decreased voiding efficiency [505]. Recent RCTs have confirmed benefits and long efficacy of BTX-A administration [506-510]. The American Urological Association (AUA) guidelines panel has upgraded BTX-A treatment from fifth to a fourth line treatment [511].

##### **Transurethral resection (TUR), coagulation and laser**

Endourological destruction of bladder tissue aims to eliminate urothelial, mostly Hunner lesions. Since the 1970s resection and fulguration have been reported to achieve symptom relief, often for more than three years [512, 513]. Prolonged amelioration of pain and urgency has been described for transurethral laser ablation as well [514].

##### **Open Surgery for BPS**

Bladder pain syndrome is benign and does not shorten life, thus operative procedures rank last in the therapeutic algorithm. There is no evidence that it relieves pain. Surgery for refractory BPS is only appropriate



as a last resort for patients with refractory end-stage disease. Major surgery should be preceded by thorough pre-operative evaluation, with an emphasis on determining the relevant disease location and subtype. If surgery is considered, the panel's advice is to refer the patient to a specialist centre experienced in managing CPP with a multi-disciplinary team approach.

Four major techniques are common:

1. Urinary diversion without cystectomy. As early as 1967, it was reported that bladder augmentation without removal of the diseased tissue was not appropriate [515]. Reports that un-resected BPS bladders cease to induce symptoms after loss of contact with urine are scarce [122, 516].
2. Supratrigonal cystectomy with subsequent bladder augmentation represents the most favoured continence-preserving surgical technique. Various intestinal segments have been used for supratrigonal augmentation [517-519].
3. Subtrigonal cystectomy. Subtrigonal resection has the potential of removing the trigone as a possible disease site, but at the cost of requiring ureteral re-implantation. Trigonal disease is reported in 50% of patients and surgical failure has been blamed on the trigone being left in place [520]. In contrast, another study [521] reported six out of seventeen patients being completely cured by supratrigonal resection [520]. A recent study on female sexuality after cystectomy and orthotopic ileal neobladder showed pain relief in all patients, but only one regained normal sexual activity [522].
4. Cystectomy with formation of an ileal conduit still ranks first in current USA practice trends for BPS surgery [523]. For cosmetic reasons, continent diversion is preferred, particularly in younger patients. After orthotopic bladder augmentation, particularly when removing the trigone, voiding may be incomplete and require intermittent self-catheterisation. Patients considering these procedures must be capable of performing, accepting and tolerating self-catheterisation. For patients with BPS who develop recurrent pain in the augmented bladder or continent pouch after enterocystoplasty or continent urinary diversion, retubularisation of a previously used bowel segment to form a urinary conduit has been recommended [524]. It is important to note that pregnancies with subsequent lower-segment Caesarean section have been reported after ileocystoplasty [524, 525].

### **Prostate Pain Syndrome**

There is no evidence for surgical management, including transurethral incision of the bladder neck, radical transurethral resection of the prostate or, in particular, radical prostatectomy in the management of chronic pain in patients with PPS. Recently, a large Chinese randomised-controlled trial of circumcision combined with a triple oral therapy (ciprofloxacin, ibuprofen, tamsulosin) vs. oral therapy alone has been published for patients with PPS (total n=774) [526]. It is hypothesised that there may be some immunological interaction via pathogenic antigen presenting cells in the foreskin with CD4+ T cells causing autoimmunity to the prostate gland. They reported an improvement in total NIH-CPSI score and subdomain scores at twelve weeks. However, despite a large cohort, the study results are questionable because of the weak theoretical background, and a potential large placebo effect lacking a sham control. In addition, no long-term effectiveness has been reported. Before having an impact on recommendations, the results of this study have to be independently confirmed and the treatment effect must persist.

### **Testicular Pain Syndrome**

Microsurgical denervation of the spermatic cord can be offered to patients with testicular pain. In a long-term follow-up study, patients who had a positive result on blocking the spermatic cord were found to have a good result following denervation [527].

### **Chronic Anal and Abdominal Pain Syndrome**

Chronic anal pain syndrome after stapled procedures, such as hemorrhoidopexy (PPH) or stapled transanal rectal resection (STARR) may respond to excision of the scarred staple line as shown in 21 consecutive patients with an overall improvement of pain in 85.7% of patients undergoing scar excision surgery [528]. An early scar excision before three to six months after pain onset was associated with better pain relief. Adhesiolysis is still in discussion in the pain management after laparotomy/laparoscopy for different surgical indications in the pelvis and entire abdomen. A recent study has shown, that adhesiolysis is associated with an increased risk of operative complications, and additional operations and increased health care costs as compared to laparoscopy alone [529].

### **Urethral Pain Syndrome**

There is no specific treatment that can be advised. Management should be multi-disciplinary and multi-modal [530]. Laser therapy of the trigonal region may be a specific treatment. One trial comparing two forms of laser reported good results, but did not compare with sham treatment [531]. The majority of publications on treatment of urethral pain syndrome have come from psychologists [191].

### **Presumed intra-abdominal adhesions**

In gynaecological patients with CPP and presumed adhesions, there is no consensus as to whether adhesiolysis should be performed to improve pain [532].

Extensive surgery for endometriosis is challenging and is still considered to be controversial, as there is at least one RCT showing no benefit in pain relief after the removal of early extensive endometriosis compared to sham surgery [304, 533]. In patients with adenomyosis, the only curative surgery is hysterectomy but patients can benefit from hormonal therapy and analgesics (see 5.2.1).

### **Pudendal Neuralgia and surgery**

Decompression of an entrapped or injured nerve is a routine approach and probably should apply to the pudendal nerve as it applies to all other nerves. There are several approaches and the approach of choice probably depends upon the nature of the pathology. The most traditional approach is transgluteal; however, a transperineal approach may be an alternative, particularly if the nerve damage is thought to be related to previous pelvic surgery [214, 282, 534-538]. Currently, there has been only one prospective randomised study (transgluteal approach) [536]. This study suggests that, if the patient has had the pain for less than six years, 66% of patients will see some improvement with surgery (compared to 40% if the pain has been present for more than six years). Surgery is not the answer for all patients. On talking to patients that have undergone surgery, providing the diagnosis was clear-cut; most patients are grateful to have undergone surgery but many still have symptoms that need management.

### **Chronic Pelvic Pain and Prolapse/Incontinence Mesh**

Removing an existing mesh is a complex procedure [539]. Each patient is approached on an individual basis depending on the type of mesh and extent of complications [540]. The complexity of surgery often involves removal of dense scar tissue, reformation of inflamed vaginal skin and surgical reconstruction of the urethra and bladder [541]. Such surgery requires specialist skills, often provided with a multidisciplinary tertiary setting. Possible complications as a result of this surgery removal include bleeding, infection, damage to surrounding organs as well as lower urinary tracts symptoms, chronic pain and recurrent USI, which occurs after mesh removal [542].

Removal of mesh, whilst complex, does have beneficial outcomes generally, which are also durable particularly in chronic pain [543]. However, the long-term consequences after the mesh is removed still can include chronic persistent pain but also autoimmune responses and complex neuropathies affecting the pelvis and the lower limbs [544, 545]. Some of these can be treated effectively using a multi-disciplinary pain medicine approach [546]. In other cases, the residual symptoms may require the input of an immunologist, rheumatologist or other symptom-defined specialist.

The alternative to continence and prolapse mesh surgery is dependent on the clinical findings at the time. They include behavioural change, physiotherapy (for USI and Grade I-II uterovaginal prolapse) or traditional surgical techniques. Studies have shown that over 70% who committed to physiotherapy for stress urinary incontinence often did not need any further intervention [547]. So, many clinicians are reverting to conservative measures first, before re-considering surgery. Clinicians are also now retraining in traditional continence surgical techniques, which existed in the pre-mesh era, such as the Burch colposuspension and autologous fascial sling; as well as traditional utero-vaginal prolapse techniques such as vaginal hysterectomy, sacro-spinous fixation and fascial repair of vaginal wall prolapse.

#### **5.3.2 *Neuromodulation***

The role of neuromodulation in the management of pelvic pain should only be considered by specialists in pelvic pain management. These techniques are only used as part of a broader management plan and require regular follow-up. The research base is developing and the techniques broadening (e.g., spinal cord stimulation (SCS), sacral root stimulation, dorsal root ganglion stimulation or peripheral nerve stimulation). These are expensive interventional techniques for patients refractory to other therapies. Therefore, it is inappropriate to provide a detailed review in this publication. In the UK, guidance has been published for SCS in neuropathic pain [548]. This emphasises the comments above. This guidance suggests a trial period of stimulation before

full implementation. Neuromodulation is still finding its role in pelvic pain management. There has been growing evidence in small case series or pilot studies, but more detailed research is required [549]. Its role in overactive bladder and faecal incontinence is more robust but is limited for pain.

### **Bladder Pain Syndrome**

A comparison of sacral neuromodulation (SNM) vs. pudendal nerve stimulation (PNS), showed an overall 59% improvement in symptoms with PNS vs. 44% with SNM. Most patients who tested both a sacral and pudendal electrode chose PNS as the better site. Follow-up showed marked improvements in voiding variables and validated BPS symptom questionnaires. Over 90% of patients treated with neuromodulation stated that they would undergo implantation again [550]. Long-term results were verified in a retrospective study of patients from 1994 to 2008 [551]. Permanent SNM implantation was performed in patients who showed at least 50% improvement in symptoms with a temporary peripheral nerve evaluation test [551]. Median follow-up was 61.5 months. Good long-term success of SNM was seen in 72%, with a 28% explantation rate. The most frequent reason for explantation was poor outcome (54% of the failed patients). The revision rate was 50%. In a study of women who underwent permanent device implantation from 2002 to 2004 [495], mean pre- /postoperative pelvic pain and urgency/frequency scores were  $21.61 \pm 8.6/9.22 \pm 6.6$ , and mean pre-/post-operative VAS scores were  $6.5 \pm 2.9/2.4 \pm 1.1$ . Mean follow-up was  $86 \pm 9.8$  months. Sacral neuromodulation showed adequate improvement for the symptoms of refractory BPS. The re-operation rate was 25%.

### **Pudendal Neuralgia**

Pudendal neuralgia represents a peripheral nerve injury and as such should respond to neuromodulation by implanted pulse generators. However, it is important that the stimulation is perceived in the same site as the perceived pain. Spinal cord stimulation (SCS) may be effective for thoraco-lumbar afferents. However, it is difficult to obtain appropriate stimulation from SCS for the sacral nerves including pudendal. There is limited experience with sacral root stimulation and as a result stimulation for pudendal neuralgia should only be undertaken in specialised centres and in centres that can provide multi-disciplinary care [552-555].

### **Chronic Anal Pain Syndrome**

In a large cohort of 170 patients with functional anorectal pain from the St. Mark's Hospital (Harrow, Middlesex, United Kingdom) sacral nerve stimulation was used in three patients (two improved), while biofeedback was the most used modality with the greatest treatment effect in patients with defecatory dysfunction (29 patients, 17 improved) [481]. Sacral neuromodulation has been reported to be somewhat beneficial in two uncontrolled studies, showing improvement in about half the patients [556, 557]. Martellucci *et al.* have evaluated sacral neuromodulation in 27 patients, including 18 patients with previous pelvic surgery. Sixteen patients (59%) responded to testing and had a definitive implantation with long-term follow-up of 37 months with sustained response, while no patients after stapler surgery responded to neuromodulation [557]. Sacral neuromodulation may be a choice in patients with CPP who failed to respond to biofeedback and drug therapy. The less invasive PTNS was tested in twelve women with CPP lasting for at least six months and showed an improvement in pain, QoL and sexual life [558]. No "sham" SNM or PTNS control group were used in either cited studies, which limits their value as an important placebo effect cannot be ruled out.

#### **5.3.3 Nerve blocks**

Nerve blocks for pain management are usually carried out by specialists in pain medicine as part of a broader management plan [67]. They may have a diagnostic or therapeutic role. Textbooks have been written on the subject and practitioners using them should be trained in appropriate patient selection, indications, risks and benefits. Many such interventions also require understanding and expertise in using imaging techniques to perform the blocks accurately. Diagnostic blocks can be difficult to interpret due to the complex mechanisms underlying the painful condition or syndrome. Sustained but limited benefit may lead to more permanent procedures (e.g., radiofrequency procedures). There is a weak evidence base for these interventions for chronic non-malignant pain [559].

### **Pudendal Neuralgia**

The role of injections may be divided into two. First, an injection of local anaesthetic and steroid at the site of nerve injury may produce a therapeutic action. The possible reasons for this are related to the fact that steroids may reduce any inflammation and swelling at the site of nerve irritation, but also because steroids may block sodium channels and reduce irritable firing from the nerve [560]. However, a recent paper by Labat *et al.* challenges this [561]. The second possible benefit is diagnostic. It has already been indicated that when the pudendal nerve is injured there are several sites where this may occur. Differential block of the pudendal nerve helps to provide information in relation to the site where the nerve may be trapped [280-290].

Infiltration at the ischial spine requires the use of a nerve stimulator/locator. Both motor (anal contraction) and sensory endpoints may be noted. The anatomical endpoint may be localised by fluoroscopy, CT guidance, or the use of US, the latter avoids any radiation, whereas CT guidance involves a significant amount of radiation. Currently, fluoroscopy is probably the imaging technique most frequently used because it is readily available to most anaesthetists that perform the block. Currently, infiltration of the pudendal nerve within Alcock's canal is primarily undertaken with the use of CT. As well as injecting around the pudendal nerve, specific blocks of other nerves arising from the pelvis may be performed. Pulsed radio frequency stimulation has also been suggested as a treatment [562].

## 5.4 Summary of evidence and recommendations: management

### 5.4.1 Management of PPS

Summary of evidence	LE
Phenotypically directed treatment may improve treatment success.	3
$\alpha$ -blockers have moderate treatment effect regarding total pain, voiding, and QoL scores in PPS.	1a
Antimicrobial therapy has a moderate effect on total pain, voiding, and QoL scores in PPS.	1a
NSAIDs have moderate overall treatment effects on PPS.	1a
Phytotherapy has some beneficial effect on pain and overall favourable treatment response in PPS.	1a
Pentosane polysulphate improves global assessment and QoL score in PPS.	1b
There are insufficient data on the effectiveness of muscle relaxants in PPS.	2b
Pregabalin is not effective for the treatment of PPS.	1b
BTX-A injection into the pelvic floor (or prostate) may have a modest effect in PPS.	2b
Acupuncture is superior to sham acupuncture in improving symptoms and QoL.	1a
Posterior tibial nerve stimulation is probably effective for the treatment of PPS.	1b
Extracorporeal shock wave therapy is probably effective over the short term.	1b
There are insufficient data supporting the use of other surgical treatments, such as transurethral incision of the bladder neck, transurethral resection of the prostate, or radical prostatectomy in patients with PPS.	3
Cognitive behavioural therapy designed for PPS may improve pain and QoL.	3

Recommendations	Strength rating
Offer multimodal and phenotypically directed treatment options for Prostate Pain Syndrome (PPS).	Weak
Use antimicrobial therapy (quinolones or tetracyclines) over a minimum of six weeks in treatment-naïve patients with a duration of PPS less than one year.	Strong
Use $\alpha$ -blockers for patients with a duration of PPS less than one year.	Strong
Offer high-dose oral pentosane polysulphate in PPS.	Weak
Offer acupuncture in PPS.	Strong
Offer non-steroidal anti-inflammatory drugs (NSAIDs) in PPS, but long-term side-effects have to be considered.	Weak

#### 5.4.2 Management of BPS

Summary of evidence	LE
There is insufficient data for the long-term use of corticosteroids.	3
Limited data exist on effectiveness of cimetidine in BPS.	2b
Amitriptyline is effective for pain and related symptoms of BPS.	1b
Oral pentosane polysulphate is effective for pain and related symptoms of BPS.	1a
Oral pentosane polysulphate plus subcutaneous heparin is effective for pain and related symptoms of BPS, especially in initially low responders to pentosane polysulphate alone.	1b
Intravesical lidocaine plus sodium bicarbonate is effective in the short term.	1b
Intravesical pentosane polysulphate is effective, based on limited data, and may enhance oral treatment.	1b
There are limited data on the effectiveness of intravesical heparin.	3
Intravesical chondroitin sulphate may be effective.	2b
There is insufficient data for the use of bladder distension as a therapeutic intervention.	3
Hydrodistension plus BTX-A is superior to hydrodistension alone.	1b
Intravesical BCG is not effective in BPS.	1b
Transurethral resection (coagulation and laser) may be effective in BPS type 3 C.	3
Sacral neuromodulation may be effective in BPS.	3
Pudendal nerve stimulation is superior to SNM for treatment of BPS.	1b
Avoidance of certain foods and drink may reduce symptoms.	3
Outcome of cystectomy for BPS is variable.	3

Recommendations	Strength rating
Offer subtype and phenotype-oriented therapy for the treatment of Bladder Pain Syndrome (BPS).	Strong
Always consider offering multimodal behavioural, physical and psychological techniques alongside oral or invasive treatments of BPS.	Strong
Administer amitriptyline for treatment of BPS.	Strong
Offer oral pentosane polysulphate for the treatment of BPS.	Strong
Offer oral pentosane polysulphate plus subcutaneous heparin in low responders to pentosane polysulphate alone.	Weak
Administer intravesical lidocaine plus sodium bicarbonate prior to more invasive methods.	Weak
Administer intravesical pentosane polysulphate before more invasive treatment alone or combined with oral pentosane polysulphate.	Strong
Administer submucosal injection of botulinum toxin type A (BTX-A) plus hydrodistension if intravesical instillation therapies have failed.	Strong
Only undertake ablative organ surgery as the last resort and only by experienced and BPS-knowledgeable surgeons.	Strong
Offer intravesical hyaluronic acid before more invasive measures.	Weak
Offer intravesical chondroitin sulphate before more invasive measures.	Weak
Offer transurethral resection (or coagulation or laser) of bladder lesions, but in BPS type 3 C only.	Strong
Offer neuromodulation before more invasive interventions.	Weak
Offer dietary advice.	Weak
Offer intravesical heparin before more invasive measures alone or in combination treatment.	Weak
Offer intravesical bladder wall and trigonal injection of BTX-A if intravesical instillation therapies have failed.	Strong
Do not recommend oral corticosteroids for long-term treatment.	Strong
Do not use bladder distension as a treatment of BPS.	Weak

#### 5.4.3 *Management of scrotal pain syndrome*

Summary of evidence	LE
Microsurgical denervation of the spermatic cord is an effective therapy for scrotal pain syndrome.	2b
Vasovasostomy is effective in post-vasectomy pain.	2b

Recommendations	Strength rating
Inform about the risk of post-vasectomy pain when counselling patients planned for vasectomy.	Strong
Do open instead of laparoscopic inguinal hernia repair, to reduce the risk of scrotal pain.	Strong
In patients with testicular pain improving after spermatic block, offer microsurgical denervation of the spermatic cord.	Weak

#### 5.4.4 *Management of urethral pain syndrome*

Summary of evidence	LE
There is no specific treatment for urethral pain syndrome.	4

#### 5.4.5 *Management of gynaecological aspects of chronic pelvic pain*

Summary of evidence	LE
Therapeutic options, including pharmacotherapy and surgery, can treat endometriosis effectively.	1b
Psychological treatment (CBT or supportive psychotherapy) can improve pain and sexual and emotional function in vaginal and vulvar pain syndrome.	1b
All other gynaecological conditions (including dysmenorrhea, obstetric injury, pelvic organ prolapse, non-absorbable mesh insertion and gynaecological malignancy) can be treated effectively using pharmacotherapy.	3
All other gynaecological conditions (including dysmenorrhea, obstetric injury, pelvic organ prolapse, non-absorbable mesh insertion and gynaecological malignancy) can be treated effectively using surgery.	2

Recommendations	Strength rating
Involve a gynaecologist to provide therapeutic options such as hormonal therapy or surgery in well-defined disease states.	Strong
Provide a multi-disciplinary approach to pain management in persistent disease states.	Strong
All patients who have developed complications after mesh insertion should be referred to a multidisciplinary service (incorporating pain medicine and surgery).	Strong

#### 5.4.6 *Management of anorectal pain syndrome*

Summary of evidence	LE
Biofeedback is the preferred treatment for chronic anal pain syndrome.	1a
Electrogalvanic stimulation is less effective than biofeedback.	1b
Botulinum toxin type A is effective.	1b
Percutaneous tibial nerve stimulation is effective in anal pain.	3
Sacral neuromodulation is effective in anal pain.	3
Inhaled salbutamol is effective in intermittent chronic anal pain syndrome.	3

<b>Recommendations</b>	<b>Strength rating</b>
Undertake biofeedback treatment in patients with chronic anal pain.	Strong
Offer botulinum toxin type A in chronic anal pain syndrome.	Weak
Offer percutaneous tibial nerve stimulation in chronic anal pain syndrome.	Weak
Offer sacral neuromodulation in chronic anal pain syndrome.	Weak
Offer inhaled salbutamol in intermittent chronic anal pain syndrome.	Weak

#### 5.4.7 *Management of pudendal neuralgia*

<b>Summary of evidence</b>	<b>LE</b>
There are multiple treatment options with varying levels of evidence.	3

<b>Recommendation</b>	<b>Strength rating</b>
Neuropathic pain guidelines are well-established. Use standard approaches to management of neuropathic pain.	Strong

#### 5.4.8 *Management of sexological aspects in CPP*

<b>Summary of evidence</b>	<b>LE</b>
Pelvic floor muscle physical therapy may offer relief of pain and reduction in sexual complaints.	2b

<b>Recommendations</b>	<b>Strength rating</b>
Offer behavioural strategies to the patient and his/her partner to reduce sexual dysfunctions.	Weak
Offer pelvic floor muscle therapy as part of the treatment plan to improve quality of life and sexual function.	Weak

#### 5.4.9 *Management of psychological aspects in CPP*

<b>Recommendation</b>	<b>Strength rating</b>
For CPP with significant psychological distress, refer patient for CPP-focused psychological treatment.	Strong

#### 5.4.10 *Management of pelvic floor dysfunction*

<b>Summary of evidence</b>	<b>LE</b>
Myofascial treatment is effective.	1b
Biofeedback improves the outcome of myofascial therapy.	1a

<b>Recommendations</b>	<b>Strength rating</b>
Apply myofascial treatment as first-line treatment.	Weak
Offer biofeedback as therapy adjuvant to muscle exercises, in patients with anal pain due to an overactive pelvic floor.	Strong

#### 5.4.11 Management of chronic/non-acute urogenital pain by opioids

Recommendations	Strength rating
Prescribe opioid treatment, following multi-disciplinary assessment and only after other reasonable treatments have been tried and failed.	Strong
The decision to instigate long-term opioid therapy should be made by an appropriately trained specialist in consultation with the patient and their family doctor.	Strong
Where there is a history or suspicion of drug abuse, involve a psychiatrist or psychologist with an interest in pain management and drug addiction.	Strong

## 6. EVALUATION OF TREATMENT RESULTS

### 6.1 Evaluation of treatment

For patients with chronic visceral pain, a visit to the clinician is important because they can ask questions, talk about how the process is going and have some time with the caregiver who understands the nature of their pain. First evaluation should take place after about six weeks to see if the treatment has been successful or not. When necessary adaptations are made and a next evaluation is planned.

#### 6.1.1 Treatment has not been effective

##### 6.1.1.1 Alternative treatment

In cases where the treatment initiated did not have enough effect, an alternative approach is advised. The first thing to do is a thorough evaluation of the patients' or care providers' adherence to the treatment that was initiated. Ask the patient if they have taken the medication according to the prescription, if there were any side-effects and if there were any changes in pain and function. Adjustment of medication or dose schemes might help. Another important thing to do is to read the reports of other caregivers like the physiotherapist and the psychologist. Has the therapy been followed until the end, what was the opinion of the therapist about the changes that were observed? In cases where the sessions had been ended by the patient, ask the patient why they made that decision. Check if the patient has understood the idea behind the therapy that was prematurely stopped.

##### 6.1.1.2 Referral to next envelope of care

If patients and doctors come to the conclusion that none of the therapies given showed enough effect, then referral to a next envelope of care is advised. Unfortunately, the terminology used to describe the nature and specialisation level of centres providing specialised care for visceral pain patients is not standardised and country-based. This does not facilitate easy referral schemes. It is advised that patients are referred to a centre that is working with a multi-disciplinary team and nationally recognised as specialised in pelvic pain. Such a centre will re-evaluate what has been done and when available, provide specialised care.

##### 6.1.1.3 Self-management and shared care

Patients who find themselves confronted with CPP, for which there is no specific treatment option available, will have to live with their pain. They will need to manage their pain, meaning that they will have to find a way to deal with the impact of their pain on daily activities in all domains of life. Self-help programmes maybe advised and can be of help. The patient may also benefit from shared care, which means that a caregiver is available for supporting the self-management strategies. Together with this caregiver the patient can optimise and use the management strategies.

#### 6.1.2 Treatment has been effective

In cases where treatment has been effective the caregiver may pay attention to fallback prevention. If the patient feels the same pain again, it helps to start at an early stage with the self-management strategies that he/she has learned during the former treatment. By doing so they will have the best chance of preventing the development of pelvic pain syndromes again.



## 7. REFERENCES

1. Fall, M., *et al.*, EAU Guidelines on Chronic Pelvic Pain., In: EAU Guidelines on Chronic Pelvic Pain. Presented at the 18th EAU Annual Congress Madrid 2003. 2003, European Association of Urology: Arnhem.  
<https://uroweb.org/guideline/chronic-pelvic-pain/?type=archive>
2. Fall, M., *et al.* EAU guidelines on chronic pelvic pain. *Eur Urol*, 2004. 46: 681.  
<https://www.ncbi.nlm.nih.gov/pubmed/15548433>
3. Fall, M., *et al.*, EAU Guidelines on Chronic Pelvic Pain, In: EAU Guidelines on Chronic Pelvic Pain. Presented at the 18th EAU Annual Congress Barcelona 2010. 2010, EAU: Arnhem.  
<https://uroweb.org/guideline/chronic-pelvic-pain/?type=archive>
4. Fall, M., *et al.* EAU guidelines on chronic pelvic pain. *Eur Urol*, 2010. 57: 35.  
<https://www.ncbi.nlm.nih.gov/pubmed/19733958>
5. Engeler, D.S., *et al.* The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. *Eur Urol*, 2013. 64: 431.  
<https://www.ncbi.nlm.nih.gov/pubmed/23684447>
6. McMahon, S.B., *et al.* Visceral pain. *Br J Anaesth*, 1995. 75: 132.  
<https://www.ncbi.nlm.nih.gov/pubmed/7577247>
7. Shoskes, D.A., *et al.* Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. *Urology*, 2009. 73: 538.  
<https://www.ncbi.nlm.nih.gov/pubmed/19118880>
8. Magri, V., *et al.* Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. *J Urol*, 2010. 184: 2339.  
<https://www.ncbi.nlm.nih.gov/pubmed/20952019>
9. Merskey, H., *et al.*, Classification of Chronic Pain. 1994, Seattle.  
<https://pdfs.semanticscholar.org/281f/3f5476d2444bb53553f473ec83634e090ee2.pdf>
10. Krieger, J.N., *et al.* NIH consensus definition and classification of prostatitis. *JAMA*, 1999. 282: 236.  
<https://www.ncbi.nlm.nih.gov/pubmed/10422990>
11. van de Merwe, J.P., *et al.* Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. *Eur Urol*, 2008. 53: 60.  
<https://www.ncbi.nlm.nih.gov/pubmed/17900797>
12. Longstreth, G.F., *et al.* Functional bowel disorders. *Gastroenterology*, 2006. 130: 1480.  
<https://www.ncbi.nlm.nih.gov/pubmed/16678561>
13. Guyatt, G.H., *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *Bmj*, 2008. 336: 924.  
<https://www.ncbi.nlm.nih.gov/pubmed/18436948>
14. Guyatt, G.H., *et al.* What is "quality of evidence" and why is it important to clinicians? *Bmj*, 2008. 336: 995.  
<https://www.ncbi.nlm.nih.gov/pubmed/18456631>
15. Phillips B, *et al.* Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998. Access date February 2014.  
<https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>
16. Guyatt, G.H., *et al.* Going from evidence to recommendations. *Bmj*, 2008. 336: 1049.  
<https://www.ncbi.nlm.nih.gov/pubmed/18467413>
17. Schneider M.P., *et al.* What are the benefits and harms of electrical neuromodulation vs best clinical practice or no treatment in chronic pelvic pain (CPP)? PROSPERO: International prospective register of systematic reviews, 2017: CRD42017054893.  
[http://www.crd.york.ac.uk/PROSPERO/display\\_record.php?ID=CRD42017054893](http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017054893)
18. Breivik, H., *et al.* Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *Eur J Pain*, 2006. 10: 287.  
<https://www.ncbi.nlm.nih.gov/pubmed/16095934>
19. Ayorinde, A.A., *et al.* Chronic pelvic pain in women of reproductive and post-reproductive age: a population-based study. *Eur J Pain*, 2017. 21: 445.  
<https://www.ncbi.nlm.nih.gov/pubmed/27634190>
20. Choung, R.S., *et al.* Irritable bowel syndrome and chronic pelvic pain: a population-based study. *J Clin Gastroenterol*, 2010. 44: 696.  
<https://www.ncbi.nlm.nih.gov/pubmed/20375730>
21. Fenton, B.W. Measuring quality of life in chronic pelvic pain syndrome. *Exp Rev Obstet Gynecol*, 2010. 5: 115.  
<https://www.karger.com/Article/Abstract/336768>

22. Baranowski, A.P. Chronic pelvic pain. *Best Pract Res Clin Gastroenterol*, 2009. 23: 593.  
<https://www.ncbi.nlm.nih.gov/pubmed/19647692>
23. Krieger, J., *et al.* Non-urolological syndromes and severity of urological pain symptoms: Baseline evaluation of the national institutes of health multidisciplinary approach to pelvic pain study. *J Urol*, 2013. 1: e181.  
<https://www.ncbi.nlm.nih.gov/pubmed/71031385>
24. Kanter, G., *et al.* Important role of physicians in addressing psychological aspects of interstitial cystitis/bladder pain syndrome (IC/BPS): a qualitative analysis. *Int Urogynecol J*, 2017. 28: 249.  
<https://www.ncbi.nlm.nih.gov/pubmed/27581769>
25. Chuang, Y.C., *et al.* Increased risks of healthcare-seeking behaviors of anxiety, depression and insomnia among patients with bladder pain syndrome/interstitial cystitis: a nationwide population-based study. *Int Urol Nephrol*, 2015. 47: 275.  
<https://www.ncbi.nlm.nih.gov/pubmed/25577231>
26. Mulak, A., *et al.* Irritable bowel syndrome as an interdisciplinary clinical problem. *Adv Clin Exp Med*, 2008. 17: 667.  
[http://www.dbc.wroc.pl/Content/2600/1111\\_Mula.pdf](http://www.dbc.wroc.pl/Content/2600/1111_Mula.pdf)
27. Riedl, A., *et al.* Somatic comorbidities of irritable bowel syndrome: A systematic analysis. *J Psychosom Res*, 2008. 64: 573.  
<https://www.ncbi.nlm.nih.gov/pubmed/18501257>
28. Savidge, C.J., *et al.* Psychological aspects of chronic pelvic pain. *J Psychosom Res*, 1997. 42: 433.  
<https://www.ncbi.nlm.nih.gov/pubmed/9194016>
29. Anda, R.F., *et al.* The enduring effects of abuse and related adverse experiences in childhood. A convergence of evidence from neurobiology and epidemiology. *Eur Arch Psychiatry Clin Neurosci*, 2006. 256: 174.  
<https://www.ncbi.nlm.nih.gov/pubmed/16311898>
30. Raphael, K.G. Childhood abuse and pain in adulthood: more than a modest relationship? *Clin J Pain*, 2005. 21: 371.  
<https://www.ncbi.nlm.nih.gov/pubmed/11323150>
31. Raphael, K.G., *et al.* Childhood victimization and pain in adulthood: a prospective investigation. *Pain*, 2001. 92: 283.  
<https://www.ncbi.nlm.nih.gov/pubmed/11323150>
32. Tunitsky, E., *et al.* Bladder pain syndrome/interstitial cystitis in twin sisters. *J Urol*, 2012. 187: 148.  
<https://www.ncbi.nlm.nih.gov/pubmed/20227820>
33. Vehof, J., *et al.* Shared genetic factors underlie chronic pain syndromes. *Pain*, 2014. 155: 1562.  
<https://www.ncbi.nlm.nih.gov/pubmed/24879916>
34. Roth, R.S., *et al.* Patient beliefs about pain diagnosis in chronic pelvic pain: relation to pain experience, mood and disability. *J Reprod Med*, 2011. 56: 123.  
<https://www.ncbi.nlm.nih.gov/pubmed/21542529>
35. Berman, S.M., *et al.* Reduced brainstem inhibition during anticipated pelvic visceral pain correlates with enhanced brain response to the visceral stimulus in women with irritable bowel syndrome. *J Neurosci*, 2008. 28: 349.  
<https://www.ncbi.nlm.nih.gov/pubmed/18184777>
36. Naliboff, B.D., *et al.* Clinical and Psychosocial Predictors of Urological Chronic Pelvic Pain Symptom Change in 1 Year: A Prospective Study from the MAPP Research Network. *J Urol*, 2017. 198: 848.  
<https://www.ncbi.nlm.nih.gov/pubmed/28528930>
37. Bajaj, P., *et al.* Endometriosis is associated with central sensitization: a psychophysical controlled study. *J Pain*, 2003. 4: 372.  
<https://www.ncbi.nlm.nih.gov/pubmed/14622679>
38. Berkley, K.J., *et al.* Don't dismiss dysmenorrhea! *Pain*, 2011. 152: 1940.  
<https://www.ncbi.nlm.nih.gov/pubmed/21514053>
39. Zondervan, K.T., *et al.* The community prevalence of chronic pelvic pain in women and associated illness behaviour. *Br J Gen Pract*, 2001. 51: 541.  
<https://www.ncbi.nlm.nih.gov/pubmed/11462313>
40. Savidge, C.J., *et al.* Women's Perspectives on their Experiences of Chronic Pelvic Pain and Medical Care. *J Health Psychol*, 1998. 3: 103.  
<https://www.ncbi.nlm.nih.gov/pubmed/22021346>
41. Price, J., *et al.* Attitudes of women with chronic pelvic pain to the gynaecological consultation: a qualitative study. *BJOG*, 2006. 113: 446.  
<https://www.ncbi.nlm.nih.gov/pubmed/16489938>

42. Fry, R.P., *et al.* Sociopsychological factors in chronic pelvic pain: a review. *J Psychosom Res*, 1997. 42: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/9055210>
43. Martin, C.E., *et al.* Catastrophizing: A predictor of persistent pain among women with endometriosis at 1 year. *Human Reprod*, 2011. 26: 3078.  
<https://www.ncbi.nlm.nih.gov/pubmed/21900393>
44. Riegel, B., *et al.* Assessing psychological factors, social aspects and psychiatric co-morbidity associated with Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) in men - A systematic review. *J Psychos Res*, 2014. 77: 333.  
<https://www.ncbi.nlm.nih.gov/pubmed/25300538>
45. Watkins, K.E., *et al.* Depressive disorders and panic attacks in women with bladder pain syndrome/interstitial cystitis: a population-based sample. *Gen Hosp Psychiatry*, 2011. 33: 143.  
<https://www.ncbi.nlm.nih.gov/pubmed/21596207>
46. Chung, S.D., *et al.* Association between chronic prostatitis/chronic pelvic pain syndrome and anxiety disorder: a population-based study. *PLoS ONE [Electronic Resource]*, 2013. 8.  
<https://www.ncbi.nlm.nih.gov/pubmed/23691256>
47. Latthe, P., *et al.* Factors predisposing women to chronic pelvic pain: systematic review. *BMJ*, 2006. 332: 749.  
<https://www.ncbi.nlm.nih.gov/pubmed/16484239>
48. Hilden, M., *et al.* A history of sexual abuse and health: a Nordic multicentre study. *BJOG*, 2004. 111: 1121.  
<https://www.ncbi.nlm.nih.gov/pubmed/15383115>
49. Lampe, A., *et al.* Chronic pelvic pain and previous sexual abuse. *Obstet Gynecol*, 2000. 96: 929.  
<https://www.ncbi.nlm.nih.gov/pubmed/11084180>
50. Angst, J. Sexual problems in healthy and depressed persons. *Int Clin Psychopharmacol*, 1998. 13 Suppl 6: S1.  
<https://www.ncbi.nlm.nih.gov/pubmed/9728667>
51. Leonard, L.M., *et al.* Sexual functioning in women reporting a history of child sexual abuse: review of the empirical literature and clinical implications. *Annu Rev Sex Res*, 2002. 13: 346.  
<https://www.ncbi.nlm.nih.gov/pubmed/12836736>
52. McGowan, L., *et al.* Chronic pelvic pain: A meta-analytic review. *Psychol Health*, 1998. 13: 937.  
<https://www.tandfonline.com/doi/abs/10.1080/08870449808407441>
53. Roelofs, K., *et al.* Trauma and medically unexplained symptoms towards an integration of cognitive and neuro-biological accounts. *Clin Psychol Rev*, 2007. 27: 798.  
<https://www.ncbi.nlm.nih.gov/pubmed/17728032>
54. Walker, E.A., *et al.* Psychiatric diagnoses and sexual victimization in women with chronic pelvic pain. *Psychosomatics*, 1995. 36: 531.  
<https://www.ncbi.nlm.nih.gov/pubmed/7501783>
55. Nickel, J.C., *et al.* Childhood sexual trauma in women with interstitial cystitis/bladder pain syndrome: a case control study. *Can Urol Assoc J*, 2011. 5: 410.  
<https://www.ncbi.nlm.nih.gov/pubmed/22154637>
56. Paras, M.L., *et al.* Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis. *JAMA*, 2009. 302: 550.  
<https://www.ncbi.nlm.nih.gov/pubmed/19654389>
57. Campbell, R., *et al.* Gynecological health impact of sexual assault. *Res Nurs Health*, 2006. 29: 399.  
<https://www.ncbi.nlm.nih.gov/pubmed/16977640>
58. Leserman, J. Sexual abuse history: prevalence, health effects, mediators, and psychological treatment. *Psychosom Med*, 2005. 67: 906.  
<https://www.ncbi.nlm.nih.gov/pubmed/16314595>
59. Hu, J.C., *et al.* The association of abuse and symptoms suggestive of chronic prostatitis/chronic pelvic pain syndrome: results from the Boston Area Community Health survey. *J Gen Intern Med*, 2007. 22: 1532.  
<https://www.ncbi.nlm.nih.gov/pubmed/17763912>
60. Linley, J.E., *et al.* Understanding inflammatory pain: ion channels contributing to acute and chronic nociception. *Pflugers Arch*, 2010. 459: 657.  
<https://www.ncbi.nlm.nih.gov/pubmed/20162302>
61. Nickel, J.C., *et al.* Prevalence and impact of bacteriuria and/or urinary tract infection in interstitial cystitis/painful bladder syndrome. *Urology*, 2010. 76: 799.  
<https://www.ncbi.nlm.nih.gov/pubmed/20573386>

62. Tripp, D.A., *et al.* Sexual functioning, catastrophizing, depression, and pain, as predictors of quality of life in women with interstitial cystitis/painful bladder syndrome. *Urology*, 2009. 73: 987.  
<https://www.ncbi.nlm.nih.gov/pubmed/20573386>
63. Tripp, D.A., *et al.* Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome. *J Pain*, 2006. 7: 697.  
<https://www.ncbi.nlm.nih.gov/pubmed/17018330>
64. Whitaker, L.H., *et al.* An Exploratory Study into Objective and Reported Characteristics of Neuropathic Pain in Women with Chronic Pelvic Pain. *PLoS One*, 2016. 11: e0151950.  
<https://www.ncbi.nlm.nih.gov/pubmed/27046128>
65. Kutch, J.J., *et al.* Altered resting state neuromotor connectivity in men with chronic prostatitis/chronic pelvic pain syndrome: A MAPP: Research Network Neuroimaging Study. *Neuroimage Clin*, 2015. 8: 493.  
<https://www.ncbi.nlm.nih.gov/pubmed/26106574>
66. Abrams, P., *et al.* A new classification is needed for pelvic pain syndromes--are existing terminologies of spurious diagnostic authority bad for patients? *J Urol*, 2006. 175: 1989.  
<https://www.ncbi.nlm.nih.gov/pubmed/16697782>
67. Baranowski, A., *et al.*, *Urogenital Pain in Clinical Practice*. 2008, New York.
68. Baranowski, A.P., *et al.* Urogenital pain--time to accept a new approach to phenotyping and, as a consequence, management. *Eur Urol*, 2008. 53: 33.  
<https://www.ncbi.nlm.nih.gov/pubmed/17961909>
69. Hanno, P., *et al.* Bladder Pain Syndrome Committee of the International Consultation on Incontinence. *Neurourol Urodyn*, 2010. 29: 191.  
<https://www.ncbi.nlm.nih.gov/pubmed/20025029>
70. Yoon, B.I., *et al.* Clinical courses following acute bacterial prostatitis. *Prostate Int*, 2013. 1: 89.  
<https://www.ncbi.nlm.nih.gov/pubmed/24223408>
71. Giamberardino, M.A., *et al.* Viscero-visceral hyperalgesia: characterization in different clinical models. *Pain*, 2010. 151: 307.  
<https://www.ncbi.nlm.nih.gov/pubmed/20638177>
72. Wesselmann, U., *et al.* Emerging Therapies and Novel Approaches to Visceral Pain. *Drug Discov Today Ther Strateg*, 2009. 6: 89.  
<https://www.ncbi.nlm.nih.gov/pubmed/21243067>
73. Pezet, S., *et al.* Neurotrophins: mediators and modulators of pain. *Annu Rev Neurosci*, 2006. 29: 507.  
<https://www.ncbi.nlm.nih.gov/pubmed/16776595>
74. Cervero, F., *et al.* Understanding the signaling and transmission of visceral nociceptive events. *J Neurobiol*, 2004. 61: 45.  
<https://www.ncbi.nlm.nih.gov/pubmed/15362152>
75. Kobayashi, H., *et al.* Mechanism of pain generation for endometriosis-associated pelvic pain. *Arch Gynecol Obstet*, 2014. 289: 13.  
<https://www.ncbi.nlm.nih.gov/pubmed/24121693>
76. Langan, K.L., *et al.* Endometriosis: translation of molecular insights to management. *Minerva Endocrinol*, 2014. 39: 141.  
<https://www.ncbi.nlm.nih.gov/pubmed/25003227>
77. Nazif, O., *et al.* Neural upregulation in interstitial cystitis. *Urology*, 2007. 69: 24.  
<https://www.ncbi.nlm.nih.gov/pubmed/17462476>
78. Melzack, R., *et al.* Central neuroplasticity and pathological pain. *Ann N Y Acad Sci*, 2001. 933: 157.  
<https://www.ncbi.nlm.nih.gov/pubmed/12000018>
79. Fulbright, R.K., *et al.* Functional MR imaging of regional brain activation associated with the affective experience of pain. *AJR Am J Roentgenol*, 2001. 177: 1205.  
<https://www.ncbi.nlm.nih.gov/pubmed/11641204>
80. Rygh, L.J., *et al.* Cellular memory in spinal nociceptive circuitry. *Scand J Psychol*, 2002. 43: 153.  
<https://www.ncbi.nlm.nih.gov/pubmed/12004953>
81. Grace, V.M. Pitfalls of the medical paradigm in chronic pelvic pain. *Baillieres Best Pract Res Clin Obstet Gynaecol*, 2000. 14: 525.  
<https://www.ncbi.nlm.nih.gov/pubmed/10962640>
82. Sharpe, M., *et al.* "Unexplained" somatic symptoms, functional syndromes, and somatization: do we need a paradigm shift? *Ann Intern Med*, 2001. 134: 926.  
<https://www.ncbi.nlm.nih.gov/pubmed/11346330>
83. Malykhina, A.P. Neural mechanisms of pelvic organ cross-sensitization. *Neuroscience*, 2007. 149: 660.  
<https://www.ncbi.nlm.nih.gov/pubmed/17920206>

84. Sanford, M.T., *et al.* The role of environmental stress on lower urinary tract symptoms. *Curr Opin Urol*, 2017. 27: 268.  
<https://www.ncbi.nlm.nih.gov/pubmed/28376513>
85. Binik, Y.M. The DSM diagnostic criteria for dyspareunia. *Arch Sex Behav*, 2010. 39: 292.  
<https://www.ncbi.nlm.nih.gov/pubmed/19830537>
86. Farmer, M., *et al.* Psychology is from Mars, sexology is from Venus: can they meet on earth? *Can Psychol*, 2005. 46: 46.  
<https://www.scholars.northwestern.edu/en/publications/psychology-is-from-mars-sexology-is-from-venus-can-they-meet-on-e>
87. Bergeron, S., *et al.* Genital pain in women: Beyond interference with intercourse. *Pain*, 2011. 152: 1223.  
<https://www.ncbi.nlm.nih.gov/pubmed/21324589>
88. Davis, S.N., *et al.* Sexual dysfunction and pelvic pain in men: a male sexual pain disorder? *J Sex Marital Ther*, 2009. 35: 182.  
<https://www.ncbi.nlm.nih.gov/pubmed/19360518>
89. Leserman, J., *et al.* Identification of diagnostic subtypes of chronic pelvic pain and how subtypes differ in health status and trauma history. *Am J Obstet Gynecol*, 2006. 195: 554.  
<https://www.ncbi.nlm.nih.gov/pubmed/16769027>
90. Meltzer-Brody, S., *et al.* Trauma and posttraumatic stress disorder in women with chronic pelvic pain. *Obstet Gynecol*, 2007. 109: 902.  
<https://www.ncbi.nlm.nih.gov/pubmed/17400852>
91. Iglesias-Rios, L., *et al.* Depression and Posttraumatic Stress Disorder Among Women with Vulvodynia: Evidence from the Population-Based Woman to Woman Health Study. *Journal of Women's Health* (15409996), 2015. 24: 557.  
<https://www.ncbi.nlm.nih.gov/pubmed/25950702>
92. Anderson, A.B., *et al.* Associations Between Penetration Cognitions, Genital Pain, and Sexual Well-being in Women with Provoked Vestibulodynia. *J Sex Med*, 2016. 13: 444.  
<https://www.ncbi.nlm.nih.gov/pubmed/26853045>
93. Roth, R.S., *et al.* Psychological factors and chronic pelvic pain in women: a comparative study with women with chronic migraine headaches. *Health Care Women Int*, 2011. 32: 746.  
<https://www.ncbi.nlm.nih.gov/pubmed/21767098>
94. Souza, P.P., *et al.* Qualitative research as the basis for a biopsychosocial approach to women with chronic pelvic pain. *J Psychosom Obstet Gynaecol*, 2011. 32: 165.  
<https://www.ncbi.nlm.nih.gov/pubmed/21919820>
95. Berna, C., *et al.* Presence of mental imagery associated with chronic pelvic pain: a pilot study. *Pain Med*, 2011. 12: 1086.  
<https://www.ncbi.nlm.nih.gov/pubmed/21668746>
96. Allaire, C., *et al.*, History-taking, physical examination and psychological assessment. In: *Consensus guidelines for the management of chronic pelvic pain.*, Jarrell JF, Vilos GJ (editors). *J Obstet Gynaecol Can*. 2005. p. 869.
97. Toye, F., *et al.* A meta-ethnography of patients' experiences of chronic pelvic pain: struggling to construct chronic pelvic pain as 'real'. *J Adv Nurs*, 2014. 70: 2713.  
<https://www.ncbi.nlm.nih.gov/pubmed/25081990>
98. Dworkin, R.H., *et al.* Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain*, 2005. 113: 9.  
<https://www.ncbi.nlm.nih.gov/pubmed/15621359>
99. Awad, S.A., *et al.* Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. *Br J Urol*, 1998. 81: 569.  
<https://www.ncbi.nlm.nih.gov/pubmed/9598629>
100. Vecchiet, L., *et al.* Referred Muscle Pain: Clinical and Pathophysiologic Aspects. *Curr Rev Pain*, 1999. 3: 489.  
<https://www.ncbi.nlm.nih.gov/pubmed/10998708>
101. Slocumb, J.C. Neurological factors in chronic pelvic pain: trigger points and the abdominal pelvic pain syndrome. *Am J Obstet Gynecol*, 1984. 149: 536.  
<https://www.ncbi.nlm.nih.gov/pubmed/6234807>
102. Barry, M.J., *et al.* Overlap of different urological symptom complexes in a racially and ethnically diverse, community-based population of men and women. *BJU Int*, 2008. 101: 45.  
<https://www.ncbi.nlm.nih.gov/pubmed/17868419>
103. Roberts, R.O., *et al.* Low agreement between previous physician diagnosed prostatitis and national institutes of health chronic prostatitis symptom index pain measures. *J Urol*, 2004. 171: 279.  
<https://www.ncbi.nlm.nih.gov/pubmed/14665894>

104. Krieger, J.N., *et al.* Epidemiology of prostatitis. *Int J Antimicrob Agents*, 2008. 31 Suppl 1: S85.  
<https://www.ncbi.nlm.nih.gov/pubmed/18164907>
105. Mehik, A., *et al.* Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. *BJU Int*, 2000. 86: 443.  
<https://www.ncbi.nlm.nih.gov/pubmed/10971269>
106. Bade, J.J., *et al.* Interstitial cystitis in The Netherlands: prevalence, diagnostic criteria and therapeutic preferences. *J Urol*, 1995. 154: 2035.  
<https://www.ncbi.nlm.nih.gov/pubmed/10971269>
107. Burkman, R.T. Chronic pelvic pain of bladder origin: epidemiology, pathogenesis and quality of life. *J Reprod Med*, 2004. 49: 225.  
<https://www.ncbi.nlm.nih.gov/pubmed/15088860>
108. Curhan, G.C., *et al.* Epidemiology of interstitial cystitis: a population based study. *J Urol*, 1999. 161: 549.  
<https://www.ncbi.nlm.nih.gov/pubmed/9915446>
109. Held, P., *et al.*, Interstitial Cystitis. In: *Epidemiology of interstitial cystitis*. Hanno PM, Staskin DR, Krane RJ, Wein AJ, eds. 1990, Springer Verlag: London.
110. Jones, C., *et al.* Prevalence of interstitial cystitis in the United States. *Proc Am Urol Ass J Urol*, 1994. 151 (Suppl). [No abstract available].
111. Leppilahti, M., *et al.* Prevalence of clinically confirmed interstitial cystitis in women: a population based study in Finland. *J Urol*, 2005. 174: 581.  
<https://www.ncbi.nlm.nih.gov/pubmed/16006902>
112. Oravisto, K.J. Epidemiology of interstitial cystitis. *Ann Chir Gynaecol Fenn*, 1975. 64: 75.  
<https://www.ncbi.nlm.nih.gov/pubmed/971677>
113. Parsons, C.L., *et al.* Prevalence of interstitial cystitis in young women. *Urology*, 2004. 64: 866.  
<https://www.ncbi.nlm.nih.gov/pubmed/15533465>
114. Roberts, R.O., *et al.* Incidence of physician-diagnosed interstitial cystitis in Olmsted County: a community-based study. *BJU Int*, 2003. 91: 181.  
<https://www.ncbi.nlm.nih.gov/pubmed/12581000>
115. Temml, C., *et al.* Prevalence and correlates for interstitial cystitis symptoms in women participating in a health screening project. *Eur Urol*, 2007. 51: 803.  
<https://www.ncbi.nlm.nih.gov/pubmed/16979286>
116. Greenberg, E., *et al.* Transurethral resection of Hunner's ulcer. *J Urol*, 1974. 111: 764.  
<https://www.ncbi.nlm.nih.gov/pubmed/4830879>
117. Hand, J.R. Interstitial cystitis; report of 223 cases (204 women and 19 men). *J Urol*, 1949. 61: 291.  
<https://www.ncbi.nlm.nih.gov/pubmed/18111850>
118. Koziol, J.A. Epidemiology of interstitial cystitis. *Urol Clin North Am*, 1994. 21: 7.  
<https://www.ncbi.nlm.nih.gov/pubmed/8284848>
119. Berry, S.H., *et al.* Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. *J Urol*, 2011. 186: 540.  
<https://www.ncbi.nlm.nih.gov/pubmed/21683389>
120. Song, Y., *et al.* Prevalence and correlates of painful bladder syndrome symptoms in Fuzhou Chinese women. *Neurourol Urodyn*, 2009. 28: 22.  
<https://www.ncbi.nlm.nih.gov/pubmed/18671294>
121. Koziol, J.A., *et al.* Discrimination between the ulcerous and the nonulcerous forms of interstitial cystitis by noninvasive findings. *J Urol*, 1996. 155: 87.  
<https://www.ncbi.nlm.nih.gov/pubmed/7490906>
122. Messing, E.M., *et al.* Interstitial cystitis: early diagnosis, pathology, and treatment. *Urology*, 1978. 12: 381.  
<https://www.ncbi.nlm.nih.gov/pubmed/213864>
123. Parsons, C. Interstitial cystitis: clinical manifestations and diagnostic criteria in over 200 cases. *Neurourol Urodyn*, 1990. 9.  
<https://onlinelibrary.wiley.com/doi/abs/10.1002/nau.1930090302>
124. Peeker, R., *et al.* Toward a precise definition of interstitial cystitis: further evidence of differences in classic and nonulcer disease. *J Urol*, 2002. 167: 2470.  
<https://www.ncbi.nlm.nih.gov/pubmed/11992059>
125. Smith, C.P., *et al.* Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. *Urology*, 2004. 64: 871.  
<https://www.ncbi.nlm.nih.gov/pubmed/15533466>
126. Mattox, T.F. Interstitial cystitis in adolescents and children: a review. *J Pediatr Adolesc Gynecol*, 2004. 17: 7.  
<https://www.ncbi.nlm.nih.gov/pubmed/15010032>

127. Berghuis, J.P., *et al.* Psychological and physical factors involved in chronic idiopathic prostatitis. *J Psychosom Res*, 1996. 41: 313.  
<https://www.ncbi.nlm.nih.gov/pubmed/8971661>
128. Jacobsen, S.J., *et al.* Frequency of sexual activity and prostatic health: fact or fairy tale? *Urology*, 2003. 61: 348.  
<https://www.ncbi.nlm.nih.gov/pubmed/12597946>
129. Lee, S.W., *et al.* Adverse impact of sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. *Urology*, 2008. 71: 79.  
<https://www.ncbi.nlm.nih.gov/pubmed/18242370>
130. Liang, C.Z., *et al.* Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. *BJU Int*, 2004. 93: 568.  
<https://www.ncbi.nlm.nih.gov/pubmed/15008731>
131. Bartoletti, R., *et al.* Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. *J Urol*, 2007. 178: 2411.  
<https://www.ncbi.nlm.nih.gov/pubmed/17937946>
132. Gonen, M., *et al.* Prevalence of premature ejaculation in Turkish men with chronic pelvic pain syndrome. *J Androl*, 2005. 26: 601.  
<https://www.ncbi.nlm.nih.gov/pubmed/16088036>
133. Mehik, A., *et al.* Fears, sexual disturbances and personality features in men with prostatitis: a population-based cross-sectional study in Finland. *BJU Int*, 2001. 88: 35.  
<https://www.ncbi.nlm.nih.gov/pubmed/11446842>
134. O'Leary, M.P., *et al.* A brief male sexual function inventory for urology. *Urology*, 1995. 46: 697.  
<https://www.ncbi.nlm.nih.gov/pubmed/7495124>
135. Weidner, W., *et al.* Acute bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: andrological implications. *Andrologia*, 2008. 40: 105.  
<https://www.ncbi.nlm.nih.gov/pubmed/18336460>
136. van Ophoven, A., *et al.* Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial. *J Urol*, 2006. 176: 1442.  
<https://www.ncbi.nlm.nih.gov/pubmed/16952654>
137. Rosen, R.C., *et al.* The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology*, 1997. 49: 822.  
<https://www.ncbi.nlm.nih.gov/pubmed/9187685>
138. Anderson, R.U., *et al.* Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training. *J Urol*, 2006. 176: 1534.  
<https://www.ncbi.nlm.nih.gov/pubmed/16952676>
139. Trinchieri, A., *et al.* Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome. *Arch Ital Urol Androl*, 2007. 79: 67.  
<https://www.ncbi.nlm.nih.gov/pubmed/17695411>
140. Zondervan, K.T., *et al.* The prevalence of chronic pelvic pain in women in the United Kingdom: a systematic review. *Br J Obstet Gynaecol*, 1998. 105: 93.  
<https://www.ncbi.nlm.nih.gov/pubmed/9442169>
141. Grace, V., *et al.* Chronic pelvic pain in women in New Zealand: comparative well-being, comorbidity, and impact on work and other activities. *Health Care Women Int*, 2006. 27: 585.  
<https://www.ncbi.nlm.nih.gov/pubmed/16844672>
142. Pitts, M.K., *et al.* Prevalence and correlates of three types of pelvic pain in a nationally representative sample of Australian women. *Med J Aust*, 2008. 189: 138.  
<https://www.ncbi.nlm.nih.gov/pubmed/18673099>
143. Verit, F.F., *et al.* The prevalence of sexual dysfunction and associated risk factors in women with chronic pelvic pain: a cross-sectional study. *Arch Gynecol Obstet*, 2006. 274: 297.  
<https://www.ncbi.nlm.nih.gov/pubmed/16705463>
144. Florido, J., *et al.* Sexual behavior and findings on laparoscopy or laparotomy in women with severe chronic pelvic pain. *Eur J Obstet Gynecol Reprod Biol*, 2008. 139: 233.  
<https://www.ncbi.nlm.nih.gov/pubmed/18403089>
145. Phillips, N.A. The clinical evaluation of dyspareunia. *Int J Impot Res*, 1998. 10 Suppl 2: S117.  
<https://www.ncbi.nlm.nih.gov/pubmed/9647973>
146. Ambler, N., *et al.* Sexual difficulties of chronic pain patients. *Clin J Pain*, 2001. 17: 138.  
<https://www.ncbi.nlm.nih.gov/pubmed/11444715>

147. Loving, S., *et al.* Pelvic floor muscle dysfunctions are prevalent in female chronic pelvic pain: A cross-sectional population-based study. *Eur J Pain*, 2014. 18: 1259.  
<https://www.ncbi.nlm.nih.gov/pubmed/24700500>
148. Chiarioni, G., *et al.* Biofeedback is superior to electrogalvanic stimulation and massage for treatment of levator ani syndrome. *Gastroenterology*, 2010. 138: 1321.  
<https://www.ncbi.nlm.nih.gov/pubmed/20044997>
149. Rao, S.S., *et al.* ANMS-ESNM position paper and consensus guidelines on biofeedback therapy for anorectal disorders. *Neurogastroenterol Motil*, 2015. 27: 594.  
<https://www.ncbi.nlm.nih.gov/pubmed/25828100>
150. Zermann, D., *et al.* Chronic prostatitis: a myofascial pain syndrome? *Infect Urol*, 1999. 12: 84.  
<https://www.prostatitis.org/myofascial.html>
151. Shoskes, D.A., *et al.* Muscle tenderness in men with chronic prostatitis/chronic pelvic pain syndrome: the chronic prostatitis cohort study. *J Urol*, 2008. 179: 556.  
<https://www.ncbi.nlm.nih.gov/pubmed/18082223>
152. Peters, K.M., *et al.* Prevalence of pelvic floor dysfunction in patients with interstitial cystitis. *Urology*, 2007. 70: 16.  
<https://www.ncbi.nlm.nih.gov/pubmed/17656199>
153. Reissing, E.D., *et al.* Pelvic floor muscle functioning in women with vulvar vestibulitis syndrome. *J Psychosom Obstet Gynaecol*, 2005. 26: 107.  
<https://www.ncbi.nlm.nih.gov/pubmed/16050536>
154. Nickel, J., *et al.* Management of men diagnosed with chronic prostatitis/chronic pelvic pain syndrome who have failed traditional management. *Rev Urol*, 2007. 9: 63.  
<https://www.ncbi.nlm.nih.gov/pubmed/17592539>
155. Nickel, J.C., *et al.* Chronic Prostate Inflammation Predicts Symptom Progression in Patients with Chronic Prostatitis/Chronic Pelvic Pain. *J Urol*, 2017. 198: 122.  
<https://www.ncbi.nlm.nih.gov/pubmed/28089730>
156. Peters, K.M., *et al.* Childhood symptoms and events in women with interstitial cystitis/painful bladder syndrome. *Urology*, 2009. 73: 258.  
<https://www.ncbi.nlm.nih.gov/pubmed/19036420>
157. Rudick, C.N., *et al.* O-antigen modulates infection-induced pain states. *PLoS One*, 2012. 7: e41273.  
<https://www.ncbi.nlm.nih.gov/pubmed/22899994>
158. Richter, B., *et al.* YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. *Histopathology*, 2010. 57: 371.  
<https://www.ncbi.nlm.nih.gov/pubmed/20840668>
159. Dundore, P.A., *et al.* Mast cell counts are not useful in the diagnosis of nonulcerative interstitial cystitis. *J Urol*, 1996. 155: 885.  
<https://www.ncbi.nlm.nih.gov/pubmed/8583599>
160. Peeker, R., *et al.* Recruitment, distribution and phenotypes of mast cells in interstitial cystitis. *J Urol*, 2000. 163: 1009.  
<https://www.ncbi.nlm.nih.gov/pubmed/10688040>
161. Anderstrom, C.R., *et al.* Scanning electron microscopic findings in interstitial cystitis. *Br J Urol*, 1989. 63: 270.  
<https://www.ncbi.nlm.nih.gov/pubmed/2702424>
162. Johansson, S.L., *et al.* Clinical features and spectrum of light microscopic changes in interstitial cystitis. *J Urol*, 1990. 143: 1118.  
<https://www.ncbi.nlm.nih.gov/pubmed/2342171>
163. Lin, X.C., *et al.* Caveolin-1 may participate in the pathogenesis of bladder pain syndrome/ interstitial cystitis. *Urol Int*, 2011. 86: 334.  
<https://www.ncbi.nlm.nih.gov/pubmed/21335944>
164. Logadottir, Y.R., *et al.* Intravesical nitric oxide production discriminates between classic and nonulcer interstitial cystitis. *J Urol*, 2004. 171: 1148.  
<https://www.ncbi.nlm.nih.gov/pubmed/14767289>
165. Lokeshwar, V.B., *et al.* Urinary uronate and sulfated glycosaminoglycan levels: markers for interstitial cystitis severity. *J Urol*, 2005. 174: 344.  
<https://www.ncbi.nlm.nih.gov/pubmed/15947687>
166. Parsons, C.L., *et al.* Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). *J Urol*, 1991. 145: 732.  
<https://www.ncbi.nlm.nih.gov/pubmed/2005689>



167. Parsons, C.L., *et al.* Successful therapy of interstitial cystitis with pentosanpolysulfate. *J Urol*, 1987. 138: 513.  
<https://www.ncbi.nlm.nih.gov/pubmed/2442417>
168. Sanchez-Freire, V., *et al.* Acid-sensing channels in human bladder: expression, function and alterations during bladder pain syndrome. *J Urol*, 2011. 186: 1509.  
<https://www.ncbi.nlm.nih.gov/pubmed/21855903>
169. Hang, L., *et al.* Cytokine repertoire of epithelial cells lining the human urinary tract. *J Urol*, 1998. 159: 2185.  
<https://www.ncbi.nlm.nih.gov/pubmed/9598567>
170. Parsons, C.L., *et al.* Cyto-injury factors in urine: a possible mechanism for the development of interstitial cystitis. *J Urol*, 2000. 164: 1381.  
<https://www.ncbi.nlm.nih.gov/pubmed/10992419>
171. Chelmsky, G., *et al.* Autonomic Testing in Women with Chronic Pelvic Pain. *J Urol*, 2016. 196: 429.  
<https://www.ncbi.nlm.nih.gov/pubmed/27026035>
172. Charrua, A., *et al.* Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. *Neurourol Urodyn*, 2015. 34: 489.  
<https://www.ncbi.nlm.nih.gov/pubmed/24375689>
173. Alagiri, M., *et al.* Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. *Urology*, 1997. 49: 52.  
<https://www.ncbi.nlm.nih.gov/pubmed/9146002>
174. Buffington, C.A. Comorbidity of interstitial cystitis with other unexplained clinical conditions. *J Urol*, 2004. 172: 1242.  
<https://www.ncbi.nlm.nih.gov/pubmed/15371816>
175. Clauw, D.J., *et al.* The relationship between fibromyalgia and interstitial cystitis. *J Psychiatr Res*, 1997. 31: 125.  
<https://www.ncbi.nlm.nih.gov/pubmed/9201654>
176. Erickson, D.R., *et al.* Nonbladder related symptoms in patients with interstitial cystitis. *J Urol*, 2001. 166: 557.  
<https://www.ncbi.nlm.nih.gov/pubmed/11458068>
177. Warren, J., *et al.* Fishbein/interstitial cystitis association (ICA) survey of interstitial cystitis among family members of ICA members: preliminary analysis. *Urology*, 2001. 57: 126.  
<https://www.ncbi.nlm.nih.gov/pubmed/11378121>
178. Warren, J.W., *et al.* Antecedent nonbladder syndromes in case-control study of interstitial cystitis/painful bladder syndrome. *Urology*, 2009. 73: 52.  
<https://www.ncbi.nlm.nih.gov/pubmed/18995888>
179. Weissman, M., *et al.* Interstitial Cystitis and Panic Disorder - A Potential Genetic Syndrome. *Arch Gen Psych*, 2004. 61.  
<https://www.ncbi.nlm.nih.gov/pubmed/14993115>
180. Warren, J.W., *et al.* Numbers and types of nonbladder syndromes as risk factors for interstitial cystitis/painful bladder syndrome. *Urology*, 2011. 77: 313.  
<https://www.ncbi.nlm.nih.gov/pubmed/21295246>
181. Peters, K.M., *et al.* Are ulcerative and nonulcerative interstitial cystitis/painful bladder syndrome 2 distinct diseases? A study of coexisting conditions. *Urology*, 2011. 78: 301.  
<https://www.ncbi.nlm.nih.gov/pubmed/21703668>
182. Rab, M., *et al.* Anatomic variability of the ilioinguinal and genitofemoral nerve: implications for the treatment of groin pain. *Plast Reconstr Surg*, 2001. 108: 1618.  
<https://www.ncbi.nlm.nih.gov/pubmed/11711938>
183. Eklund, A., *et al.* Chronic pain 5 years after randomized comparison of laparoscopic and Lichtenstein inguinal hernia repair. *Br J Surg*, 2010. 97: 600.  
<https://www.ncbi.nlm.nih.gov/pubmed/20186889>
184. Nariculam, J., *et al.* A review of the efficacy of surgical treatment for and pathological changes in patients with chronic scrotal pain. *BJU Int*, 2007. 99: 1091.  
<https://www.ncbi.nlm.nih.gov/pubmed/17244279>
185. Manikandan, R., *et al.* Early and late morbidity after vasectomy: a comparison of chronic scrotal pain at 1 and 10 years. *BJU Int*, 2004. 93: 571.  
<https://www.ncbi.nlm.nih.gov/pubmed/15008732>
186. Leslie, T.A., *et al.* The incidence of chronic scrotal pain after vasectomy: a prospective audit. *BJU Int*, 2007. 100: 1330.  
<https://www.ncbi.nlm.nih.gov/pubmed/17850378>

187. Hallen, M., *et al.* Laparoscopic extraperitoneal inguinal hernia repair versus open mesh repair: long-term follow-up of a randomized controlled trial. *Surgery*, 2008. 143: 313.  
<https://www.ncbi.nlm.nih.gov/pubmed/18291251>
188. Grant, A.M., *et al.* Five-year follow-up of a randomized trial to assess pain and numbness after laparoscopic or open repair of groin hernia. *Br J Surg*, 2004. 91: 1570.  
<https://www.ncbi.nlm.nih.gov/pubmed/15515112>
189. Parsons, C.L. The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain. *BJU Int*, 2011. 107: 370.  
<https://www.ncbi.nlm.nih.gov/pubmed/21176078>
190. Parsons, C.L., *et al.* Intravesical potassium sensitivity in patients with interstitial cystitis and urethral syndrome. *Urology*, 2001. 57: 428.  
<https://www.ncbi.nlm.nih.gov/pubmed/11248610>
191. Kaur, H., *et al.* Urethral pain syndrome and its management. *Obstet Gynecol Surv*, 2007. 62: 348.  
<https://www.ncbi.nlm.nih.gov/pubmed/17425813>
192. Gurel, H., *et al.* Urethral syndrome and associated risk factors related to obstetrics and gynecology. *Eur J Obstet Gynecol Reprod Biol*, 1999. 83: 5.  
<https://www.ncbi.nlm.nih.gov/pubmed/10221602>
193. Gornall, J. The trial that launched millions of mesh implant procedures: did money compromise the outcome? *BMJ*, 2018. 363: k4155.  
<https://www.ncbi.nlm.nih.gov/pubmed/30305291>
194. Gornall, J. How mesh became a four letter word. *BMJ*, 2018. 363: k4137.  
<https://www.ncbi.nlm.nih.gov/pubmed/30305315>
195. Heneghan, C., *et al.* Surgical mesh and patient safety. *BMJ*, 2018. 363: k4231.  
<https://www.ncbi.nlm.nih.gov/pubmed/30305286>
196. Nilsson, C.G. Creating a gold standard surgical procedure: the development and implementation of TVT. *Int Urogynecol J*, 2015. 26: 467.  
<https://www.ncbi.nlm.nih.gov/pubmed/25731721>
197. Waltregny, D. TVT-O: a new gold standard surgical treatment of female stress urinary incontinence? *Eur Urol*, 2013. 63: 879.  
<https://www.ncbi.nlm.nih.gov/pubmed/23352654>
198. Jirova, J., *et al.* [Current state of transvaginal meshes by resolution of pelvic organ prolapse]. *Ceska Gynekol*. 82: 72.  
<https://www.ncbi.nlm.nih.gov/pubmed/28252314>
199. Keltie, K., *et al.* Complications following vaginal mesh procedures for stress urinary incontinence: an 8 year study of 92,246 women. *Sci Rep*, 2017. 7: 12015.  
<https://www.ncbi.nlm.nih.gov/pubmed/28931856>
200. Wang, C., *et al.* Synthetic mid-urethral sling complications: Evolution of presenting symptoms over time. *Neurourol Urodyn*, 2018.  
<https://www.ncbi.nlm.nih.gov/pubmed/29464783>
201. Vancaillie, T., *et al.* Pain after vaginal prolapse repair surgery with mesh is a post-surgical neuropathy which needs to be treated - and can possibly be prevented in some cases. *Aust N Z J Obstet Gynaecol*, 2018.  
<https://www.ncbi.nlm.nih.gov/pubmed/29577243>
202. Mellano, E.M., *et al.* The Role of Chronic Mesh Infection in Delayed-Onset Vaginal Mesh Complications or Recurrent Urinary Tract Infections: Results From Explanted Mesh Cultures. *Female Pelvic Med Reconstr Surg*, 2016. 22: 166.  
<https://www.ncbi.nlm.nih.gov/pubmed/26829350>
203. Ubertazzi, E.P., *et al.* Long-term outcomes of transvaginal mesh (TVM) In patients with pelvic organ prolapse: A 5-year follow-up. *Eur J Obstet Gynecol Reprod Biol*, 2018. 225: 90.  
<https://www.ncbi.nlm.nih.gov/pubmed/29680466>
204. Mateu Arrom, L., *et al.* Pelvic Organ Prolapse Repair with Mesh: Mid-Term Efficacy and Complications. *Urol Int*, 2018: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/29874667>
205. Cho, M.K., *et al.* Non-absorbable and partially-absorbable mesh during pelvic organ prolapse repair: A comparison of clinical outcomes. *Int J Surg*, 2018. 55: 5.  
<https://www.ncbi.nlm.nih.gov/pubmed/29753954>
206. Rogo-Gupta, L., *et al.* When and how to excise vaginal mesh. *Curr Opin Obstet Gynecol*, 2016. 28: 311.  
<https://www.ncbi.nlm.nih.gov/pubmed/27273309>

207. Khatri, G., *et al.* Diagnostic Evaluation of Chronic Pelvic Pain. *Phys Med Rehabil Clin N Am*, 2017. 28: 477.  
<https://www.ncbi.nlm.nih.gov/pubmed/28676360>
208. Bendavid, R., *et al.* A mechanism of mesh-related post-herniorrhaphy neuralgia. *Hernia*, 2016. 20: 357.  
<https://www.ncbi.nlm.nih.gov/pubmed/26597872>
209. Hahn, L. Treatment of ilioinguinal nerve entrapment - a randomized controlled trial. *Acta Obstet Gynecol Scand*, 2011. 90: 955.  
<https://www.ncbi.nlm.nih.gov/pubmed/21615360>
210. Antolak, S.J., Jr., *et al.* Anatomical basis of chronic pelvic pain syndrome: the ischial spine and pudendal nerve entrapment. *Med Hypotheses*, 2002. 59: 349.  
<https://www.ncbi.nlm.nih.gov/pubmed/12208168>
211. Mahakkanukrauh, P., *et al.* Anatomical study of the pudendal nerve adjacent to the sacrospinous ligament. *Clin Anat*, 2005. 18: 200.  
<https://www.ncbi.nlm.nih.gov/pubmed/15768420>
212. Labat, J.J., *et al.* Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). *NeuroUrol Urodyn*, 2008. 27: 306.  
<https://www.ncbi.nlm.nih.gov/pubmed/17828787>
213. Robert, R., *et al.* Anatomic basis of chronic perineal pain: role of the pudendal nerve. *Surg Radiol Anat*, 1998. 20: 93.  
<https://www.ncbi.nlm.nih.gov/pubmed/9658526>
214. Shafik, A. Pudendal canal syndrome as a cause of vulvodynia and its treatment by pudendal nerve decompression. *Eur J Obstet Gynecol Reprod Biol*, 1998. 80: 215.  
<https://www.ncbi.nlm.nih.gov/pubmed/9846672>
215. Amarenco, G., *et al.* Electrophysiological analysis of pudendal neuropathy following traction. *Muscle Nerve*, 2001. 24: 116.  
<https://www.ncbi.nlm.nih.gov/pubmed/11150974>
216. Goldet, R., *et al.* [Traction on the orthopedic table and pudendal nerve injury. Importance of electrophysiologic examination]. *Rev Chir Orthop Reparatrice Appar Mot*, 1998. 84: 523.  
<https://www.ncbi.nlm.nih.gov/pubmed/9846326>
217. Alevizon, S.J., *et al.* Sacrospinous colpopexy: management of postoperative pudendal nerve entrapment. *Obstet Gynecol*, 1996. 88: 713.  
<https://www.ncbi.nlm.nih.gov/pubmed/8841264>
218. Fisher, H.W., *et al.* Nerve injury locations during retropubic sling procedures. *Int Urogynecol J*, 2011. 22: 439.  
<https://www.ncbi.nlm.nih.gov/pubmed/21060989>
219. Moszkowicz, D., *et al.* Where does pelvic nerve injury occur during rectal surgery for cancer? *Colorectal Dis*, 2011. 13: 1326.  
<https://www.ncbi.nlm.nih.gov/pubmed/20718836>
220. Ashton-Miller, J.A., *et al.* Functional anatomy of the female pelvic floor. *Ann N Y Acad Sci*, 2007. 1101: 266.  
<https://www.ncbi.nlm.nih.gov/pubmed/17416924>
221. Amarenco, G., *et al.* [Perineal neuropathy due to stretching and urinary incontinence. Physiopathology, diagnosis and therapeutic implications]. *Ann Urol (Paris)*, 1990. 24: 463.  
<https://www.ncbi.nlm.nih.gov/pubmed/2176777>
222. Fleming, M., *et al.* Sexuality and chronic pain. *J Sex Educ Ther*, 2001. 26: 204.  
<https://www.ncbi.nlm.nih.gov/pubmed/7230895>
223. Maruta, T., *et al.* Chronic pain patients and spouses: marital and sexual adjustment. *Mayo Clin Proc*, 1981. 56: 307.  
<https://www.ncbi.nlm.nih.gov/pubmed/7230895>
224. Muller, A., *et al.* Sexual dysfunction in the patient with prostatitis. *Curr Opin Urol*, 2005. 15: 404.  
<https://www.ncbi.nlm.nih.gov/pubmed/16205492>
225. Chen, X., *et al.* The effect of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) on erectile function: A systematic review and meta-analysis. *PLoS ONE*, 2015. 10 (10) (no pagination).  
<https://www.ncbi.nlm.nih.gov/pubmed/26509575>
226. Tripp, D.A., *et al.* Prevalence, symptom impact and predictors of chronic prostatitis-like symptoms in Canadian males aged 16-19 years. *BJU Int*, 2009. 103: 1080.  
<https://www.ncbi.nlm.nih.gov/pubmed/19007369>
227. Pereira, R., *et al.* Sexual Functioning and Cognitions During Sexual Activity in Men With Genital Pain: A Comparative Study. *J Sex Marital Ther*, 2016. 42: 602.  
<https://www.ncbi.nlm.nih.gov/pubmed/26548315>

228. Egan, K.J., *et al.* Psychological problems in chronic prostatitis patients with pain. *Clin J Pain*, 1994. 10: 218.  
<https://www.ncbi.nlm.nih.gov/pubmed/7833580>
229. Smith, K.B., *et al.* Sexual and relationship functioning in men with chronic prostatitis/chronic pelvic pain syndrome and their partners. *Arch Sex Behav*, 2007. 36: 301.  
<https://www.ncbi.nlm.nih.gov/pubmed/17186130>
230. Gunter, J. Chronic pelvic pain: an integrated approach to diagnosis and treatment. *Obstet Gynecol Surv*, 2003. 58: 615.  
<https://www.ncbi.nlm.nih.gov/pubmed/12972837>
231. Latthe, P., *et al.* WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. *BMC Public Health*, 2006. 6: 177.  
<https://www.ncbi.nlm.nih.gov/pubmed/16824213>
232. Pearce, C., *et al.* A multidisciplinary approach to self care in chronic pelvic pain. *Br J Nurs*, 2007. 16: 82.  
<https://www.ncbi.nlm.nih.gov/pubmed/17353816>
233. ter Kuile, M.M., *et al.* Sexual functioning in women with chronic pelvic pain: the role of anxiety and depression. *J Sex Med*, 2010. 7: 1901.  
<https://www.ncbi.nlm.nih.gov/pubmed/19678881>
234. Fry, R.P., *et al.* Patients' illness models in chronic pelvic pain. *Psychother Psychosom*, 1991. 55: 158.  
<https://www.ncbi.nlm.nih.gov/pubmed/1891563>
235. Collett, B.J., *et al.* A comparative study of women with chronic pelvic pain, chronic nonpelvic pain and those with no history of pain attending general practitioners. *Br J Obstet Gynaecol*, 1998. 105: 87.  
<https://www.ncbi.nlm.nih.gov/pubmed/9442168>
236. McCabe, M.P., *et al.* Intercorrelations among general arousability, emerging and current sexual desire, and severity of sexual dysfunction in women. *Psychol Rep*, 1989. 65: 147.  
<https://www.ncbi.nlm.nih.gov/pubmed/2780925>
237. Flor, H., *et al.* The role of spouse reinforcement, perceived pain, and activity levels of chronic pain patients. *J Psychosom Res*, 1987. 31: 251.  
<https://www.ncbi.nlm.nih.gov/pubmed/3585827>
238. Paice, J. Sexuality and chronic pain. *Am J Nurs*, 2003. 103: 87.  
<https://www.ncbi.nlm.nih.gov/pubmed/12544064>
239. Verit, F.F., *et al.* Validation of the female sexual function index in women with chronic pelvic pain. *J Sex Med*, 2007. 4: 1635.  
<https://www.ncbi.nlm.nih.gov/pubmed/17888066>
240. Hetrick, D.C., *et al.* Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III: a case-control study. *J Urol*, 2003. 170: 828.  
<https://www.ncbi.nlm.nih.gov/pubmed/17888066>
241. Clemens, J.Q., *et al.* Biofeedback, pelvic floor re-education, and bladder training for male chronic pelvic pain syndrome. *Urology*, 2000. 56: 951.  
<https://www.ncbi.nlm.nih.gov/pubmed/11113739>
242. Ishigooka, M., *et al.* Similarity of distributions of spinal c-Fos and plasma extravasation after acute chemical irritation of the bladder and the prostate. *J Urol*, 2000. 164: 1751.  
<https://www.ncbi.nlm.nih.gov/pubmed/11025764>
243. Liao, C.H., *et al.* Chronic Prostatitis/Chronic Pelvic Pain Syndrome is associated with Irritable Bowel Syndrome: A Population-based Study. *Sci Rep*, 2016. 6: 26939.  
<https://www.ncbi.nlm.nih.gov/pubmed/27225866>
244. Zondervan, K.T., *et al.* Prevalence and incidence of chronic pelvic pain in primary care: evidence from a national general practice database. *Br J Obstet Gynaecol*, 1999. 106: 1149.  
<https://www.ncbi.nlm.nih.gov/pubmed/10549959>
245. Drossman, D.A., *et al.* U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. *Dig Dis Sci*, 1993. 38: 1569.  
<https://www.ncbi.nlm.nih.gov/pubmed/8359066>
246. Prior, A., *et al.* Gynaecological consultation in patients with the irritable bowel syndrome. *Gut*, 1989. 30: 996.  
<https://www.ncbi.nlm.nih.gov/pubmed/2759494>
247. Longstreth, G.F., *et al.* Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome. *Dig Dis Sci*, 1990. 35: 1285.  
<https://www.ncbi.nlm.nih.gov/pubmed/2145139>

248. Sperber, A.D., *et al.* Development of abdominal pain and IBS following gynecological surgery: a prospective, controlled study. *Gastroenterology*, 2008. 134: 75.  
<https://www.ncbi.nlm.nih.gov/pubmed/18166349>
249. Monnikes, H. Quality of life in patients with irritable bowel syndrome. *J Clin Gastroenterol*, 2011. 45 Suppl: S98.  
<https://www.ncbi.nlm.nih.gov/pubmed/21666428>
250. Canavan, C., *et al.* Review article: the economic impact of the irritable bowel syndrome. *Aliment Pharmacol Ther*, 2014. 40: 1023.  
<https://www.ncbi.nlm.nih.gov/pubmed/25199904>
251. Morgan, C.J., *et al.* Ketamine use: a review. *Addiction*, 2012. 107: 27.  
<https://www.ncbi.nlm.nih.gov/pubmed/21777321>
252. Lorencatto, C., *et al.* Depression in women with endometriosis with and without chronic pelvic pain. *Acta Obstet Gynecol Scand*, 2006. 85: 88.  
<https://www.ncbi.nlm.nih.gov/pubmed/16521687>
253. Pincus, T., *et al.* Models and measurements of depression in chronic pain. *J Psychosom Res*, 1999. 47: 211.  
<https://www.ncbi.nlm.nih.gov/pubmed/10576470>
254. Stones, R.W., *et al.* Psychosocial and economic impact of chronic pelvic pain. *Baillieres Best Pract Res Clin Obstet Gynaecol*, 2000. 14: 415.  
<https://www.ncbi.nlm.nih.gov/pubmed/10962635>
255. Howard, F.M. Chronic pelvic pain. *Obstet Gynecol*, 2003. 101: 594.  
<https://www.ncbi.nlm.nih.gov/pubmed/12636968>
256. Fitzgerald, M.P., *et al.* Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses. *Eur Urol*, 2007. 52: 407.  
<https://www.ncbi.nlm.nih.gov/pubmed/17382458>
257. Davis, S.N., *et al.* Is a sexual dysfunction domain important for quality of life in men with urological chronic pelvic pain syndrome? Signs "UPOINT" to yes. *J Urol*, 2013. 189: 146.  
<https://www.ncbi.nlm.nih.gov/pubmed/23164384>
258. Cleeland, C.S. The Brief Pain Inventory User Guide. 2009.  
[https://www.mdanderson.org/documents/Departments-and-Divisions/Symptom-Research/BPI\\_UserGuide.pdf](https://www.mdanderson.org/documents/Departments-and-Divisions/Symptom-Research/BPI_UserGuide.pdf)
259. Turk, D.C., *et al.* Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. *Pain*, 2003. 106: 337.  
<https://www.ncbi.nlm.nih.gov/pubmed/14659516>
260. Bullock, A.D., *et al.* Experimental autoimmune cystitis: a potential murine model for ulcerative interstitial cystitis. *J Urol*, 1992. 148: 1951.  
<https://www.ncbi.nlm.nih.gov/pubmed/1433651>
261. Dodd, L.G., *et al.* Cytologic examination of urine from patients with interstitial cystitis. *Acta Cytol*, 1998. 42: 923.  
<https://www.ncbi.nlm.nih.gov/pubmed/14659516>
262. Erickson, D.R., *et al.* Interstitial cystitis. *Int Urogynecol J Pelvic Floor Dysfunct*, 1998. 9: 174.  
<https://www.ncbi.nlm.nih.gov/pubmed/9745978>
263. Fall, M., *et al.* Chronic interstitial cystitis: a heterogeneous syndrome. *J Urol*, 1987. 137: 35.  
<https://www.ncbi.nlm.nih.gov/pubmed/3795363>
264. Warren, J.W., *et al.* Evidence-based criteria for pain of interstitial cystitis/painful bladder syndrome in women. *Urology*, 2008. 71: 444.  
<https://www.ncbi.nlm.nih.gov/pubmed/18342184>
265. Bharucha, A.E., *et al.* Functional anorectal disorders. *Gastroenterology*, 2006. 130: 1510.  
<https://www.ncbi.nlm.nih.gov/pubmed/16678564>
266. McNaughton Collins, M., *et al.* Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. *J Gen Intern Med*, 2001. 16: 656.  
<https://www.ncbi.nlm.nih.gov/pubmed/11679032>
267. Wenninger, K., *et al.* Sickness impact of chronic nonbacterial prostatitis and its correlates. *J Urol*, 1996. 155: 965.  
<https://www.ncbi.nlm.nih.gov/pubmed/8583619>
268. Gerlinger, C., *et al.* Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. *Health Qual Life Outcomes*, 2010. 8: 138.  
<https://www.ncbi.nlm.nih.gov/pubmed/21106059>

269. Litwin, M.S., *et al.* The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. *J Urol*, 1999. 162: 369.  
<https://www.ncbi.nlm.nih.gov/pubmed/10411041>
270. Mebust, W., *et al.*, Symptom evaluation, quality of life and sexuality. In: 2nd Consultation on Benign Prostatic Hyperplasia (BPH). 1993, Jersey, Channel Islands.
271. Lubeck, D.P., *et al.* Psychometric validation of the O'leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. *Urology*, 2001. 57: 62.  
<https://www.ncbi.nlm.nih.gov/pubmed/11378052>
272. Francis, C.Y., *et al.* The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. *Aliment Pharmacol Ther*, 1997. 11: 395.  
<https://www.ncbi.nlm.nih.gov/pubmed/9146781>
273. Spiegel, B.M., *et al.* Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice. *Aliment Pharmacol Ther*, 2010. 32: 1192.  
<https://www.ncbi.nlm.nih.gov/pubmed/20807217>
274. Slieker-ten Hove, M.C., *et al.* Face validity and reliability of the first digital assessment scheme of pelvic floor muscle function conform the new standardized terminology of the International Continence Society. *Neurourol Urodyn*, 2009. 28: 295.  
<https://www.ncbi.nlm.nih.gov/pubmed/19090583>
275. Wyndaele, J.J., *et al.* Reproducibility of digital testing of the pelvic floor muscles in men. *Arch Phys Med Rehabil*, 1996. 77: 1179.  
<https://www.ncbi.nlm.nih.gov/pubmed/8931532>
276. Davis, S.N., *et al.* Use of pelvic floor ultrasound to assess pelvic floor muscle function in urological chronic pelvic pain syndrome in men. *J Sex Med*, 2011. 8: 3173.  
<https://www.ncbi.nlm.nih.gov/pubmed/21883952>
277. Anderson, R.U., *et al.* Painful myofascial trigger points and pain sites in men with chronic prostatitis/chronic pelvic pain syndrome. *J Urol*, 2009. 182: 2753.  
<https://www.ncbi.nlm.nih.gov/pubmed/19837420>
278. Sanses, T.V., *et al.* The Pelvis and Beyond: Musculoskeletal Tender Points in Women With Chronic Pelvic Pain. *Clin J Pain*, 2016. 32: 659.  
<https://www.ncbi.nlm.nih.gov/pubmed/26491938>
279. Yang, C.C., *et al.* Physical Examination for Men and Women With Urologic Chronic Pelvic Pain Syndrome: A MAPP (Multidisciplinary Approach to the Study of Chronic Pelvic Pain) Network Study. *Urology*, 2018. 116: 23.  
<https://www.ncbi.nlm.nih.gov/pubmed/29604315>
280. Antolak, S.J., Jr., *et al.* Therapeutic pudendal nerve blocks using corticosteroids cure pelvic pain after failure of sacral neuromodulation. *Pain Med*, 2009. 10: 186.  
<https://www.ncbi.nlm.nih.gov/pubmed/19222779>
281. Bolandard, F., *et al.* Nerve stimulator guided pudendal nerve blocks. *Can J Anaesth*, 2005. 52: 773; author reply 773.  
<https://www.ncbi.nlm.nih.gov/pubmed/16103396>
282. Filler, A.G. Diagnosis and treatment of pudendal nerve entrapment syndrome subtypes: imaging, injections, and minimal access surgery. *Neurosurg Focus*, 2009. 26: E9.  
<https://www.ncbi.nlm.nih.gov/pubmed/19323602>
283. Kim, S.H., *et al.* Nerve-stimulator-guided pudendal nerve block by pararectal approach. *Colorectal Dis*, 2012. 14: 611.  
<https://www.ncbi.nlm.nih.gov/pubmed/21752174>
284. Kovacs, P., *et al.* New, simple, ultrasound-guided infiltration of the pudendal nerve: ultrasonographic technique. *Dis Colon Rectum*, 2001. 44: 1381.  
<https://www.ncbi.nlm.nih.gov/pubmed/11584221>
285. Naja, M.Z., *et al.* Nerve-stimulator-guided repeated pudendal nerve block for treatment of pudendal neuralgia. *Eur J Anaesthesiol*, 2006. 23: 442.  
<https://www.ncbi.nlm.nih.gov/pubmed/16573866>
286. Peng, P.W., *et al.* Ultrasound-guided interventional procedures for patients with chronic pelvic pain - a description of techniques and review of literature. *Pain Physician*, 2008. 11: 215.  
<https://www.ncbi.nlm.nih.gov/pubmed/18354713>
287. Rigaud, J., *et al.* [Somatic nerve block in the management of chronic pelvic and perineal pain]. *Prog Urol*, 2010. 20: 1072.  
<https://www.ncbi.nlm.nih.gov/pubmed/21056387>
288. Romanzi, L. Techniques of pudendal nerve block. *J Sex Med*, 2010. 7: 1716.  
<https://www.ncbi.nlm.nih.gov/pubmed/20537059>

289. Thoumas, D., *et al.* Pudendal neuralgia: CT-guided pudendal nerve block technique. *Abdom Imaging*, 1999. 24: 309.  
<https://www.ncbi.nlm.nih.gov/pubmed/10227901>
290. Wey, P.F., *et al.* [Nerve stimulator guided pudendal nerve block for postoperative analgesia. An evaluation of professional practice]. *Ann Fr Anesth Reanim*, 2007. 26: 1087.  
<https://www.ncbi.nlm.nih.gov/pubmed/17961968>
291. Bates, S.M., *et al.* A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. *BJU Int*, 2007. 99: 355.  
<https://www.ncbi.nlm.nih.gov/pubmed/17313424>
292. Dragoman, M.V. The combined oral contraceptive pill -- recent developments, risks and benefits. *Best Pract Res Clin Obstet Gynaecol*, 2014. 28: 825.  
<https://www.ncbi.nlm.nih.gov/pubmed/25028259>
293. Ghaly, A. The psychological and physical benefits of pelvic ultrasonography in patients with chronic pelvic pain and negative laparoscopy. A random allocation trial. *J Obstet Gynaecol*, 1994. 14.  
<https://www.tandfonline.com/doi/abs/10.3109/01443619409027849>
294. Nickel, J.C., *et al.* Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. *J Urol*, 2004. 171: 1594.  
<https://www.ncbi.nlm.nih.gov/pubmed/15017228>
295. Zhao, W.P., *et al.* Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). *Braz J Med Biol Res*, 2009. 42: 963.  
<https://www.ncbi.nlm.nih.gov/pubmed/19787151>
296. Poldrack, R., *et al.* Scanning the Horizon: challenges and solutions for neuroimaging research. *Nat Rev Neurosci*. 2017 18: 115.  
<https://www.ncbi.nlm.nih.gov/pubmed/28053326>
297. Salomons, T.V., *et al.* THE "pain matrix" in pain-free individuals. *JAMA Neurology*, 2016. 73: 755.  
<https://www.ncbi.nlm.nih.gov/pubmed/27111250>
298. Meares, E.M., *et al.* Bacteriologic localization patterns in bacterial prostatitis and urethritis. *Invest Urol*, 1968. 5: 492.  
<https://www.ncbi.nlm.nih.gov/pubmed/4870505>
299. Nickel, J.C. The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. *Tech Urol*, 1997. 3: 38.  
<https://www.ncbi.nlm.nih.gov/pubmed/9170224>
300. Nickel, J.C., *et al.* How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? *J Urol*, 2006. 176: 119.  
<https://www.ncbi.nlm.nih.gov/pubmed/16753385>
301. Nickel, J.C., *et al.* A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. *J Urol*, 2003. 169: 1401.  
<https://www.ncbi.nlm.nih.gov/pubmed/12629372>
302. Manganaro, L., *et al.* Diffusion tensor imaging and tractography to evaluate sacral nerve root abnormalities in endometriosis-related pain: a pilot study. *Eur Radiol*, 2014. 24: 95.  
<https://www.ncbi.nlm.nih.gov/pubmed/23982288>
303. Howard, F.M. The role of laparoscopy as a diagnostic tool in chronic pelvic pain. *Baillieres Best Pract Res Clin Obstet Gynaecol*, 2000. 14: 467.  
<https://www.ncbi.nlm.nih.gov/pubmed/10962637>
304. Jacobson, T.Z., *et al.* Laparoscopic surgery for pelvic pain associated with endometriosis. *Cochrane Database Syst Rev*, 2009: CD001300.  
<https://www.ncbi.nlm.nih.gov/pubmed/19821276>
305. Porpora, M.G., *et al.* The role of laparoscopy in the management of pelvic pain in women of reproductive age. *Fertil Steril*, 1997. 68: 765.  
<https://www.ncbi.nlm.nih.gov/pubmed/9389799>
306. Seracchioli, R., *et al.* Cystoscopy-assisted laparoscopic resection of extramucosal bladder endometriosis. *J Endourol*, 2002. 16: 663.  
<https://www.ncbi.nlm.nih.gov/pubmed/12490020>
307. Wyndaele, J.J., *et al.* Cystoscopy and bladder biopsies in patients with bladder pain syndrome carried out following ESSIC guidelines. *Scand J Urol Nephrol*, 2009. 43: 471.  
<https://www.ncbi.nlm.nih.gov/pubmed/19707951>
308. Elcombe, S., *et al.* The psychological effects of laparoscopy on women with chronic pelvic pain. *Psychol Med*, 1997. 27: 1041.  
<https://www.ncbi.nlm.nih.gov/pubmed/9300510>

309. Onwude, J.L., *et al.* A randomised trial of photographic reinforcement during postoperative counselling after diagnostic laparoscopy for pelvic pain. *Eur J Obstet Gynecol Reprod Biol*, 2004. 112: 89.  
<https://www.ncbi.nlm.nih.gov/pubmed/14687747>
310. Peters, A.A., *et al.* A randomized clinical trial to compare two different approaches in women with chronic pelvic pain. *Obstet Gynecol*, 1991. 77: 740.  
<https://www.ncbi.nlm.nih.gov/pubmed/1826544>
311. Cole, E.E., *et al.* Are patient symptoms predictive of the diagnostic and/or therapeutic value of hydrodistention? *Neurourol Urodyn*, 2005. 24: 638.  
<https://www.ncbi.nlm.nih.gov/pubmed/16208660>
312. Lamale, L.M., *et al.* Symptoms and cystoscopic findings in patients with untreated interstitial cystitis. *Urology*, 2006. 67: 242.  
<https://www.ncbi.nlm.nih.gov/pubmed/16442603>
313. Ottem, D.P., *et al.* What is the value of cystoscopy with hydrodistension for interstitial cystitis? *Urology*, 2005. 66: 494.  
<https://www.ncbi.nlm.nih.gov/pubmed/16140064>
314. Shear, S., *et al.* Development of glomerulations in younger women with interstitial cystitis. *Urology*, 2006. 68: 253.  
<https://www.ncbi.nlm.nih.gov/pubmed/16904429>
315. Tamaki, M., *et al.* Possible mechanisms inducing glomerulations in interstitial cystitis: relationship between endoscopic findings and expression of angiogenic growth factors. *J Urol*, 2004. 172: 945.  
<https://www.ncbi.nlm.nih.gov/pubmed/15311005>
316. Aihara, K., *et al.* Hydrodistension under local anesthesia for patients with suspected painful bladder syndrome/interstitial cystitis: safety, diagnostic potential and therapeutic efficacy. *Int J Urol*, 2009. 16: 947.  
<https://www.ncbi.nlm.nih.gov/pubmed/19817916>
317. Messing, E., *et al.* Associations among cystoscopic findings and symptoms and physical examination findings in women enrolled in the Interstitial Cystitis Data Base (ICDB) Study. *Urology*, 1997. 49: 81.  
<https://www.ncbi.nlm.nih.gov/pubmed/9146006>
318. Waxman, J.A., *et al.* Cystoscopic findings consistent with interstitial cystitis in normal women undergoing tubal ligation. *J Urol*, 1998. 160: 1663.  
<https://www.ncbi.nlm.nih.gov/pubmed/9783927>
319. Geurts, N., *et al.* Bladder pain syndrome: do the different morphological and cystoscopic features correlate? *Scand J Urol Nephrol*, 2011. 45: 20.  
<https://www.ncbi.nlm.nih.gov/pubmed/20846081>
320. Johansson, S.L., *et al.* Pathology of interstitial cystitis. *Urol Clin North Am*, 1994. 21: 55.  
<https://www.ncbi.nlm.nih.gov/pubmed/8284845>
321. Wassong, C., *et al.* Radiologic findings of pelvic venous congestion in an adolescent girl with angiographic confirmation and interventional treatment. *Pediatr Radiol*, 2012. 42: 636.  
<https://www.ncbi.nlm.nih.gov/pubmed/21912968>
322. Ness, R.B., *et al.* Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. *Am J Obstet Gynecol*, 2002. 186: 929.  
<https://www.ncbi.nlm.nih.gov/pubmed/12015517>
323. Corey, L., *et al.* Genital herpes simplex virus infections: clinical manifestations, course, and complications. *Ann Intern Med*, 1983. 98: 958.  
<https://www.ncbi.nlm.nih.gov/pubmed/6344712>
324. Young, H., *et al.* Screening for treponemal infection by a new enzyme immunoassay. *Genitourin Med*, 1989. 65: 72.  
<https://www.ncbi.nlm.nih.gov/pubmed/2666302>
325. Culley, L., *et al.* The social and psychological impact of endometriosis on women's lives: A critical narrative review. *Human Reprod Update*, 2013. 19: 625.  
<https://www.ncbi.nlm.nih.gov/pubmed/23884896>
326. Souza, C.A., *et al.* Quality of life associated to chronic pelvic pain is independent of endometriosis diagnosis--a cross-sectional survey. *Health Qual Life Outcomes*, 2011. 9.  
<https://www.ncbi.nlm.nih.gov/pubmed/21663624>
327. Barri, P.N., *et al.* Endometriosis-associated infertility: surgery and IVF, a comprehensive therapeutic approach. *Reprod Biomed Online*, 2010. 21: 179.  
<https://www.ncbi.nlm.nih.gov/pubmed/20541976>



328. Fauconnier, A., *et al.* Relation between pain symptoms and the anatomic location of deep infiltrating endometriosis. *Fertil Steril*, 2002. 78: 719.  
<https://www.ncbi.nlm.nih.gov/pubmed/12372446>
329. Vercellini, P., *et al.* The effect of surgery for symptomatic endometriosis: the other side of the story. *Hum Reprod Update*, 2009. 15: 177.  
<https://www.ncbi.nlm.nih.gov/pubmed/19136455>
330. Vercellini, P., *et al.* Medical treatment for rectovaginal endometriosis: what is the evidence? *Hum Reprod*, 2009. 24: 2504.  
<https://www.ncbi.nlm.nih.gov/pubmed/19574277>
331. Walters, C., *et al.* Pelvic girdle pain in pregnancy. *Aust J Gen Pract*, 2018. 47: 439.  
<https://www.ncbi.nlm.nih.gov/pubmed/30114872>
- 332a. Khan, K.S., *et al.* MRI versus laparoscopy to diagnose the main causes of chronic pelvic pain in women: a test-accuracy study and economic evaluation. *Health Technol Assess*, 2018. 22: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/30045805>
- 332b. Kaminski, P., *et al.* The usefulness of laparoscopy and hysteroscopy in the diagnostics and treatment of infertility. *Neuro Endocrinol Lett*, 2006. 27: 813.  
<https://www.ncbi.nlm.nih.gov/pubmed/17187014>
333. Hay-Smith, E.J. Therapeutic ultrasound for postpartum perineal pain and dyspareunia. *Cochrane Database Syst Rev*, 2000: CD000495.  
<https://www.ncbi.nlm.nih.gov/pubmed/10796210>
334. Cappell, J., *et al.* Clinical profile of persistent genito-pelvic postpartum pain. *Midwifery*, 2017. 50: 125.  
<https://www.ncbi.nlm.nih.gov/pubmed/28419979>
335. Landau, R., *et al.* Chronic pain after childbirth. *Int J Obstet Anesth*, 2013. 22: 133.  
<https://www.ncbi.nlm.nih.gov/pubmed/23477888>
336. Roovers, J.P., *et al.* A randomised controlled trial comparing abdominal and vaginal prolapse surgery: effects on urogenital function. *BJOG*, 2004. 111: 50.  
<https://www.ncbi.nlm.nih.gov/pubmed/14687052>
337. Lin, L.L., *et al.* Dyspareunia and chronic pelvic pain after polypropylene mesh augmentation for transvaginal repair of anterior vaginal wall prolapse. *Int Urogynecol J Pelvic Floor Dysfunct*, 2007. 18: 675.  
<https://www.ncbi.nlm.nih.gov/pubmed/16988779>
338. Niro, J., *et al.* [Postoperative pain after transvaginal repair of pelvic organ prolapse with or without mesh]. *Gynecol Obstet Fertil*, 2010. 38: 648.  
<https://www.ncbi.nlm.nih.gov/pubmed/21030280>
339. Withagen, M.I., *et al.* Risk factors for exposure, pain, and dyspareunia after tension-free vaginal mesh procedure. *Obstet Gynecol*, 2011. 118: 629.  
<https://www.ncbi.nlm.nih.gov/pubmed/21860293>
340. Vancaillie, T., *et al.* Sacral neuromodulation for pelvic pain and pelvic organ dysfunction: A case series. *Aust N Z J Obstet Gynaecol*, 2018. 58: 102.  
<https://www.ncbi.nlm.nih.gov/pubmed/29218704>
341. Eisenberg, V.H., *et al.* Ultrasound visualization of sacrocolpopexy polyvinylidene fluoride meshes containing paramagnetic Fe particles compared with polypropylene mesh. *Int Urogynecol J*, 2018.  
<https://www.ncbi.nlm.nih.gov/pubmed/30083941>
342. Kim, K.Y., *et al.* Translabial Ultrasound Evaluation of Pelvic Floor Structures and Mesh in the Urology Office and Intraoperative Setting. *Urology*, 2018. 120: 267.  
<https://www.ncbi.nlm.nih.gov/pubmed/30031831>
343. Sindhwani, N., *et al.* Short term post-operative morphing of sacrocolpopexy mesh measured by magnetic resonance imaging. *J Mech Behav Biomed Mater*, 2018. 80: 269.  
<https://www.ncbi.nlm.nih.gov/pubmed/29455036>
344. Zacharakis, D., *et al.* Pre- and postoperative magnetic resonance imaging (MRI) findings in patients treated with laparoscopic sacrocolpopexy. Is it a safe procedure for all patients? *Neurourol Urodyn*, 2018. 37: 316.  
<https://www.ncbi.nlm.nih.gov/pubmed/28481045>
345. Brandt, L.J., *et al.* An evidence-based position statement on the management of irritable bowel syndrome. *Am J Gastroenterol*, 2009. 104 Suppl 1: S1.  
<https://www.ncbi.nlm.nih.gov/pubmed/19521341>
346. Spiller, R., *et al.* Guidelines on the irritable bowel syndrome: mechanisms and practical management. *Gut*, 2007. 56: 1770.  
<https://www.ncbi.nlm.nih.gov/pubmed/17488783>

347. McGowan, L., *et al.* How do you explain a pain that can't be seen?: the narratives of women with chronic pelvic pain and their disengagement with the diagnostic cycle. *Br J Health Psychol*, 2007. 12: 261.  
<https://www.ncbi.nlm.nih.gov/pubmed/17456285>
348. European Association of Urology (EAU). EAU Survey: What do you tell your patients?
349. Loving, S., *et al.* Does evidence support physiotherapy management of adult female chronic pelvic pain?. *Scand J Pain*, 2012. 3: 70.  
<https://www.ncbi.nlm.nih.gov/pubmed/29913781>
350. Haugstad, G.K., *et al.* Mensendieck somatocognitive therapy as treatment approach to chronic pelvic pain: results of a randomized controlled intervention study. *Am J Obstet Gynecol*, 2006. 194: 1303.  
<https://www.ncbi.nlm.nih.gov/pubmed/16647914>
351. Fitzgerald, M.P., *et al.* Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. *J Urol*, 2013. 189: S75.  
<https://www.ncbi.nlm.nih.gov/pubmed/23234638>
352. de las Penas, C., *et al.* Manual therapies in myofascial trigger point treatment: a systematic review. *J Bodyw Mov Ther*, 2005. 9: 27.  
[https://www.somasimple.com/pdf\\_files/myofascial.pdf](https://www.somasimple.com/pdf_files/myofascial.pdf)
353. Tough, E.A., *et al.* Acupuncture and dry needling in the management of myofascial trigger point pain: a systematic review and meta-analysis of randomised controlled trials. *Eur J Pain*, 2009. 13: 3.  
<https://www.ncbi.nlm.nih.gov/pubmed/18395479>
354. Cummings, T.M., *et al.* Needling therapies in the management of myofascial trigger point pain: a systematic review. *Arch Phys Med Rehabil*, 2001. 82: 986.  
<https://www.ncbi.nlm.nih.gov/pubmed/11441390>
355. Scott, N.A., *et al.* Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review. *Pain Med*, 2009. 10: 54.  
<https://www.ncbi.nlm.nih.gov/pubmed/18992040>
356. Karper, W.B. Exercise effects on interstitial cystitis: two case reports. *Urol Nurs*, 2004. 24: 202.  
<https://www.ncbi.nlm.nih.gov/pubmed/15311489>
357. Oyama, I.A., *et al.* Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. *Urology*, 2004. 64: 862.  
<https://www.ncbi.nlm.nih.gov/pubmed/15533464>
358. Langford, C.F., *et al.* Levator ani trigger point injections: An underutilized treatment for chronic pelvic pain. *Neurourol Urodyn*, 2007. 26: 59.  
<https://www.ncbi.nlm.nih.gov/pubmed/17195176>
359. FitzGerald, M.P., *et al.* Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. *J Urol*, 2012. 187: 2113.  
<https://www.ncbi.nlm.nih.gov/pubmed/22503015>
360. Kellog-Spadt, S., *et al.*, Role of the female urologist/urogynecologist. In: *Women's sexual function and dysfunction: Study, diagnosis and treatment*. 2006, Taylor and Francis: London.
361. Webster, D.C., *et al.* Use and effectiveness of physical self-care strategies for interstitial cystitis. *Nurse Pract*, 1994. 19: 55.  
<https://www.ncbi.nlm.nih.gov/pubmed/2913346>
362. Hayes, R.D., *et al.* What can prevalence studies tell us about female sexual difficulty and dysfunction? *J Sex Med*, 2006. 3: 589.  
<https://www.ncbi.nlm.nih.gov/pubmed/16839314>
363. Rosenbaum, T.Y., *et al.* The role of pelvic floor physical therapy in the treatment of pelvic and genital pain-related sexual dysfunction (CME). *J Sex Med*, 2008. 5: 513.  
<https://www.ncbi.nlm.nih.gov/pubmed/18304280>
364. Rowe, E., *et al.* A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup. *J Urol*, 2005. 173: 2044.  
<https://www.ncbi.nlm.nih.gov/pubmed/15879822>
365. Kastner, C., *et al.* Cooled transurethral microwave thermotherapy for intractable chronic prostatitis--results of a pilot study after 1 year. *Urology*, 2004. 64: 1149.  
<https://www.ncbi.nlm.nih.gov/pubmed/15596188>
366. Montorsi, F., *et al.* Is there a role for transrectal microwave hyperthermia of the prostate in the treatment of abacterial prostatitis and prostatodynia? *Prostate*, 1993. 22: 139.  
<https://www.ncbi.nlm.nih.gov/pubmed/8456052>

367. Zimmermann, R., *et al.* Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome in males: a randomised, double-blind, placebo-controlled study. *Eur Urol*, 2009. 56: 418. <https://www.ncbi.nlm.nih.gov/pubmed/19372000>
368. Zeng, X.Y., *et al.* Extracorporeal shock wave treatment for non-inflammatory chronic pelvic pain syndrome: A prospective, randomized and sham-controlled study. *Chin Med J*, 2012. 125: 114. <https://www.ncbi.nlm.nih.gov/pubmed/22340476>
369. Vahdatpour B, *et al.* Efficacy of extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome: A randomized, controlled trial. *ISRN Urol*, 2013. 1. <https://www.ncbi.nlm.nih.gov/pubmed/24000311>
370. Moayednia, A., *et al.* Long-term effect of extracorporeal shock wave therapy on the treatment of chronic pelvic pain syndrome due to non bacterial prostatitis. *J Res Med Sci*, 2014. 19: 293. <https://www.ncbi.nlm.nih.gov/pubmed/25097599>
371. Lee, S.H., *et al.* Electroacupuncture relieves pain in men with chronic prostatitis/chronic pelvic pain syndrome: three-arm randomized trial. *Urology*, 2009. 73: 1036. <https://www.ncbi.nlm.nih.gov/pubmed/19394499>
372. Sahin, S., *et al.* Acupuncture relieves symptoms in chronic prostatitis/chronic pelvic pain syndrome: A randomized, sham-controlled trial. *Prostate Cancer and Prostatic Diseases*, 2015. 18: 249. <https://www.ncbi.nlm.nih.gov/pubmed/25939517>
373. Qin, Z., *et al.* Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Randomized, Sham Acupuncture Controlled Trial. *J Urol*, 2018. 200: 815. <https://www.ncbi.nlm.nih.gov/pubmed/26986148>
374. Chang, S.C., *et al.* The efficacy of acupuncture in managing patients with chronic prostatitis/chronic pelvic pain syndrome: A systemic review and meta-analysis. *Neurourol Urodyn*, 2016. 6: 6. <https://www.ncbi.nlm.nih.gov/pubmed/26741647>
375. Qin, Z., *et al.* Systematic review of acupuncture for chronic prostatitis/chronic pelvic pain syndrome. *Medicine (United States)*, 2016. 95 (11) (no pagination). <https://www.ncbi.nlm.nih.gov/pubmed/26986148>
376. Franco, J.V., *et al.* Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. *Cochrane Database Syst Rev*, 2018. 1: CD012551. <https://www.ncbi.nlm.nih.gov/pubmed/30019814>
377. Kabay, S., *et al.* Efficiency of posterior tibial nerve stimulation in category IIIB chronic prostatitis/chronic pelvic pain: a Sham-Controlled Comparative Study. *Urol Int*, 2009. 83: 33. <https://www.ncbi.nlm.nih.gov/pubmed/19641356>
378. Nnoaham, K.E., *et al.* Transcutaneous electrical nerve stimulation (TENS) for chronic pain. *Cochrane Database Syst Rev*, 2008: CD003222. <https://www.ncbi.nlm.nih.gov/pubmed/18646088>
379. Nickel, J.C., *et al.* Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis. *J Urol*, 2007. 177: 1832. <https://www.ncbi.nlm.nih.gov/pubmed/17437831>
380. Williams, A.C., *et al.* Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev*, 2012. 11: CD007407. <https://www.ncbi.nlm.nih.gov/pubmed/23152245>
381. Cheong, Y.C., *et al.* Non-surgical interventions for the management of chronic pelvic pain. *Cochrane Database Syst Rev*, 2014. 3: CD008797. <https://www.ncbi.nlm.nih.gov/pubmed/24595586>
382. Champaneria, R., *et al.* Psychological therapies for chronic pelvic pain: Systematic review of randomized controlled trials. *Acta Obstet Gynecol Scand*, 2012. 91: 281. <https://www.ncbi.nlm.nih.gov/pubmed/22050516>
383. Norman, S.A., *et al.* For whom does it work? Moderators of the effects of written emotional disclosure in a randomized trial among women with chronic pelvic pain. *Psychosom Med*, 2004. 66: 174. <https://www.ncbi.nlm.nih.gov/pubmed/15039501>
384. Brunahl, C.A., *et al.* Combined Cognitive-Behavioural and Physiotherapeutic Therapy for Patients with Chronic Pelvic Pain Syndrome (COMBI-CPPS): study protocol for a controlled feasibility trial. *Trials*, 2018. 19: 20. <https://www.ncbi.nlm.nih.gov/pubmed/29316946>
385. Meissner, K., *et al.* Psychotherapy With Somatosensory Stimulation for Endometriosis-Associated Pain: A Randomized Controlled Trial with 24-month follow-up. *Obstetrical and Gynecological Survey*, 2017. 73: 163. <https://www.ncbi.nlm.nih.gov/pubmed/27741200>

386. Farquhar, C.M., *et al.* A randomized controlled trial of medroxyprogesterone acetate and psychotherapy for the treatment of pelvic congestion. *Br J Obstet Gynaecol*, 1989. 96: 1153.  
<https://www.ncbi.nlm.nih.gov/pubmed/2531611>
387. Poleshuck, E.L., *et al.* Randomized controlled trial of interpersonal psychotherapy versus enhanced treatment as usual for women with co-occurring depression and pelvic pain. *J Psychosoma Res*, 2014. 77: 264.  
<https://www.ncbi.nlm.nih.gov/pubmed/25280823>
388. Kanter, G., *et al.* Mindfulness-based stress reduction as a novel treatment for interstitial cystitis/bladder pain syndrome: a randomized controlled trial. *Int Urogynecol J*, 2016. 26: 26.  
<https://www.ncbi.nlm.nih.gov/pubmed/27116196>
389. Daniels, J.P., *et al.* Chronic pelvic pain in women. *BMJ*, 2010. 341: c4834.  
<https://www.ncbi.nlm.nih.gov/pubmed/20923840>
390. Rosenbaum, T.Y. How well is the multidisciplinary model working? *J Sex Med*, 2011. 8: 2957.  
<https://www.ncbi.nlm.nih.gov/pubmed/22032406>
391. Macea, D.D., *et al.* The efficacy of Web-based cognitive behavioral interventions for chronic pain: a systematic review and meta-analysis. *J Pain*, 2010. 11: 917.  
<https://www.ncbi.nlm.nih.gov/pubmed/20650691>
392. Bordman, R., *et al.* Below the belt: approach to chronic pelvic pain. *Can Fam Physician*, 2006. 52: 1556.  
<https://www.ncbi.nlm.nih.gov/pubmed/17279236>
393. Shoskes, D.A., *et al.* Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. *Urology*, 2010. 75: 1249.  
<https://www.ncbi.nlm.nih.gov/pubmed/20363491>
394. Cheah, P.Y., *et al.* Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. *J Urol*, 2003. 169: 592.  
<https://www.ncbi.nlm.nih.gov/pubmed/12544314>
395. Gul, O., *et al.* Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. *Int Urol Nephrol*, 2001. 32: 433.  
<https://www.ncbi.nlm.nih.gov/pubmed/11583367>
396. Mehik, A., *et al.* Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. *Urology*, 2003. 62: 425.  
<https://www.ncbi.nlm.nih.gov/pubmed/12946740>
397. Evliyaoglu, Y., *et al.* Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo. *Int Urol Nephrol*, 2002. 34: 351.  
<https://www.ncbi.nlm.nih.gov/pubmed/12899226>
398. Tugcu, V., *et al.* A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). *Eur Urol*, 2007. 51: 1113.  
<https://www.ncbi.nlm.nih.gov/pubmed/17084960>
399. Chen, Y., *et al.* Effects of a 6-month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial. *World J Urol*, 2011. 29: 381.  
<https://www.ncbi.nlm.nih.gov/pubmed/20336302>
400. Nickel, J.C., *et al.* A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). *BJU Int*, 2004. 93: 991.  
<https://www.ncbi.nlm.nih.gov/pubmed/15142149>
401. Nickel, J.C., *et al.* Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. *J Urol*, 2011. 186: 125.  
<https://www.ncbi.nlm.nih.gov/pubmed/21571345>
402. Cohen, J.M., *et al.* Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): A systematic review and meta-analysis. *PLoS ONE*, 2012. 7 (8) (no pagination).  
<https://www.ncbi.nlm.nih.gov/pubmed/22870266>
403. Anothaisintawee, T., *et al.* Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. *JAMA*, 2011. 305: 78.  
<https://www.ncbi.nlm.nih.gov/pubmed/21205969>
404. Nickel, J.C., *et al.* Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. *N Engl J Med*, 2008. 359: 2663.  
<https://www.ncbi.nlm.nih.gov/pubmed/19092152>
405. Nickel, J.C., *et al.* Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. *J Urol*, 2001. 165: 1539.  
<https://www.ncbi.nlm.nih.gov/pubmed/11342913>

406. Lee, J.C., *et al.* Prostate biopsy culture findings of men with chronic pelvic pain syndrome do not differ from those of healthy controls. *J Urol*, 2003. 169: 584.  
<https://www.ncbi.nlm.nih.gov/pubmed/11342913>
407. Nickel, J.C., *et al.* Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. *Urology*, 2003. 62: 614.  
<https://www.ncbi.nlm.nih.gov/pubmed/14550427>
408. Zhou, Z., *et al.* Detection of nanobacteria infection in type III prostatitis. *Urology*, 2008. 71: 1091.  
<https://www.ncbi.nlm.nih.gov/pubmed/18538692>
409. Thakkinstian, A., *et al.* alpha-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. *BJU Int*, 2012. 110: 1014.  
<https://www.ncbi.nlm.nih.gov/pubmed/22471591>
410. Leskinen, M., *et al.* Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo-controlled, pilot study. *Urology*, 1999. 53: 502.  
<https://www.ncbi.nlm.nih.gov/pubmed/10096374>
411. Kaplan, S.A., *et al.* A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. *J Urol*, 2004. 171: 284.  
<https://www.ncbi.nlm.nih.gov/pubmed/14665895>
412. Nickel, J.C., *et al.* Failure of a monotherapy strategy for difficult chronic prostatitis/chronic pelvic pain syndrome. *J Urol*, 2004. 172: 551.  
<https://www.ncbi.nlm.nih.gov/pubmed/15247727>
413. Nickel, J.C., *et al.* Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. *J Urol*, 2011. 186: 1313.  
<https://www.ncbi.nlm.nih.gov/pubmed/21849186>
414. Wagenlehner, F.M., *et al.* A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. *Eur Urol*, 2009. 56: 544.  
<https://www.ncbi.nlm.nih.gov/pubmed/19524353>
415. Cai, T., *et al.* Pollen extract in association with vitamins provides early pain relief in patients affected by chronic prostatitis/chronic pelvic pain syndrome. *Experimental and Therapeutic Medicine*, 2014. 8: 1032.  
<https://www.ncbi.nlm.nih.gov/pubmed/25187793>
416. Cai, T., *et al.* The role of flower pollen extract in managing patients affected by chronic prostatitis/chronic pelvic pain syndrome: a comprehensive analysis of all published clinical trials. *BMC Urol*, 2017. 17: 32.  
<https://www.ncbi.nlm.nih.gov/pubmed/28431537>
417. Shoskes, D.A., *et al.* Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. *Urology*, 1999. 54: 960.  
<https://www.ncbi.nlm.nih.gov/pubmed/10604689>
418. Aboumarzouk, O.M., *et al.* Pregabalin for chronic prostatitis. *Cochrane Database Syst Rev*, 2012. 8: CD009063.  
<https://www.ncbi.nlm.nih.gov/pubmed/22895982>
419. Pontari, M.A., *et al.* Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. *Arch Intern Med*, 2010. 170: 1586.  
<https://www.ncbi.nlm.nih.gov/pubmed/20876412>
420. Nickel, J.C., *et al.* Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. *J Urol*, 2005. 173: 1252.  
<https://www.ncbi.nlm.nih.gov/pubmed/15758763>
421. Gottsch, H.P., *et al.* A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. *Scand J Urol Nephrol*, 2011. 45: 72.  
<https://www.ncbi.nlm.nih.gov/pubmed/21062115>
422. Falahatkar, S., *et al.* Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: Results of a prospective pilot double-blind and randomized placebo-controlled study. *BJU Int*, 2015. 116: 641.  
<https://www.ncbi.nlm.nih.gov/pubmed/25307409>
423. Goldmeier, D., *et al.* Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. *Int J STD AIDS*, 2005. 16: 196.  
<https://www.ncbi.nlm.nih.gov/pubmed/15829018>
424. Nickel, J.C., *et al.* Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. *Urology*, 2012. 80: 1105.  
<https://www.ncbi.nlm.nih.gov/pubmed/23010344>

425. McNaughton, C.O., *et al.* Allopurinol for chronic prostatitis. *Cochrane Database Syst Rev*, 2002: CD001041.  
<https://www.ncbi.nlm.nih.gov/pubmed/12519549>
426. Ziaee, A.M., *et al.* Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial. *Int Braz J Urol*, 2006. 32: 181.  
<https://www.ncbi.nlm.nih.gov/pubmed/16650295>
427. Theoharides, T.C. Hydroxyzine in the treatment of interstitial cystitis. *Urol Clin North Am*, 1994. 21: 113.  
<https://www.ncbi.nlm.nih.gov/pubmed/8284834>
428. Seshadri, P., *et al.* Cimetidine in the treatment of interstitial cystitis. *Urology*, 1994. 44: 614.  
<https://www.ncbi.nlm.nih.gov/pubmed/7941209>
429. Sant, G.R., *et al.* A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. *J Urol*, 2003. 170: 810.  
<https://www.ncbi.nlm.nih.gov/pubmed/12913705>
430. Hanno, P.M., *et al.* Use of amitriptyline in the treatment of interstitial cystitis. *J Urol*, 1989. 141: 846.  
<https://www.ncbi.nlm.nih.gov/pubmed/2926877>
431. Kirkemo, A., *et al.* Use of amitriptyline in interstitial cystitis. *J Urol*, 1990. 143 Suppl. [No abstract available].
432. Foster, H.E., Jr., *et al.* Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome. *J Urol*, 2010. 183: 1853.  
<https://www.ncbi.nlm.nih.gov/pubmed/20303115>
433. Hwang, P., *et al.* Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis. *Urology*, 1997. 50: 39.  
<https://www.ncbi.nlm.nih.gov/pubmed/9218016>
434. Mulholland, S.G., *et al.* Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. *Urology*, 1990. 35: 552.  
<https://www.ncbi.nlm.nih.gov/pubmed/1693797>
435. Fritjofsson, A., *et al.* Treatment of ulcer and nonulcer interstitial cystitis with sodium pentosanpolysulfate: a multicenter trial. *J Urol*, 1987. 138: 508.  
<https://www.ncbi.nlm.nih.gov/pubmed/2442416>
436. van Ophoven, A., *et al.* Safety and efficacy of concurrent application of oral pentosan polysulfate and subcutaneous low-dose heparin for patients with interstitial cystitis. *Urology*, 2005. 66: 707.  
<https://www.ncbi.nlm.nih.gov/pubmed/16230121>
437. Nickel, J.C., *et al.* Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. *J Urol*, 2015. 193: 857.  
<https://www.ncbi.nlm.nih.gov/pubmed/25245489>
438. Oravisto, K.J., *et al.* Treatment of interstitial cystitis with immunosuppression and chloroquine derivatives. *Eur Urol*, 1976. 2: 82.  
<https://www.ncbi.nlm.nih.gov/pubmed/971677>
439. Forsell, T., *et al.* Cyclosporine in severe interstitial cystitis. *J Urol*, 1996. 155: 1591.  
<https://www.ncbi.nlm.nih.gov/pubmed/8627830>
440. Moran, P.A., *et al.* Oral methotrexate in the management of refractory interstitial cystitis. *Aust N Z J Obstet Gynaecol*, 1999. 39: 468.  
<https://www.ncbi.nlm.nih.gov/pubmed/10687766>
441. Barua, J.M., *et al.* A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis. *Int Urogynecol J*, 2016. 27: 1137.  
<https://www.ncbi.nlm.nih.gov/pubmed/26590137>
442. Asklin, B., *et al.* Intravesical lidocaine in severe interstitial cystitis. Case report. *Scand J Urol Nephrol*, 1989. 23: 311.  
<https://www.ncbi.nlm.nih.gov/pubmed/2595329>
443. Giannakopoulos, X., *et al.* Chronic interstitial cystitis. Successful treatment with intravesical idocaine. *Arch Ital Urol Nefrol Androl*, 1992. 64: 337.  
<https://www.ncbi.nlm.nih.gov/pubmed/1462157>
444. Henry, R., *et al.* Absorption of alkalinized intravesical lidocaine in normal and inflamed bladders: a simple method for improving bladder anesthesia. *J Urol*, 2001. 165: 1900.  
<https://www.ncbi.nlm.nih.gov/pubmed/11371877>
445. Parsons, C.L. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. *Urology*, 2005. 65: 45.  
<https://www.ncbi.nlm.nih.gov/pubmed/15667861>

446. Nickel, J.C., *et al.* Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. *BJU Int*, 2009. 103: 910.  
<https://www.ncbi.nlm.nih.gov/pubmed/19021619>
447. Cervigni, M., *et al.* A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. *Neurourol Urodyn*, 2017. 36: 1178.  
<https://www.ncbi.nlm.nih.gov/pubmed/27654012>
448. Pyo, J.S., *et al.* Systematic Review and Meta-Analysis of Intravesical Hyaluronic Acid and Hyaluronic Acid/Chondroitin Sulfate Instillation for Interstitial Cystitis/Painful Bladder Syndrome. *Cell Physiol Biochem*, 2016. 39: 1618.  
<https://www.ncbi.nlm.nih.gov/pubmed/27627755>
449. Parsons, C.L., *et al.* Treatment of interstitial cystitis with intravesical heparin. *Br J Urol*, 1994. 73: 504.  
<https://www.ncbi.nlm.nih.gov/pubmed/8012771>
450. Kuo, H.C. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis. *J Formos Med Assoc*, 2001. 100: 309.  
<https://www.ncbi.nlm.nih.gov/pubmed/11432309>
451. Baykal, K., *et al.* Intravesical heparin and peripheral neuromodulation on interstitial cystitis. *Urol Int*, 2005. 74: 361.  
<https://www.ncbi.nlm.nih.gov/pubmed/15897705>
452. Dasgupta, P., *et al.* Cimetidine in painful bladder syndrome: a histopathological study. *BJU Int*, 2001. 88: 183.  
<https://www.ncbi.nlm.nih.gov/pubmed/11488726>
453. Thilagarajah, R., *et al.* Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. *BJU Int*, 2001. 87: 207.  
<https://www.ncbi.nlm.nih.gov/pubmed/11167643>
454. Kelly, J.D., *et al.* Clinical response to an oral prostaglandin analogue in patients with interstitial cystitis. *Eur Urol*, 1998. 34: 53.  
<https://www.ncbi.nlm.nih.gov/pubmed/9676414>
455. Korting, G.E., *et al.* A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. *J Urol*, 1999. 161: 558.  
<https://www.ncbi.nlm.nih.gov/pubmed/9915448>
456. Smith, S.D., *et al.* Improvement in interstitial cystitis symptom scores during treatment with oral L-arginine. *J Urol*, 1997. 158: 703.  
<https://www.ncbi.nlm.nih.gov/pubmed/9258064>
457. Wheeler, M.A., *et al.* Effect of long-term oral L-arginine on the nitric oxide synthase pathway in the urine from patients with interstitial cystitis. *J Urol*, 1997. 158: 2045.  
<https://www.ncbi.nlm.nih.gov/pubmed/9366309>
458. Lundberg, J.O., *et al.* Elevated nitric oxide in the urinary bladder in infectious and noninfectious cystitis. *Urology*, 1996. 48: 700.  
<https://www.ncbi.nlm.nih.gov/pubmed/9836549>
459. Cartledge, J.J., *et al.* A randomized double-blind placebo-controlled crossover trial of the efficacy of L-arginine in the treatment of interstitial cystitis. *BJU Int*, 2000. 85: 421.  
<https://www.ncbi.nlm.nih.gov/pubmed/10691818>
460. Ehren, I., *et al.* Effects of L-arginine treatment on symptoms and bladder nitric oxide levels in patients with interstitial cystitis. *Urology*, 1998. 52: 1026.  
<https://www.ncbi.nlm.nih.gov/pubmed/9836549>
461. Barbalias, G.A., *et al.* Interstitial cystitis: bladder training with intravesical oxybutynin. *J Urol*, 2000. 163: 1818.  
<https://www.ncbi.nlm.nih.gov/pubmed/10799190>
462. van Ophoven, A., *et al.* The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observational study. *J Urol*, 2007. 177: 552.  
<https://www.ncbi.nlm.nih.gov/pubmed/17222632>
463. Messing, E.M., *et al.* Complication of Clorpactin WCS90 therapy for interstitial cystitis. *Urology*, 1979. 13: 389.  
<https://www.ncbi.nlm.nih.gov/pubmed/219578>
464. Murnaghan, G.F., *et al.* Interstitial cystitis--treatment with Chlorpactin WCS 90. *Br J Urol*, 1970. 42: 744.  
<https://www.ncbi.nlm.nih.gov/pubmed/5491939>

465. O'Connor, V.J. Clorpactin WCS-90 in the treatment of interstitial cystitis. *Q Bull Northwest Univ Med Sch*, 1955. 29: 392.  
<https://www.ncbi.nlm.nih.gov/pubmed/13273619>
466. von Heyden, B., *et al.* [Intravesical therapy of interstitial cystitis]. *Urologe A*, 2000. 39: 542.  
<https://www.ncbi.nlm.nih.gov/pubmed/13273619>
467. Wishard, W.N., Jr., *et al.* Use of clorpactin WCS 90 for relief of symptoms due to interstitial cystitis. *J Urol*, 1957. 77: 420.  
<https://www.ncbi.nlm.nih.gov/pubmed/13417272>
468. Hanno, P. Interstitial cystitis and related diseases. In: Campbell's Urology. Walsh PC, Retik AB, Stamey TA, Vaughan ED, eds. *Campbell's Urology*, 1998, WB Saunders Co.: Philadelphia.
469. Warren, J.W., *et al.* Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. *Urology*, 2008. 71: 1085.  
<https://www.ncbi.nlm.nih.gov/pubmed/18538691>
470. Messelink, E.J. The pelvic pain centre. *World J Urol*, 2001. 19: 208.  
<https://www.ncbi.nlm.nih.gov/pubmed/11469609>
471. Barra, F., *et al.* Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. *Expert Opin Drug Metab Toxicol*, 2018. 14: 399.  
<https://www.ncbi.nlm.nih.gov/pubmed/29617576>
472. Gemzell-Danielsson, K., *et al.* The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial. *PLoS One*, 2015. 10: e0135309.  
<https://www.ncbi.nlm.nih.gov/pubmed/26378938>
473. Sauvan, M., *et al.* [Medical treatment for the management of painful endometriosis without infertility: CNGOF-HAS Endometriosis Guidelines]. *Gynecol Obstet Fertil Senol*, 2018. 46: 267.  
<https://www.ncbi.nlm.nih.gov/pubmed/29510966>
474. Kamanli, A., *et al.* Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. *Rheumatol Int*, 2005. 25: 604.  
<https://www.ncbi.nlm.nih.gov/pubmed/15372199>
475. Ho, K.Y., *et al.* Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review. *Eur J Pain*, 2007. 11: 519.  
<https://www.ncbi.nlm.nih.gov/pubmed/17071119>
476. Abbott, J.A., *et al.* Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. *Obstet Gynecol*, 2006. 108: 915.  
<https://www.ncbi.nlm.nih.gov/pubmed/17012454>
477. Zermann, D., *et al.* Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? *Eur Urol*, 2000. 38: 393.  
<https://www.ncbi.nlm.nih.gov/pubmed/11025376>
478. Jarvis, S.K., *et al.* Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. *Aust N Z J Obstet Gynaecol*, 2004. 44: 46.  
<https://www.ncbi.nlm.nih.gov/pubmed/15089868>
479. Rao, S.S., *et al.* Clinical trial: effects of botulinum toxin on Levator ani syndrome--a double-blind, placebo-controlled study. *Aliment Pharmacol Ther*, 2009. 29: 985.  
<https://www.ncbi.nlm.nih.gov/pubmed/19222415>
480. Eckardt, V.F., *et al.* Treatment of proctalgia fugax with salbutamol inhalation. *Am J Gastroenterol*, 1996. 91: 686.  
<https://www.ncbi.nlm.nih.gov/pubmed/8677929>
481. Atkin, G.K., *et al.* Patient characteristics and treatment outcome in functional anorectal pain. *Dis Colon Rectum*, 2011. 54: 870.  
<https://www.ncbi.nlm.nih.gov/pubmed/21654255>
482. Chey W.D., Effects of 26 weeks of linaclotide treatment on adequate relief and IBS severity in patients with irritable bowel syndrome with constipation. *Gastroenterol*, 2012. 142.  
[https://www.gastrojournal.org/article/S0016-5085\(12\)63175-8/abstract](https://www.gastrojournal.org/article/S0016-5085(12)63175-8/abstract)
483. de Vries, M., *et al.* Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study. *Clin Gastroenterol Hepatol*, 2017. 15: 1079.  
<https://www.ncbi.nlm.nih.gov/pubmed/27720917>
484. Stones, R.W., *et al.* Interventions for treating chronic pelvic pain in women. *Cochrane Database Syst Rev*, 2000: CD000387.  
<https://www.ncbi.nlm.nih.gov/pubmed/11034686>



485. Remy, C., *et al.* State of the art of paracetamol in acute pain therapy. *Curr Opin Anaesthesiol*, 2006. 19: 562.  
<https://www.ncbi.nlm.nih.gov/pubmed/16960492>
486. Moore, R.A., *et al.* Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. *Eur J Pain*, 2015. 19: 1213.  
<https://www.ncbi.nlm.nih.gov/pubmed/25530283>
487. Marjoribanks, J., *et al.* Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. *Cochrane Database Syst Rev*, 2010: CD001751.  
<https://www.ncbi.nlm.nih.gov/pubmed/20091521>
488. Allen, C., *et al.* Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. *Cochrane Database Syst Rev*, 2009: CD004753.  
<https://www.ncbi.nlm.nih.gov/pubmed/19370608>
489. NICE, NCG 173. Neuropathic pain. The pharmacological management of neuropathic pain in adults in non-specialist settings. 2013.  
<https://www.ncbi.nlm.nih.gov/pubmed/25577930>
490. Baldessarini, R., Drugs and the treatment of psychiatric disorders. In: Goodman and Gilman's the pharmacological basis of therapeutics. Bunton L.L., Hilal-Dandan R., Knollmann B.C. eds. 1985, New York.
491. Saarto, T., *et al.* Antidepressants for neuropathic pain. *Cochrane Database Syst Rev*, 2007: CD005454.  
<https://www.ncbi.nlm.nih.gov/pubmed/17943857>
492. Lunn, M.P., *et al.* Duloxetine for treating painful neuropathy or chronic pain. *Cochrane Database Syst Rev*, 2009: CD007115.  
<https://www.ncbi.nlm.nih.gov/pubmed/19821395>
493. Engel, C.C., Jr., *et al.* A randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain. *J Psychosom Res*, 1998. 44: 203.  
<https://www.ncbi.nlm.nih.gov/pubmed/9532549>
494. Wiffen, P.J., *et al.* Carbamazepine for acute and chronic pain in adults. *Cochrane Database Syst Rev*, 2011: CD005451.  
<https://www.ncbi.nlm.nih.gov/pubmed/21249671>
495. Moore, R.A., *et al.* Gabapentin for chronic neuropathic pain and fibromyalgia in adults. *Cochrane Database Syst Rev*, 2011: CD007938.  
<https://www.ncbi.nlm.nih.gov/pubmed/21412914>
496. Sator-Katzenschlager, S.M., *et al.* Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. *Wien Klin Wochenschr*, 2005. 117: 761.  
<https://www.ncbi.nlm.nih.gov/pubmed/16416358>
497. Lewis, S.C., *et al.* Gabapentin for the Management of Chronic Pelvic Pain in Women (GaPP1): A Pilot Randomised Controlled Trial. *PLoS ONE [Electronic Resource]*, 2016. 11.  
<https://www.ncbi.nlm.nih.gov/pubmed/27070434>
498. Moore, R.A., *et al.* Pregabalin for acute and chronic pain in adults. *Cochrane Database Syst Rev*, 2009: CD007076.  
<https://www.ncbi.nlm.nih.gov/pubmed/19588419>
499. Noble, M., *et al.* Long-term opioid management for chronic noncancer pain. *Cochrane Database Syst Rev*, 2010: CD006605.  
<https://www.ncbi.nlm.nih.gov/pubmed/20091598>
500. Faculty of Pain Medicine, P., Opioids Aware: A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain. 2015.  
<https://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware>
501. Sotgiu, M.L., *et al.* Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. *Pharmacol Res*, 2009. 60: 284.  
<https://www.ncbi.nlm.nih.gov/pubmed/19717013>
502. Olesen, A.E., *et al.* Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study. *Br J Clin Pharmacol*, 2010. 70: 189.  
<https://www.ncbi.nlm.nih.gov/pubmed/20653672>
503. Kuo, H.C., *et al.* Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. *BJU Int*, 2009. 104: 657.  
<https://www.ncbi.nlm.nih.gov/pubmed/19338543>

504. Pinto, R., *et al.* Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. *Eur Urol*, 2010. 58: 360.  
<https://www.ncbi.nlm.nih.gov/pubmed/20227820>
505. Kuo, Y.C., *et al.* Adverse Events of Intravesical Onabotulinum Toxin A Injection between Patients with Overactive Bladder and Interstitial Cystitis-Different Mechanisms of Action of Botox on Bladder Dysfunction? *Toxins*, 2016. 8.  
<https://www.ncbi.nlm.nih.gov/pubmed/19338543>
506. Akiyama, Y., *et al.* Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. *Int J Urol*, 2015. 22: 835.  
<https://www.ncbi.nlm.nih.gov/pubmed/26041274>
507. Kuo, H.C., *et al.* Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. *Neurourology & Urodynamics*, 2015. 24: 24.  
<https://www.ncbi.nlm.nih.gov/pubmed/25914337>
508. Lee, C.L., *et al.* Long-term efficacy and safety of repeated intravesical onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/bladder pain syndrome. *Toxins*, 2015. 7: 4283.  
<https://www.ncbi.nlm.nih.gov/pubmed/26506388>
509. Pinto, R., *et al.* Persistent therapeutic effect of repeated injections of onabotulinum toxin A in refractory bladder pain syndrome/interstitial cystitis. *J Urol*, 2013. 189: 548.  
<https://www.ncbi.nlm.nih.gov/pubmed/23253961>
510. Pinto, R.A., *et al.* Intratrigoal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial. *J Urol*, 2018. 199: 998.  
<https://www.ncbi.nlm.nih.gov/pubmed/29031769>
511. Hanno, P.M., *et al.* Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. *J Urol*, 2015. 193: 1545.  
<https://www.ncbi.nlm.nih.gov/pubmed/25623737>
512. Kerr, W.S., Jr. Interstitial cystitis: treatment by transurethral resection. *J Urol*, 1971. 105: 664.  
<https://www.ncbi.nlm.nih.gov/pubmed/4397018>
513. Peeker, R., *et al.* Complete transurethral resection of ulcers in classic interstitial cystitis. *Int Urogynecol J Pelvic Floor Dysfunct*, 2000. 11: 290.  
<https://www.ncbi.nlm.nih.gov/pubmed/11052564>
514. Rofeim, O., *et al.* Use of the neodymium: YAG laser for interstitial cystitis: a prospective study. *J Urol*, 2001. 166: 134.  
<https://www.ncbi.nlm.nih.gov/pubmed/11435840>
515. Warwick, R.T., *et al.* The functional results of partial, subtotal and total cystoplasty with special reference to ureteroceecocystoplasty, selective sphincterotomy and cystocystoplasty. *Br J Urol*, 1967. 39: 3.  
<https://www.ncbi.nlm.nih.gov/pubmed/5336762>
516. Freiha, F.S., *et al.* The surgical treatment of intractable interstitial cystitis. *J Urol*, 1980. 123: 632.  
<https://www.ncbi.nlm.nih.gov/pubmed/7420547>
517. Shirley, S.W., *et al.* Experiences with colcystoplasties, cecocystoplasties and ileocystoplasties in urologic surgery: 40 patients. *J Urol*, 1978. 120: 165.  
<https://www.ncbi.nlm.nih.gov/pubmed/671623>
518. von Garrelts, B. Interstitial cystitis: thirteen patients treated operatively with intestinal bladder substitutes. *Acta Chir Scand*, 1966. 132: 436.  
<https://www.ncbi.nlm.nih.gov/pubmed/5972716>
519. Webster, G.D., *et al.* The management of chronic interstitial cystitis by substitution cystoplasty. *J Urol*, 1989. 141: 287.  
<https://www.ncbi.nlm.nih.gov/pubmed/2913346>
520. Nurse, D.E., *et al.* The problems of substitution cystoplasty. *Br J Urol*, 1988. 61: 423.  
<https://www.ncbi.nlm.nih.gov/pubmed/3395801>
521. Linn, J.F., *et al.* Treatment of interstitial cystitis: comparison of subtrigoal and supratrigoal cystectomy combined with orthotopic bladder substitution. *J Urol*, 1998. 159: 774.  
<https://www.ncbi.nlm.nih.gov/pubmed/9474146>
522. Volkmer, B.G., *et al.* Cystectomy and orthotopic ileal neobladder: the impact on female sexuality. *J Urol*, 2004. 172: 2353.  
<https://www.ncbi.nlm.nih.gov/pubmed/15538266>

523. Gershbaum, D., *et al.* Practice trends for the management of interstitial cystitis. *Urology*, 2001. 57: 119.  
<https://www.ncbi.nlm.nih.gov/pubmed/11378100>
524. Elzawahri, A., *et al.* Urinary conduit formation using a retubularized bowel from continent urinary diversion or intestinal augmentations: ii. Does it have a role in patients with interstitial cystitis? *J Urol*, 2004. 171: 1559.  
<https://www.ncbi.nlm.nih.gov/pubmed/15017220>
525. Shaikh, A., *et al.* Pregnancy after augmentation cystoplasty. *J Pak Med Assoc*, 2006. 56: 465.  
<https://www.ncbi.nlm.nih.gov/pubmed/17144396>
526. Zhao, Y., *et al.* Circumcision plus antibiotic, anti-inflammatory, and alpha-blocker therapy for the treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, multicenter trial. *World J Urol*, 2015. 33: 617.  
<https://www.ncbi.nlm.nih.gov/pubmed/24980414>
527. Oomen, R.J.A., *et al.* Prospective double-blind preoperative pain clinic screening before microsurgical denervation of the spermatic cord in patients with testicular pain syndrome. *Pain*, 2014. 155: 1720.  
<https://www.ncbi.nlm.nih.gov/pubmed/24861586>
528. Menconi, C., *et al.* Persistent anal and pelvic floor pain after PPH and STARR: surgical management of the fixed scar staple line. *Int J Colorect Dis*, 2016. 31: 41.  
<https://www.ncbi.nlm.nih.gov/pubmed/26248794>
529. Molegraaf, M.J., *et al.* Twelve-year outcomes of laparoscopic adhesiolysis in patients with chronic abdominal pain: A randomized clinical trial. *Surgery*, 2017. 161: 415.  
<https://www.ncbi.nlm.nih.gov/pubmed/27866713>
530. Yoon, S.M., *et al.* Treatment of female urethral syndrome refractory to antibiotics. *Yonsei Med J*, 2002. 43: 644.  
<https://www.ncbi.nlm.nih.gov/pubmed/12402379>
531. Costantini, E., *et al.* Treatment of urethral syndrome: a prospective randomized study with Nd:YAG laser. *Urol Int*, 2006. 76: 134.  
<https://www.ncbi.nlm.nih.gov/pubmed/16493214>
532. Ploteau, S., *et al.* [Minimal and mild endometriosis: Impact of the laparoscopic surgery on pelvic pain and fertility. CNGOF-HAS Endometriosis Guidelines]. *Gynecol Obstet Fertil Senol*, 2018. 46: 273.  
<https://www.ncbi.nlm.nih.gov/pubmed/29510965>
533. de Paula Andres, M., *et al.* The current management of deep endometriosis: a systematic review. *Minerva Ginecol*, 2017. 69: 587.  
<https://www.ncbi.nlm.nih.gov/pubmed/28545293>
534. Baurant, E., *et al.* [Modern algorithm for treating pudendal neuralgia: 212 cases and 104 decompressions]. *J Gynecol Obstet Biol Reprod (Paris)*, 2003. 32: 705.  
<https://www.ncbi.nlm.nih.gov/pubmed/15067894>
535. Possover, M., *et al.* Laparoscopic neurolysis of the sacral plexus and the sciatic nerve for extensive endometriosis of the pelvic wall. *Minim Invasive Neurosurg*, 2007. 50: 33.  
<https://www.ncbi.nlm.nih.gov/pubmed/17546541>
536. Robert, R., *et al.* Decompression and transposition of the pudendal nerve in pudendal neuralgia: a randomized controlled trial and long-term evaluation. *Eur Urol*, 2005. 47: 403.  
<https://www.ncbi.nlm.nih.gov/pubmed/15716208>
537. Robert, R., *et al.* [Pudendal nerve surgery in the management of chronic pelvic and perineal pain]. *Prog Urol*, 2010. 20: 1084.  
<https://www.ncbi.nlm.nih.gov/pubmed/21056388>
538. Robert, R., *et al.* Neurosurgical treatment of perineal neuralgias. *Adv Tech Stand Neurosurg*, 2007. 32: 41.  
<https://www.ncbi.nlm.nih.gov/pubmed/17907474>
539. Duckett, J., *et al.* Mesh removal after vaginal surgery: what happens in the UK? *Int Urogynecol J*, 2017. 28: 989.  
<https://www.ncbi.nlm.nih.gov/pubmed/27924372>
540. Lee, D., *et al.* Transvaginal mesh kits--how "serious" are the complications and are they reversible? *Urology*, 2013. 81: 43.  
<https://www.ncbi.nlm.nih.gov/pubmed/23200966>
541. Shah, K., *et al.* Surgical management of lower urinary mesh perforation after mid-urethral polypropylene mesh sling: mesh excision, urinary tract reconstruction and concomitant pubovaginal sling with autologous rectus fascia. *Int Urogynecol J*, 2013. 24: 2111.  
<https://www.ncbi.nlm.nih.gov/pubmed/23824269>

542. Ramart, P., *et al.* The Risk of Recurrent Urinary Incontinence Requiring Surgery After Suburethral Sling Removal for Mesh Complications. *Urology*, 2017. 106: 203.  
<https://www.ncbi.nlm.nih.gov/pubmed/28476681>
543. Jong, K., *et al.* Is pain relief after vaginal mesh and/or sling removal durable long term? *Int Urogynecol J*, 2018. 29: 859.  
<https://www.ncbi.nlm.nih.gov/pubmed/28695345>
544. Hansen, B.L., *et al.* Long-term follow-up of treatment for synthetic mesh complications. *Female Pelvic Med Reconstr Surg*, 2014. 20: 126.  
<https://www.ncbi.nlm.nih.gov/pubmed/24763152>
545. Ridgeway, B., *et al.* Early experience with mesh excision for adverse outcomes after transvaginal mesh placement using prolapse kits. *Am J Obstet Gynecol*, 2008. 199: 703 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/18845292>
546. Gyang, A.N., *et al.* Managing chronic pelvic pain following reconstructive pelvic surgery with transvaginal mesh. *Int Urogynecol J*, 2014. 25: 313.  
<https://www.ncbi.nlm.nih.gov/pubmed/24217793>
547. Ferreira, M., *et al.* [Pelvic floor muscle training programmes: a systematic review]. *Acta Med Port*, 2011. 24: 309.  
<https://www.ncbi.nlm.nih.gov/pubmed/22011604>
548. NICE. Technology appraisal guidance 159. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin. 2008.  
<https://www.nice.org.uk/guidance/ta159>
549. Fariello, J.Y., *et al.* Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction. *Int Urogynecol J*, 2010. 21: 1553.  
<https://www.ncbi.nlm.nih.gov/pubmed/20972541>
550. Peters, K.M., *et al.* A prospective, single-blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis. *BJU Int*, 2007. 100: 835.  
<https://www.ncbi.nlm.nih.gov/pubmed/17822464>
551. Gajewski, J.B., *et al.* The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre. *BJU Int*, 2011. 107: 1258.  
<https://www.ncbi.nlm.nih.gov/pubmed/20883483>
552. Carmel, M., *et al.* Pudendal nerve neuromodulation with neurophysiology guidance: a potential treatment option for refractory chronic pelvi-perineal pain. *Int Urogynecol J*, 2010. 21: 613.  
<https://www.ncbi.nlm.nih.gov/pubmed/20012596>
553. Horowitz, S.H. The diagnostic workup of patients with neuropathic pain. *Med Clin North Am*, 2007. 91: 21.  
<https://www.ncbi.nlm.nih.gov/pubmed/17164102>
554. Marcelissen, T., *et al.* Sacral neuromodulation as a treatment for neuropathic clitoral pain after abdominal hysterectomy. *Int Urogynecol J*, 2010. 21: 1305.  
<https://www.ncbi.nlm.nih.gov/pubmed/20386879>
555. Mayer, R.D., *et al.* Sacral nerve stimulation: neuromodulation for voiding dysfunction and pain. *Neurotherapeutics*, 2008. 5: 107.  
<https://www.ncbi.nlm.nih.gov/pubmed/18164489>
556. Falletto, E., *et al.* Is sacral nerve stimulation an effective treatment for chronic idiopathic anal pain? *Dis Colon Rectum*, 2009. 52: 456.  
<https://www.ncbi.nlm.nih.gov/pubmed/19333046>
557. Martellucci, J., *et al.* Sacral nerve modulation in the treatment of chronic pain after pelvic surgery. *Colorectal Dis*, 2012. 14: 502.  
<https://www.ncbi.nlm.nih.gov/pubmed/21689334>
558. Gokyildiz, S., *et al.* Effects of percutaneous tibial nerve stimulation therapy on chronic pelvic pain. *Gynecol Obstet Invest*, 2012. 73: 99.  
<https://www.ncbi.nlm.nih.gov/pubmed/22269443>
559. Li, C.B., *et al.* The efficacy and safety of the ganglion impar block in chronic intractable pelvic and/or perineal pain: A systematic review and meta-analysis. *Int J Clin Exp Med*, 2016. 9: 15746.  
<http://www.ijcem.com/files/ijcem0021581.pdf>
560. Eker, H.E., *et al.* Management of neuropathic pain with methylprednisolone at the site of nerve injury. *Pain Med*, 2012. 13: 443.  
<https://www.ncbi.nlm.nih.gov/pubmed/22313580>
561. Labat, J.J., *et al.* Adding corticosteroids to the pudendal nerve block for pudendal neuralgia: a randomised, double-blind, controlled trial. *BJOG*, 2017. 124: 251.  
<https://www.ncbi.nlm.nih.gov/pubmed/27465823>

562. Rhame, E.E., *et al.* Successful treatment of refractory pudendal neuralgia with pulsed radiofrequency. *Pain Phys*, 2009. 12: 633.  
<https://www.ncbi.nlm.nih.gov/pubmed/19461829>

## 8. CONFLICT OF INTEREST

All members of the EAU Chronic Pelvic Pain Guidelines working panel have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of conflict of interest. This information is publically accessible through the European Association of Urology website <http://www.uroweb.org/guidelines/>. This document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

## 9. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

*EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2.*

If a publisher and/or location is required, include:

*EAU Guidelines Office, Arnhem, The Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>*

References to individual guidelines should be structured in the following way:

*Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.*

